-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, B47wccGauR2Y50u90RPyrOjXUi86fBWdpuBsbppGoTa6Fk14V72SVM0t5n7fVQfX ksrSt6Su2yuMP7PvpkrXoQ== 0001008848-10-000036.txt : 20101109 0001008848-10-000036.hdr.sgml : 20101109 20101109163209 ACCESSION NUMBER: 0001008848-10-000036 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20100930 FILED AS OF DATE: 20101109 DATE AS OF CHANGE: 20101109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACORDA THERAPEUTICS INC CENTRAL INDEX KEY: 0001008848 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-50513 FILM NUMBER: 101176684 BUSINESS ADDRESS: STREET 1: 15 SKYLINE DRIVE CITY: HAWTHORNE STATE: NY ZIP: 10532 BUSINESS PHONE: 914-347-4300 10-Q 1 form10q093010.htm FORM10Q093010 form10q093010.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
FORM 10-Q
 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2010
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to
Commission File Number 000-50513
 

 
ACORDA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
(State of Incorporation)
13-3831168
(I.R.S. Employer
Identification Number)
 
15 Skyline Drive
Hawthorne, New York 10532
(914) 347-4300
(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant’s Principal Executive Offices)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x  No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x  No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer x
Accelerated filer o
Non-accelerated filer o
(Do not check if a
smaller reporting company)
Smaller Reporting Company o
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
 
Class
Outstanding at October 31, 2010
Common Stock, $0.001 par value
per share
39,079,688 shares


 
 
 

ACORDA THERAPEUTICS, INC.
 
 
 

 


This Quarterly Report on Form 10-Q contains forward-looking statements relating to future events and our future performance within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Stockholders are cautioned that such statements involve risks and uncertainties. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s beliefs and assumptions. All statements, other than statements of historical facts, included in this report regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking st atements. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this report and in the “Risk Factors” section in our Annual Report on Form 10-K for the year ended December 31, 2009 and our Form 10-Q for the quarter ended June 30, 2010, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not assume any obligation to update any forward-looking statements.
 


 
Item 1.  Financial Statements
 
ACORDA THERAPEUTICS, INC. AND SUBSIDIARIES
 
 
   
September 30,
2010
    
December 31,
2009
  
   
(unaudited)
        
Assets
            
Current assets:
            
Cash and cash equivalents
   $ 82,404,827     $ 47,314,412  
Restricted cash
     301,848       301,160  
Short-term investments
     163,412,360       224,778,023  
Trade accounts receivable, net
     18,228,831       5,739,013  
Prepaid expenses
     5,722,357       4,274,625  
Finished goods inventory held by the Company
     24,079,937       4,497,533  
Finished goods inventory held by others
     2,101,926       2,394,980  
Other current assets
     3,260,669       3,980,601  
Total current assets
     299,512,755       293,280,347  
Property and equipment, net of accumulated depreciation
     3,320,957       1,891,321  
Intangible assets, net of accumulated amortization
     22,013,430       17,148,631  
Non-current portion of deferred cost of license revenue
     6,215,001       6,710,001  
Other assets
     359,045       440,318  
Total assets
   $ 331,421,188     $ 319,470,618  
Liabilities and Stockholders’ Equity
                
Current liabilities:
                
Accounts payable
   $ 17,363,236     $ 11,613,434  
Accrued expenses and other current liabilities
     25,803,985       14,975,794  
Deferred product revenue—Zanaflex tablets
     8,709,065       9,214,742  
Deferred product revenue—Zanaflex Capsules
     20,617,977       21,489,081  
Current portion of deferred license revenue
     9,428,571       9,428,571  
Current portion of revenue interest liability
     6,381,187       6,178,697  
Current portion of convertible notes payable
     1,144,275       —  
Total current liabilities
     89,448,296       72,900,319  
Non-current portion of deferred license revenue
     88,785,714       95,857,142  
Put/call liability
     318,500       637,500  
Non-current portion of revenue interest liability
     4,374,627       5,630,862  
Non-current portion of convertible notes payable
     6,132,134       7,112,027  
Commitments and contingencies
                
Stockholders’ equity:
                
Common stock, $0.001 par value. Authorized 80,000,000 shares at September 30, 2010 and December 31, 2009; issued and outstanding 38,568,369 and 37,935,075 shares as of September 30, 2010 and December 31, 2009, respectively
     38,569       37,935  
Additional paid-in capital
     586,058,355       565,503,101  
Accumulated deficit
     (443,757,145 )     (428,316,881 )
Accumulated other comprehensive income
     22,138       108,613  
Total stockholders’ equity
     142,361,917       137,332,768  
Total liabilities and stockholders’ equity
   $ 331,421,188     $ 319,470,618  
 
See accompanying Unaudited Notes to Consolidated Financial Statements
 

 
1


ACORDA THERAPEUTICS, INC. AND SUBSIDIARIES
 
 
(unaudited)
 
   
Three-month
period ended
September 30,
2010
    
Three-month
period ended
September 30,
2009
    
Nine-month
period ended
September 30,
2010
    
Nine-month
period ended
September 30,
2009
  
Revenues:
                        
Gross product sales
   $ 66,188,194     $ 14,463,303     $ 126,884,766     $ 43,834,948  
Less: discounts and allowances
     (4,923,295 )     (1,606,126 )     (9,751,194 )     (5,959,234 )
Net sales
     61,264,899       12,857,177       117,133,572       37,875,714  
License revenue
     2,357,143       2,357,144       7,071,428       2,357,144  
Total net revenues
     63,622,042       15,214,321       124,205,000       40,232,858  
                                 
Costs and expenses:
                                
Cost of sales
     11,666,020       2,602,064       22,573,938       8,112,490  
Research and development
     7,970,073       8,197,789       22,627,938       23,982,123  
Selling, general and administrative
     30,723,444       23,415,132       91,548,951       67,362,421  
Total operating expenses
     50,359,537       34,214,985       136,750,827       99,457,034  
Operating income (loss)
     13,262,505       (19,000,664 )     (12,545,827 )     (59,224,176 )
Other expense (net):
                                
Interest and amortization of debt discount expense
     (943,975 )     (704,229 )     (3,352,305 )     (3,703,552 )
Interest income
     110,528       314,000       449,736       1,478,996  
Other income
     8,132       —       8,132       5,365  
Loss on disposal of property and equipment
     —       (38,914 )     —       (23,514 )
Total other expense (net)
     (825,315 )     (429,143 )     (2,894,437 )     (2,242,705 )
Net income (loss)
   $ 12,437,190     $ (19,429,807 )   $ (15,440,264 )   $ (61,466,881 )
Net income (loss) per share—basic
   $ 0.32     $ (0.51 )   $ (0.40 )   $ (1.63 )
Net income (loss) per share—diluted
   $ 0.31     $ (0.51 )   $ (0.40 )   $ (1.63 )
Weighted average common shares outstanding used in computing net income (loss) per share—basic
     38,449,917       37,749,920       38,260,608       37,700,747  
Weighted average common shares outstanding used in computing net income (loss) per share—diluted
     39,987,644       37,749,920       38,260,608       37,700,747  
 
See accompanying Unaudited Notes to Consolidated Financial Statements
2


ACORDA THERAPEUTICS, INC. AND SUBSIDIARIES
 
 
(unaudited)
 
   
Nine-month
period ended
September 30,
2010
    
Nine-month
period ended
September 30,
2009
  
Cash flows from operating activities:
            
Net loss
   $ (15,440,264 )   $ (61,466,881 )
Adjustments to reconcile net loss to net cash provided by operating activities:
                
Share-based compensation expense
     12,557,768       8,885,986  
Amortization of net premiums and discounts on short-term investments
     2,891,356       3,399,860  
Amortization of revenue interest issuance cost
     80,693       78,242  
Depreciation and amortization expense
     2,818,092       2,074,183  
(Gain) loss on put/call liability
     (319,000 )     75,000  
Loss on disposal of property and equipment
     —       23,514  
Changes in assets and liabilities:
                
(Increase) decrease in accounts receivable
     (12,489,818 )     376,637  
Increase in prepaid expenses and other current assets
     (727,800 )     (3,648,754 )
(Increase) decrease in inventory held by the Company
     (19,582,404 )     823,951  
Decrease in inventory held by others
     293,054       111,871  
Decrease (increase) in non-current portion of deferred cost of license revenue
     495,000       (6,875,001 )
Decrease in other assets
     580       6,279  
Increase (decrease) in accounts payable, accrued expenses, other current liabilities
     16,731,204       (2,826,805 )
Increase in revenue interest liability interest payable
     337,487       48,675  
(Decrease) increase in non-current portion of deferred license revenue
     (7,071,428 )     107,642,856  
(Decrease) increase in deferred product revenue—Zanaflex tablets
     (505,677 )     335,887  
(Decrease) increase in deferred product revenue—Zanaflex Capsules
     (871,104 )     2,486,481  
Restricted cash
     (688 )     (2,860 )
Net cash (used in) provided by operating activities
     (20,802,949 )     51,549,121  
Cash flows from investing activities:
                
Purchases of property and equipment
     (2,207,442 )     (1,903,764 )
Purchases of intangible assets
     (6,893,914 )     —  
Purchases of short-term investments
     (217,862,168 )     (278,897,068 )
Proceeds from maturities of short-term investments
     276,250,000       224,650,000  
Net cash provided by (used in) investing activities
     49,286,476       (56,150,832 )
Cash flows from financing activities:
                
Proceeds from issuance of common stock and option exercises
     7,998,120       2,277,073  
Repayments of revenue interest liability
     (1,391,232 )     (1,580,300 )
Net cash provided by financing activities
     6,606,888       696,773  
Net increase (decrease) in cash and cash equivalents
     35,090,415       (3,904,938 )
Cash and cash equivalents at beginning of period
     47,314,412       29,612,916  
Cash and cash equivalents at end of period
   $ 82,404,827     $ 25,707,978  
Supplemental disclosure:
                
Cash paid for interest
     2,850,437       3,158,931  
 
See accompanying Unaudited Notes to Consolidated Financial Statements
 
3
 
 
 
 
 
 
ACORDA THERAPEUTICS, INC. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements
 
(unaudited)
 
(1) Organization and Business Activities
 
Acorda Therapeutics, Inc. (“Acorda” or the “Company”) is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the central nervous system (CNS).
 
The management of the Company is responsible for the accompanying unaudited interim consolidated financial statements and the related information included in the notes to the consolidated financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, including normal recurring adjustments necessary for the fair presentation of the Company’s financial position and results of operations and cash flows for the periods presented. Results of operations for interim periods are not necessarily indicative of the results to be expected for the entire year.
 
These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December 31, 2009 included in the Company’s Annual Report on Form 10-K for such year, as filed with the Securities and Exchange Commission (the “SEC”).
 
The Company finances its operations through a combination of issuance of equity securities, revenues from Zanaflex Capsules and Ampyra, loans, collaborations, and, to a lesser extent, grants. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed to fund its development and commercialization efforts. To the extent the Company’s capital resources are insufficient to meet future operating requirements, the Company will need to raise additional capital, reduce planned expenditures, or incur indebtedness to fund its operations. The Company may be unable to obtain additional debt or equity financing on acceptable terms, if at all. If adequate funds are not available, the Company may be required to curtail its sales and marketing efforts, delay, reduce the scope of or eliminate some of its research and development programs or obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain product candidates that it might otherwise seek to develop or commercialize independently.
 
(2) Summary of Significant Accounting Policies
 
Principles of Consolidation
 
The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America and include the results of operations of the Company and its majority owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
 
Use of Estimates
 
The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include research and development and share-based compensation accounting, which are largely dependent on the fair value of the Company’s equity securities. In addition, the Company recognizes Zanaflex revenue based on estimated prescriptions filled. The Company adjusts its Zanaflex inventory value based on an estimate of inventory that may be returned. Actual results could differ from those estimates.
 
Revenue Recognition
 
Zanaflex
 
The Company applies the revenue recognition guidance in Accounting Standards Codification (ASC) 605-15-25, which among other criteria requires that future returns can be reasonably estimated in order to recognize revenue. The amount of future tablet returns is uncertain due to generic competition and customer conversion to Zanaflex Capsules. The Company has accumulated some sales history with Zanaflex Capsules; however, due to existing and potential generic competition and customer conversion from Zanaflex tablets to Zanaflex Capsules, we do not believe we can reasonably determine a return rate at this time. As a result, the Company accounts for these product shipments using a deferred revenue recognition model. Under the deferred revenue model, the Company does not recognize revenue upon product shipment. For these product shipment s, the Company invoices the wholesaler, records deferred revenue at gross invoice sales price, and classifies the cost basis of the product held by the wholesaler as a component of inventory. The Company recognizes revenue when prescribed to the end-user, on a first-in first-out (FIFO) basis. The Company’s revenue to be recognized is based on (1) the estimated prescription demand, based on pharmacy sales for its products; and (2) the Company’s analysis of third-party information, including third-party market research data. The Company’s estimates are subject to the inherent limitations of estimates that rely on third-party data, as certain third-party information was itself in the form of estimates, and reflect other limitations. The Company’s sales and revenue recognition reflects the Company’s estimates of actual product prescribed to the end-user. The Company expects to be able to apply a more traditional revenue recognition policy such that revenue is recognized fo llowing shipment to the customer when it believes it has sufficient data to develop reasonable estimates of expected returns based upon historical returns and greater certainty regarding generic competition.
 
4
 
The Company’s net revenues represent total revenues less allowances for customer credits, including estimated discounts, rebates, and chargebacks. These allowances are recorded for cash consideration given by a vendor to a customer that is presumed to be a reduction of the selling prices of the vendor’s products or services and, therefore, should be characterized as a reduction of revenue when recognized in the vendor’s statement of operations. Adjustments are recorded for estimated chargebacks, rebates, and discounts. These allowances are established by management as its best estimate based on available information and are adjusted to reflect known changes in the factors that impact such allowances. Allowances for chargebacks, rebates and discounts are established based on the contractual terms with customers, ana lysis of historical levels of discounts, chargebacks and rebates, communications with customers and the levels of inventory remaining in the distribution channel, as well as expectations about the market for each product and anticipated introduction of competitive products. In addition, the Company records a charge to cost of goods sold for the cost basis of the estimated product returns the Company believes may ultimately be realized at the time of product shipment to wholesalers. The Company has recognized this charge at the date of shipment since it is probable that it will receive a level of returned products; upon the return of such product it will be unable to resell the product considering its expiration dating; and it can reasonably estimate a range of returns. This charge represents the cost basis for the low end of the range of the Company’s estimated returns. Product shipping and handling costs are included in cost of sales.
 
Ampyra
 
Ampyra is available only through a network of specialty pharmacy providers that provide the medication to patients by mail and Kaiser Permanente (“Kaiser”). Ampyra will not be available in retail pharmacies. The Company applies the revenue recognition guidance in Staff Accounting Bulletin (SAB) 104 and does not recognize revenue from product sales until there is persuasive evidence of an arrangement, delivery has occurred, the price is fixed and determinable, the buyer is obligated to pay the Company, the obligation to pay is not contingent on resale of the product, the buyer has economic substance apart from the Company, the Company has no obligation to bring about the sale of the product, the amount of returns can be reasonably estimated and collectability is reasonably assured. The Company recognizes product sales of Ampyra following shipment of product to a network of specialty pharmacy providers and Kaiser. As of September 30, 2010, inventory levels at specialty pharmacy providers that distribute Ampyra (excluding Kaiser) represented approximately two weeks of their anticipated usage. The specialty pharmacy providers and Kaiser are contractually obligated to hold no more than 30 days of inventory.
 
The Company’s net revenues represent total revenues less allowances for customer credits, including estimated rebates, discounts and returns. These allowances are recorded for cash consideration given by a vendor to a customer that is presumed to be a reduction of the selling prices of the vendor’s products or services and, therefore, are characterized as a reduction of revenue. At the time product is shipped to specialty pharmacies and Kaiser, an adjustment is recorded for estimated rebates, discounts and returns. These allowances are established by management as its best estimate based on available information and will be adjusted to reflect known changes in the factors that impact such allowances. Allowances for rebates, discounts and returns are established based on the contractual terms with customers, communication s with customers and the levels of inventory remaining in the distribution channel, as well as expectations about the market for the product and anticipated introduction of competitive products.  Product shipping and handling costs are included in cost of sales.
 
Based on the Company’s specialty distribution model where it sells to only 12 specialty pharmacies and Kaiser, the inventory and prescription data it receives from these distributors, and returns experience of other specialty products with similar selling models, the Company has been able to make a reasonable estimate for product returns. At September 30, 2010, inventory levels at the specialty pharmacies (excluding Kaiser) represented approximately two weeks of their anticipated usage. The specialty pharmacy providers and Kaiser have contractually agreed to hold no more than 30 days inventory. The Company will accept returns of Ampyra for two months prior to and six months after the product expiration date. The Company will provide a credit for such returns to customers with whom we have a direct relationship. Once product is prescribed, it cannot be returned. The Company does not exchange product from inventory for the returned product.
5
 
Milestones and royalties

Revenue from milestones is recognized when earned, as evidenced by written acknowledgement from the other party to a contract, provided that (i) the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, and the Company has no further performance obligations relating to that event, and (ii) collectability is reasonably assured. If these criteria are not met, the milestone payment is recognized over the remaining period of our performance obligations under the arrangement. Royalties are recognized as earned in accordance with the terms of various research and collaboration agreements.

Collaborations
 
The Company recognizes collaboration revenues and expenses by analyzing each element of the agreement to determine if it shall be accounted for as a separate element or single unit of accounting. If an element shall be treated separately for revenue recognition purposes, the revenue recognition principles most appropriate for that element are applied to determine when revenue shall be recognized. If an element shall not be treated separately for revenue recognition purposes, the revenue recognition principles most appropriate for the bundled group of elements are applied to determine when revenue shall be recognized. Payments received in excess of revenues recognized are recorded as deferred revenue until such time as the revenue recognition criteria have been met.
 
Ampyra Inventory
 
Prior to regulatory approval of Ampyra, the Company incurred expenses for the manufacture of bulk, unpackaged product of Ampyra that ultimately became available to support the commercial launch of this drug candidate. Until the necessary initial regulatory approval was received, we charged all such amounts to research and development expenses as there was no alternative future use prior to regulatory approval. As a result, our initial sales of Ampyra will result in higher gross margins than if the inventory costs had not previously been expensed. Upon regulatory approval of Ampyra, the Company began capitalizing the commercial inventory costs associated with manufacturing with Elan and its second manufacturer, Patheon.
 
Concentration of Risk
 
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of investments in cash and cash equivalents, restricted cash and accounts receivable. The Company maintains cash and cash equivalents and restricted cash with approved financial institutions. The Company is exposed to credit risks and liquidity risks in the event of default by the financial institutions or issuers of investments in excess of FDIC insured limits. The Company performs periodic evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any institution.
 
Segment Information
 
The Company is managed and operated as one business. The entire business is managed by a single management team that reports to the chief executive officer. The Company does not operate separate lines of business with respect to any of its product candidates. Accordingly, the Company does not prepare discrete financial information with respect to separate product candidates or by location and does not have separately reportable segments.
 
(3) Share-based Compensation
 
During the three-month periods ended September 30, 2010 and 2009, the Company recognized share-based compensation expense of $4.8 million and $3.2 million, respectively. During the nine-month periods ended September 30, 2010 and 2009, the Company recognized share-based compensation expense of $12.6 million and $8.9 million, respectively. Activity in options and restricted stock during the nine-month period ended September 30, 2010 and related balances outstanding as of that date are reflected below. The weighted average fair value per share of options granted to employees for the three-month periods ended September 30, 2010 and 2009 were approximately $19.75 and $16.75, respectively.  The weighted average fair value per share of options granted to employees for the nine-month periods ended September 30, 2010 and 2009 were approximately $19.37 and $17.59, respectively.
 
6
 
The following table summarizes share-based compensation expense included within our consolidated statements of operations:
 
 
For the three-month
  
For the nine-month
  
 
period ended September 30,
  
period ended September 30,
  
(In millions)
2010
  
2009
  
2010
  
2009
  
                         
Research and development
   $ 1.4     $ 0.9     $ 3.6     $ 2.5  
Selling, general and administrative
     3.4       2.3       9.0       6.4  
 Total
   $ 4.8     $ 3.2     $ 12.6     $ 8.9  

 
A summary of share-based compensation activity for the nine-month period ended September 30, 2010 is presented below:
 
Stock Option Activity
 
   
Number of Shares
    
Weighted Average
Exercise Price
    
Weighted Average
Remaining
Contractual
Term
    
Intrinsic Value
  
Balance at January 1, 2010
     3,711,778     $ 15.25              
Granted
     1,098,169       32.61              
Cancelled
     (88,289 )     24.89              
Exercised
     (623,294 )     12.92              
Balance at September 30, 2010
     4,098,364     $ 20.05       7.1     $ 53,896,144  
Vested and expected to vest at September 30, 2010
     4,008,207     $ 19.83       7.1     $ 53,588,108  
Vested and exercisable at September 30, 2010
     2,278,343     $ 14.12       5.9     $ 43,143,212  
 
Restricted Stock Activity
 
Restricted Stock
  
Number of Shares
  
Nonvested at January 1, 2010
     203,776  
Granted
     334,178  
Vested
     (10,000 )
Forfeited
     (12,185 )
Nonvested at September 30, 2010
     515,769  
 
As of September 30, 2010, there was $37.0 million of total unrecognized compensation costs related to unvested options and restricted stock awards that the Company expects to recognize over a weighted average period of approximately 2.6 years.
 
 
(4) Earnings Per Share
 
The following table sets forth the computation of basic and diluted earnings per share for the three and nine-month periods ended September 30, 2010 and 2009:
7



 
   
Three-month
period ended
September 30,
2010
    
Three-month
period ended
September 30,
2009
    
Nine-month
period ended
September 30,
2010
    
Nine-month
period ended
September 30,
2009
  
Basic and diluted
                        
Net income (loss)
   $ 12,437,191     $ (19,429,807 )   $ (15,440,264 )   $ (61,466,881 )
Weighted average common shares outstanding used in computing net income (loss) per share—basic
     38,449,917       37,749,920       38,260,608       37,700,747  
Plus: net effect of dilutive stock options and restricted common shares
     1,537,727       —       —       —  
Weighted average common shares outstanding used in computing net income (loss) per share—diluted
     39,987,644       37,749,920       38,260,608       37,700,747  
Net income (loss) per share—basic
   $ 0.32     $ (0.51 )   $ (0.40 )   $ (1.63 )
Net income (loss) per share—diluted
   $ 0.31     $ (0.51 )   $ (0.40 )   $ (1.63 )

 
The difference between basic and diluted shares is that diluted shares include the dilutive effect of the assumed exercise of outstanding securities. The Company’s stock options and unvested shares of restricted common stock could have the most significant impact on diluted shares.
 
Securities that could potentially be dilutive are excluded from the computation of diluted earnings per share when a loss from continuing operations exists or when the exercise price exceeds the average closing price of the Company’s common stock during the period, because their inclusion would result in an anti-dilutive effect on per share amounts.
 
For the three months ended September 30, 2010 and 2009, options to purchase 2,841,156 shares and 3,720,272 shares, respectively, of common stock that could potentially dilute basic earnings per share in the future were excluded from the calculation of diluted earnings per share as their effect would have been anti-dilutive because their exercise price was in excess of the average closing price of the common stock during the period. For the nine months ended September 30, 2010 and 2009, options to purchase 4,080,052 shares and 3,562,639 shares, respectively, of common stock that could potentially dilute basic earnings per share in the future were excluded from the calculation of diluted earnings per share as their effect would have been anti-dilutive.
 
For the three months ended September 30, 2010 and 2009, 371,945 and 332,074 shares, respectively, of unvested restricted stock that could potentially dilute basic earnings per share in the future were excluded from the calculation of diluted earnings per common share as their effect would have been anti-dilutive. For the nine months ended September 30, 2010 and 2009, 406,847 and 287,803 shares, respectively, of unvested restricted stock that could potentially dilute basic earnings per share in the future were excluded from the calculation of diluted earnings per common share as their effect would have been anti-dilutive.
 
(5) Income Taxes
 
The Company had available net operating loss carryforwards (NOL) of approximately $270.1 million and $249.5 million as of September 30, 2010 and December 31, 2009, respectively, for federal and state income tax purposes, which are available to offset future federal and state taxable income, if any, and expire between 2019 and 2030. The Company also has research and development tax credit carryforwards of approximately $1.6 million as of both September 30, 2010 and December 31, 2009, for federal income tax reporting purposes that are available to reduce federal income taxes, if any, and expire in future years beginning in 2020.
 
At September 30, 2010 and December 31, 2009, the Company had a deferred tax asset of $160.7 million and $147.2 million, respectively, offset by a full valuation allowance. Since inception, the Company has incurred substantial losses and expects to incur substantial losses in future periods. The Tax Reform Act of 1986 (the “Act”) provides for a limitation of the annual use of NOL and research and development tax credit carryforwards (following certain ownership changes, as defined by the Act) that could significantly limit the Company’s ability to utilize these carryforwards. The Company has experienced various ownership changes as a result of past financings. Accordingly, the Company’s ability to utilize the aforementioned carryforwards may be lim ited. Additionally, because U.S. tax laws limit the time during which these carryforwards may be applied against future taxes, the Company may not be able to take full advantage of these attributes for federal income tax purposes. Because of the above mentioned factors, the Company has not recognized its gross deferred tax assets as of and for all periods presented. As of September 30, 2010, management believes that it is more likely than not that the gross deferred tax assets will not be realized based on future operations and reversal of deferred tax liabilities. Accordingly, the Company has provided a full valuation allowance against its gross deferred tax assets and no tax benefit has been recognized relative to its pretax losses.
 
8
 
(6) Fair Value Measurements
 
The following table presents information about our assets and liabilities measured at fair value on a recurring basis as of September 30, 2010 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability. The Company’s Level 1 assets consist of time deposits and investments in a Treasury money market fund and high-quality government bonds. The Company’s Level 3 liability repres ents our put/call liability related to the Paul Royalty Fund (PRF) transaction. No changes in valuation techniques or inputs occurred during the three months ended September 30, 2010. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the nine-month period ended September 30, 2010.
 
   
Level 1
    
Level 2
    
Level 3
  
Assets Carried at Fair Value:
                  
Cash equivalents
   $ 76,104,201     $ —     $ —  
Short-term investments
     163,412,360       —       —  
Liabilities Carried at Fair Value:
                        
Put/call liability
     —       —       318,500  
 
The following table presents additional information about assets and/or liabilities measured at fair value on a recurring basis and for which the Company utilizes Level 3 inputs to determine fair value.
 
   
Balance as of
December 31, 2009
    
Realized (gains)
losses included
in net loss
    
Unrealized
(gains) losses included
in other
comprehensive
loss
    
Balance as of
September 30,
2010
  
Liabilities Carried at Fair Value:
                        
Put/call liability
   $ 637,500     $ (319,000 )   $ —     $ 318,500  

 
We estimate the fair value of our put/call liability using a discounted cash flow valuation technique. Using this approach, expected future cash flows are calculated over the expected life of the PRF agreement, are discounted to a single present value and then exercise scenario probabilities are applied. Some of the more significant assumptions made in the present value calculations include (i) the estimated Zanaflex revenue forecast and (ii) the likelihood of put/call exercise trigger events. Realized gain and losses are included in sales, general and administrative expenses.
 
Our put/call liability has been classified as a Level 3 asset as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market due to the lack of trading in the security. If different assumptions were used for the various inputs to the valuation approach including, but not limited to, assumptions involving the estimated Zanaflex revenue forecast and the likelihood of trigger events, the estimated fair value of these investments could be significantly higher or lower than the fair value we determined. We may be required to record losses in future periods.
 
(7) Short-Term Investments
 
The Company has determined that all of its short-term investments are classified as available-for-sale. Available-for-sale securities are carried at fair value with interest on these securities included in interest income. Available-for-sale securities consisted of the following:
9



 
   
Amortized
Cost
    
Gross
unrealized
gains
    
Gross
unrealized
losses
    
Estimated
fair
value
  
September 30, 2010
                        
US Treasury bonds
   $ 163,390,222     $ 24,182     $ (2,044 )   $ 163,412,360  
December 31, 2009
                                
US Treasury bonds
     224,669,409       126,169       (17,556 )     224,778,023  
 
The contractual maturities of available-for-sale debt securities at September 30, 2010 and December 31, 2009 are within one year. The Company has determined that there were no other-than-temporary declines in the fair values of its short term investments as of September 30, 2010. Short-term investments with maturity of three months or less from date of purchase have been classified as cash equivalents, and amounted to $76,104,201 and $43,471,757 as of September 30, 2010 and December 31, 2009, respectively.
 
(8) Biogen Collaboration Agreement
 
On June 30, 2009, the Company entered into an exclusive collaboration and license agreement with Biogen Idec International GmbH (Biogen Idec) to develop and commercialize Ampyra (known as fampridine outside the U.S.) in markets outside the United States (the “Collaboration Agreement”). Under the Collaboration Agreement, Biogen Idec was granted the exclusive right to commercialize Ampyra and other products containing aminopyridines developed under that agreement in all countries outside of the United States, which grant includes a sublicense of the Company’s rights under an existing license agreement between the Company and Elan Pharma International Limited, a subsidiary of Elan Corporation plc (Elan). Biogen Idec will have responsibility for regulatory activities and future clinical development of Am pyra in ex-U.S. markets worldwide. The Company also entered into a related supply agreement with Biogen Idec (the “Supply Agreement”), pursuant to which the Company will supply Biogen Idec with its requirements for the licensed products through the Company’s existing supply agreement with Elan.
 
Under the Collaboration Agreement, the Company was entitled to an upfront payment of $110.0 million as of June 30, 2009, which was received on July 1, 2009, and will be entitled to receive additional payments of up to approximately $400 million based on the successful achievement of future regulatory and sales milestones. Due to the uncertainty surrounding the achievement of the future regulatory and sales milestones, these payments will not be recognized as revenue unless and until they are earned. The Company is not able to reasonably predict if and when the milestones will be achieved. Under the Collaboration Agreement, Biogen Idec will be required to make double-digit tiered royalty payments to the Company on ex-U.S. sales. In addition, the consideration that Biogen Idec will pay for licensed products under t he Supply Agreement will reflect the price owed to the Company’s suppliers under its supply arrangements with Elan or other suppliers for ex-U.S. sales, including manufacturing costs and royalties owed. The Company and Biogen Idec may also carry out future joint development activities regarding licensed product under a cost-sharing arrangement. Under the terms of the Collaboration Agreement, the Company, in part through its participation in joint committees with Biogen Idec, will participate in overseeing the development and commercialization of Ampyra and other licensed products in markets outside the United States pursuant to that agreement. Acorda will continue to develop and commercialize Ampyra independently in the United States.
 
As of June 30, 2009, the Company recorded a license receivable and deferred revenue of $110.0 million for the upfront payment due to the Company from Biogen Idec under the Collaboration Agreement. Also, as a result of such payment to Acorda, a payment of $7.7 million became payable by Acorda to Elan and was recorded as a cost of license payable and deferred expense. The payment of $110.0 million was received from Biogen Idec on July 1, 2009 and the payment of $7.7 million was made to Elan on July 7, 2009.
 
The Company considered the following deliverables with respect to the revenue recognition of the $110.0 million upfront payment:  (1) the license to use the Company’s technology, (2) the Collaboration Agreement to develop and commercialize licensed product in all countries outside the U.S., and (3) the supply agreement. The Company has determined that the identified deliverables would have no value on a standalone basis if they were sold separately by a vendor and the customer could not resell the delivered items on a standalone basis, nor does the Company have objective and reliable evidence of fair value for the deliverables. Accordingly, the deliverables are treated as one unit of accountin g.  As a result, the Company will recognize the non-refundable upfront payment from Biogen Idec as revenue and the associated payment to Elan as expense ratably over the estimated term of regulatory exclusivity for the licensed products under the Collaboration Agreement as we had determined this was the most probable expected benefit period. The Company recognized $7.1 million in license revenue, a portion of the $110.0 million received from Biogen Idec and $495,000 in cost of license revenue, a portion of the $7.7 million paid to Elan during the nine-month period ended September 30, 2010. The Company currently estimates the recognition period to be approximately 12 years from the date of the Collaboration Agreement.
 
10
 
(9) Commitments and Contingencies
 
A summary of the Company’s commitments and contingencies was included in the Company’s Annual Report on Form 10-K for the twelve-month period ended December 31, 2009. The Company’s long-term contractual obligations include commitments and estimated purchase obligations entered into in the normal course of business.
 
The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when information available indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated. The Company believes that the ultimate resolution of these matters will not have a material adverse effect on the Company’s financial condition or liquidity. However, adjustments, if any, to the Company’s estimates could be material to operating results for the periods in which adjustments to the liability are recorded.
 
(10) Intangible Assets
 
The Company acquired all of Elan's U.S. sales, marketing and distribution rights to Zanaflex Capsules and Zanaflex tablets in July 2004 for $2.0 million plus $675,000 for finished goods inventory. The Company was also responsible for up to $19.5 million in future contingent milestone payments based on cumulative gross sales of Zanaflex tablets and Zanaflex Capsules. As of December 31, 2009, the Company made $19.5 million of these milestone payments which were recorded as intangible assets in the consolidated financial statements.
 
In connection with this transaction, the Company acquired the rights to the trade name "Zanaflex®", one issued U.S. patent and two patent applications related to Zanaflex Capsules, and the remaining tablet inventory on hand with Elan. Additionally, the Company assumed Elan's existing contract with Novartis to manufacture Zanaflex tablets and entered into a separate contract with Elan to manufacture Zanaflex Capsules. The Company separately launched Zanaflex Capsules in April 2005. The Company did not acquire any receivables, employees, facilities or fixed assets. The Company allocated, on a relative fair value basis, the initial and milestone payments made to Elan to the assets acquired, principally the Zanaflex trade name and the capsules patent. There is no expected residual value of these intangible assets. The Company amort izes the allocated fair value of the trade name and patent over their estimated future economic benefit to be achieved. The Zanaflex trade name was fully amortized as of December 31, 2008.
 
On January 22, 2010, the Company received marketing approval from the FDA for Ampyra triggering two milestone payments of $2.5 million to Elan and $750,000 to Rush-Presbyterian St. Luke’s Medical Center (Rush).  As of September 30, 2010, the Company made or accrued these milestone payments totaling $3.25 million and they were recorded as intangible assets in the consolidated financial statements. The payment to Elan was made during the three-months ended June 30, 2010.
 
In 1990, Elan licensed from Rush know-how relating to dalfampridine (4-aminopyridine, 4-AP, the formulation used in Ampyra), for the treatment of MS. The Company subsequently licensed this know-how from Elan. In September 2003, the Company entered into an agreement with Rush and Elan terminating the Rush license to Elan and providing for mutual releases. The Company also entered into a license agreement with Rush in 2003 in which Rush granted the Company an exclusive worldwide license to its know-how relating to dalfampridine for the treatment of MS. Rush has also assigned to the Company its Orphan Drug Designation for dalfampridine for the relief of symptoms of MS.
 
The Company agreed to pay Rush a license fee, milestone payments of up to $850,000 and royalties based on net sales of the product for neurological indications. As of December 31, 2009, the Company had made an aggregate of $100,000 in payments under this agreement.  The FDA approval of Ampyra triggered the final milestone of $750,000 which was paid during the three-months ended March 31, 2010.  As of September 30, 2010, the Company made or accrued royalty payments totaling $1.6 million.
 
11
 
In August 2003, the Company entered into an Amended and Restated License Agreement with the Canadian Spinal Research Organization (CSRO). Under this agreement, the Company was granted an exclusive and worldwide license under certain patent assets and know-how of CSRO relating to the use of dalfampridine in the reduction of chronic pain and spasticity in a spinal cord injured subject.  The agreement required the Company to pay to CSRO royalties based on a percentage of net sales of any product incorporating the licensed rights, including royalties on the sale of Ampyra and on the sale of dalfampridine for any other indication. No royalty payments have been made to date. During the three-month period ended March 31, 2010, the Company purchased CSRO’s rights to all royalty payments under the agreement with CSRO for $3.0 million.  This payment was recorded as an intangible asset in the consolidated financial statements.
 
Intangible assets also include certain website development costs which have been capitalized. The Company has developed several websites, each with its own purpose, including the general corporate website, product information websites and websites focused on the MS community.
 
The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its intangible assets may warrant revision or that the carrying value of these assets may be impaired. The Company evaluates the realizability of its intangible assets based on profitability and cash flow expectations for the related assets. As of September 30, 2010, the Company does not believe that there are any facts or circumstances that would indicate a need for changing the estimated useful life of the Zanaflex or Ampyra patents.
 
Intangible assets consisted of the following:
 
   
September 30,
2010
    
December 31,
2009
  
Estimated
remaining
useful lives as of
September 30, 2010
Zanaflex patents
   $ 19,350,000     $ 19,350,000  
11 years
Zanaflex trade name
     2,150,000       2,150,000  
0 years
Ampyra milestones
     3,250,000       —  
7 years
CSRO Royalty Buyout
     3,000,000       —  
 7 years
Website development costs(1)
     2,871,195       1,444,749  
3 years
Website development costs – in process websites (2)
     —       782,531  
3 years
      30,621,195       23,727,280    
Less accumulated amortization
     8,607,764       6,578,649    
    $ 22,013,431     $ 17,148,631    

 
(1)  Represents capitalized website development costs for fully developed and launched websites.
 
 
(2)  Represents websites in development which had not been completed and therefore had not been launched as of December 31, 2009.
 
The Company recorded $2,029,115 and $794,513 in amortization expense related to these intangible assets in the nine-month periods ended September 30, 2010 and 2009, respectively.
 
Estimated future amortization expense for these intangible assets subsequent to December 31, 2009 for the next five years is as follows:
 
2010
   $ 2,700,347  
2011
     3,127,212  
2012
     2,801,439  
2013
     2,410,262  
2014
     2,182,817  
    $ 13,222,077  

 
12


Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
The following discussion and analysis of our consolidated financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q.
 
Background
 
Since we commenced operations in 1995, we have devoted substantially all of our resources to the identification, development and commercialization of novel therapies that improve neurological function in people with MS and other neurological disorders. Ampyra, the first product for which we completed clinical development, was approved by the FDA in January 2010 for the improvement of walking in people with MS. This was demonstrated by an increase in walking speed. To our knowledge, Ampyra is the first and only product approved for this indication. Efficacy was shown in people with all four major types of MS (relapsing remitting, secondary progressive, progressive relapsing and primary progressive).  Ampyra was made commercially available in the U.S. in March 2010.  Gross sales of Ampyra were $52.6 million for the quarter ended September 30, 2010.
 
Our other marketed drug, Zanaflex Capsules, which we began marketing in 2005, is FDA-approved as a short-acting drug for the management of spasticity. Gross sales of Zanaflex Capsules, together with the generic version of tablets sold by us, were $58.3 million in 2009 and $41.1 million for the nine months ended September 30, 2010.  We expect that our gross sales of Zanaflex Capsules for 2010 will decline, principally due to increasing managed care pressure, among other factors.  Managed care organizations have increasingly established plans and programs to drive utilization of low-cost generic tizanidine tablets over higher-cost Zanaflex Capsules by making it more difficult for patients to obtain Zanaflex Capsules through restrictions and higher out-of-pocket (co-pay) costs. There was a 9% price increase on Zanaf lex Capsules and tablets effective November 1, 2010.
 
Ampyra is being marketed in the U.S. through our own specialty sales force and commercial infrastructure, which is also responsible for sales and marketing of Zanaflex Capsules. We completed the expansion of our sales force in March and currently have approximately 100 sales representatives in the field calling on a priority target list of approximately 10,000 physicians, which we expanded from our original priority target list of 5,500.  We also have established teams of Regional Scientific Managers and Managed Markets representatives who provide information on Ampyra to physicians and payors.  As of September 30, 2010, approximately 6,300 healthcare professionals had written at least one prescription for Ampyra.
 
Ampyra is available only through a network of specialty pharmacy providers that provide the medication to patients by mail and Kaiser Permanente (Kaiser), and is supported by Ampyra Patient Support Services (APSS), a dedicated resource for healthcare providers and people with MS.  This distribution process is well established within the MS community, and physicians and patients are familiar with this model.  Prior to the launch of Ampyra, we contracted with a third party organization with extensive experience in coordinating patient benefits to run APSS.  The customer care agents at Ampyra Patient Support Services are responsible for helping healthcare professionals process prescriptions, working with insurance carriers to facilitate coverage, and directing patients to available co-pay and patient assis tance programs.  The process begins when a prescription is submitted by a physician to APSS.  Once this process is completed, the prescription is sent to a specialty pharmacy, which confirms the benefits and mails the prescription directly to the patient. In some cases, the specialty pharmacy rather than APSS performs the benefits investigation.
 
A prescription request backlog was experienced at APSS early in the launch due to pent-up demand, and we implemented process improvements and staffing adjustments to address the backlog.  We continued to fill the backlog during the quarter ended June 30, 2010, and it was eliminated by the end of the quarter. Third quarter sales were significantly impacted by the large backlog of prescription requests that were submitted earlier in the year and were not all filled until the third quarter. This backlog was eliminated in the third quarter, and fourth quarter sales may be lower than third quarter sales. Processing of most incoming requests for prescriptions now begins within 24 hours of receipt. Patients will still experience a range of times to receive their first shipment based on their insurance requirements. As with any ne w prescription product, patients who are members of benefit plans that have restrictive prior authorizations may experience delays in receiving their prescription.
 
As of September 30, 2010, approximately 31,000 people with MS had filled a prescription for Ampyra, representing almost 8% of all MS patients in the U.S.  As of September 30, 2010, the rate of first refill was 67%, based on a weighted average from a cohort of approximately 17,500 patients who received an initial one-month prescription in March through August.  Approximately 85% to 90% of total prescriptions written have been for a one month supply, with most of the balance being for three months. Currently, approximately 10% of shipped product is for no-cost use by patients enrolled in the Ampyra patient assistance program.
 
13
 
 
Our managed markets representatives continue to meet with payors to provide information on Ampyra and discuss patient access. As of September 30, 2010, approximately 75% of commercially-insured individuals had no or limited prior authorizations (PAs) for Ampyra. Limited PAs are defined as those that require only an MS diagnosis, documentation of no contraindications, and/or simple documentation that the patient has walking impairment; such documentation may include a Timed 25-Foot Walk (T25W) test.  Approximately 20% of commercially-insured individuals are subject to more restrictive PAs, which may include requirements for multiple timed walk tests and/or EDSS (Expanded Disability Status Scale) score requirements to initiate therapy, and/or objective measures of ambulation improvement to reauthorize Ampyra therapy. &# 160;We estimate that approximately 5% of commercially-insured individuals are currently blocked from receiving reimbursement for Ampyra.  Access figures have been calculated based on the number of pharmacy lives reported by commercial healthcare plans.
 
As of September 30, 2010, inventory levels at the specialty pharmacy providers that distribute Ampyra (does not include Kaiser) was approximately two-weeks.  The specialty pharmacy providers and Kaiser are contractually obligated to hold no more than 30 days of inventory.
 
The FDA granted Ampyra orphan drug status, which will provide seven years of market exclusivity for the drug. In addition, we have issued patents that cover the formulation and use of Ampyra. We filed for patent term extension for Ampyra pursuant to the provisions of the Hatch-Waxman Act that allows for up to five additional years of patent protection based on the development timeline of a drug. Although we have applied to extend both Ampyra patents listed in the FDA Orange Book, we will ultimately need to select only one patent for extension, if granted. We received non-final rejection letters from the U.S. Patent and Trademark Office (USPTO) on two patent applications for Ampyra filed in late 2004 and early 2005. We have until March17, 2011 and November 25, 2010, respectively, to res pond to the letters.
 
In October 2010, the European Patent Office (EPO) posted a “Communication of Intent to Grant a Patent” for a patent we submitted with “composition for use” and other use claims directed to sustained release aminopyridine compositions for, among other things, increased walking speed, improving lower extremity muscle strength, or improving lower extremity muscle tone, in patients with MS.  A corresponding patent is currently under review by the USPTO.  The USPTO operates independently of the EPO, and the EPO’s decision should not be taken to indicate the outcome for the U.S. patent.
 
In June 2009, we entered into the Collaboration Agreement with Biogen Idec. In January 2010, Biogen Idec announced that it submitted a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) and a New Drug Submission (NDS) to Health Canada for Ampyra, which is known outside the U.S. as fampridine.
 
We have three preclinical programs focused on novel approaches to repair damaged components of the CNS. We believe all of our preclinical programs—neuregulins, remyelinating antibodies and chondroitinase—have broad applicability and have the potential to be first-in-class therapies. While these programs have initially been focused on MS and spinal cord injury (SCI), we believe they may be applicable across a number of CNS disorders, including stroke and traumatic brain injury, because many of the mechanisms of tissue damage and repair are similar. In addition, we believe that these programs may have applicability beyond the nervous system, including in such fields as cardiology, oncology, orthopedics and ophthalmology.
 
In March 2010, we filed an Investigational New Drug (IND) application for GGF2 as a therapy for heart failure, and in April 2010 the IND became effective. In 2008, we began to work with a contract manufacturer to develop larger scale manufacturing and purification processes for GGF2, one of the neuregulins, under cGMP (good manufacturing practices) in preparation for our IND application to support human clinical trials for the treatment of heart failure. If we are able to establish a proof of concept for treatment of heart failure through human clinical studies, we may decide to develop the product either by entering into a partnership, most likely with a cardiovascular-focused company, or developing it on our own. We had originally targeted the start of a Phase 1 trial for mid-2010, but there was a delay in completing production of GGF2 clinical study medication due to deficiencies in the vial filling process. We have resolved the vial filling issues and we are now completing preparations for the start of the Phase 1 trial. We and Vanderbilt University received a $1 million Cardiac Translational Research Implementation Program (C-TRIP) grant from the National Heart, Lung and Blood Institute (NHLBI) to support research on GGF2. If these studies are successful, Acorda and Vanderbilt will be eligible to apply for a second phase C-TRIP grant of at least $7.5 million.  We began work with a contract manufacturer in 2009 to scale up manufacturing and purification processes for one of the remyelinating antibodies, rHIgM22, under cGMP for preparation for a future IND application.  These manufacturing processes have been completed and we are now in formal preclinical safety and toxicity studies.  If rHIgM22 proves to have a satisfactory precl inical safety profile, we expect to file an IND for the treatment of MS. We also are continuing research on the potential use of chondroitinases for the treatment of injuries to the brain and spinal cord.  The chondroitinase program is in the research and translational development phases and has not yet entered formal preclinical development.
 
14
 
We have had significant operating losses since inception as a result of our focus on clinical and preclinical development activities and our goal of building an internal sales, managed markets and marketing organization in the U.S. We may incur losses for the next several years as we continue to support an expanded sales and marketing organization and other activities in connection with the commercial launch of Ampyra and the advancement of our clinical and preclinical development programs. We expect that our sales and marketing, general and administrative expenses in 2010 will increase substantially over 2009 levels, primarily due to launch costs and sales and marketing expenses for Ampyra, including increases in sales, managed markets and medical affairs staff and the implementation of the work needed for FDA post-marketing study commitments for Ampyra. Due to the delay in production of GGF2 clinical study medication and the consequent delay in the start of the Phase 1 trial originally targeted for mid-2010, we expect that R&D expenses for 2010 will slightly decrease over total R&D expenses incurred in 2009.
 
We will also continue to explore opportunities to expand our pipeline through the potential in-licensing and/or acquisition of select products and technologies in neurology. We are interested in both clinical and commercial state products, with a particular focus on Phase 2 product candidates, although we are open to assessing compounds at other stages as well. We do not currently plan to acquire a marketed product for launch during the first year of Ampyra's commercial launch.
 
In August 2007, the Company received a Paragraph IV Certification Notice from Apotex Inc. advising that it had submitted an ANDA to the FDA seeking marketing approval for generic versions of Zanaflex Capsules.  In October 2007, the Company filed a lawsuit against Apotex Corp. and Apotex Inc. (collectively, Apotex) for patent infringement in relation to the filing of the ANDA by Apotex. The defendants answered the Company’s complaint, asserting patent invalidity and non-infringement and counterclaiming, seeking a declaratory judgment of patent invalidity and non-infringement. The Company denied those counterclaims.  In March 2008, Apotex filed a motion, which the Company opposed, for partial judgment on the pleadings dismissing the Company’s request for relief on the ground that the case is “exceptional” under U.S.C. §§ 271(e)(4) or 285. The court ruled in the Company’s favor and denied Apotex’s motion in December 2008. Fact discovery in the case has been completed. On July 2, 2010, the U.S. District Court held a Markman hearing to determine the interpretation of certain terms in the Company’s Zanaflex Capsules patent that is at issue in this litigation. The Court ruled favorably on a number of those terms, and the case is proceeding, with expert discovery scheduled to be completed by early January 2011.
 
Our timely filing of a lawsuit against Apotex in October 2007 triggered an automatic stay on FDA approval of the Apotex ANDA for 30 months. That stay expired in March 2010. Consequently, Apotex will be able to receive FDA approval of its ANDA, if Apotex is able otherwise to satisfy FDA's review requirements for ANDAs, at which time it could begin selling a generic tizanidine hydrochloride capsule in competition with Zanaflex Capsules and Zanaflex tablets, even if our patent litigation remains pending. If Apotex begins selling its product before it is successful in challenging the validity, infringement, or enforceability of our patent, Apotex would be selling at the risk of our ultimately prevailing on our patent infringement claims and its being held liable for damages for patent infringement.
 
The Company accrues for amounts related to loss contingencies if it is probable that a liability has been incurred and the amount is reasonably estimable. As of September 30, 2010, there have been no accruals for loss contingencies aside from payments related to the litigation itself.
 

 
15

Results of Operations
 
Three-Month Period Ended September 30, 2010 Compared to September 30, 2009
 
Net Revenue
 
Total net revenues are summarized in the following table:
 
   
Three-month
period ended
September 30,
2010
    
Three-month
period ended
September 30,
2009
  
Gross product sales
            
Ampyra
   $ 52,584,094     $ —  
Zanaflex
     13,604,100       14,463,303  
Total gross product sales
     66,188,194       14,463,303  
                 
Discounts and allowances                                                        
                
Ampyra
     (2,846,762 )     —  
Zanaflex
     (2,076,533 )     (1,606,126 )
Total discounts and allowances
     (4,923,295 )     (1,606,126 )
                 
License revenue                                                        
                
Ampyra
     2,357,143       2,357,144  
Zanaflex
     —       —  
Total license revenue
     2,357,143       2,357,144  
                 
Total net revenue
   $ 63,622,042     $ 15,214,321  

 
Gross Product Sales
 
Ampyra
 
We recognize product sales of Ampyra following shipment of product to a network of specialty pharmacy providers and Kaiser.  We recognized revenue from the sale of Ampyra of $52.6 million for the three-month period ended September 30, 2010. Third quarter sales were significantly impacted by the large backlog of prescription requests that were submitted earlier in the year and were not all filled until the third quarter. This backlog was eliminated in the third quarter, and fourth quarter sales may be lower than third quarter sales.
 
 
16
 
Zanaflex
 
We recognize product sales of Zanaflex Capsules and Zanaflex tablets using a deferred revenue recognition model where shipments to wholesalers are recorded as deferred revenue and only recognized as revenue when end-user prescriptions of the product are reported. We recognized revenue from the sale of Zanaflex Capsules and Zanaflex tablets of $13.6 million for the three-month period ended September 30, 2010, as compared to $14.5 million for the three-month period ended September 30, 2009. The decrease was due to a decrease in both shipments and prescriptions due to increasing managed care pressure, among other factors, partially offset by a 15% price increase for Zanaflex Capsules effective February 1, 2010. As previously projected, we expect sales of Zanaflex Capsules to decline in 2010.
 
Discounts and Allowances
 
Ampyra
 
We recorded discounts and allowances of $2.8 million for the three-month period ended September 30, 2010 which consists of allowances for customer credits, including estimated rebates, discounts and returns. Discounts and allowances are recorded following shipment of Ampyra tablets to our network of specialty pharmacy providers and Kaiser.  Discounts and allowances may increase as a percentage of sales as we enter into managed care contracts in the future.
 
Zanaflex
 
We recorded discounts and allowances of $2.1 million for the three-month period ended September 30, 2010 as compared to $1.6 million for the three-month period ended September 30, 2009. Adjustments are recorded for estimated chargebacks, rebates, and discounts. Discounts and allowances for the three-month period ended September 30, 2010 consisted of $1.1 million in allowances for chargebacks and rebates $698,000 in fees for services payable to wholesalers, and $325,000 in cash discounts and patient program rebates. Discounts and allowances for the three-month period ended September 30, 2009 consisted of $597,000 in allowances for chargebacks and rebates, $785,000 in fees for services payable to wholesalers and $225,000 in cash discounts and patient program rebates.
 
Healthcare Reform
 
In March 2010, healthcare reform legislation was enacted in the U.S. This legislation contains several provisions that will affect our business. Although many provisions of the new legislation do not take effect immediately, several provisions became effective in the first quarter of 2010. We do not expect these 2010 changes to have a material impact on our discounts and allowances.
 
Beginning in 2011, the new law requires drug manufacturers to provide a 50% discount to Medicare beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part D coverage gap (i.e., the “donut hole”). Also, beginning in 2011, we will be assessed our share of a new fee (which will not be deductible for tax purposes) payable by all branded prescription drug manufacturers and importers. The manner in which this new legislation will be implemented is still being formulated; therefore, we cannot currently quantify the potential impact of this part of the legislation.
 
License Revenue
 
The Company recognized $2.4 million in license revenue related to the $110.0 million received from Biogen Idec in 2009 for the three-month periods ended September 30, 2010 and 2009.
 
Cost of Sales
 
Ampyra
 
We recorded cost of sales of $9.3 million for the three-month period ended September 30, 2010. Cost of sales for the three-month period ended September 30, 2010 consisted primarily of $8.0 million in inventory costs related to recognized revenues.  Our launch stock inventory was received in bulk form prior to regulatory approval; therefore, the manufacturing cost associated with this inventory was classified as research and development expense as there was no alternative future use prior to regulatory approval. This expensed inventory represented approximately 8% of the total cost basis of our launch stock inventory.  The remaining packaged portion of the inventory cost was received after regulatory approval and thus capitalized.  This reduction to our cost basis effectively reduced our cost of sales re lated to recognized revenues by approximately $683,000 for the three-month period ended September 30, 2010.  At September 30, 2010, we are carrying the launch inventory on our balance sheet with a reduction to the cost basis of approximately $191,000.  We expect our reduced cost basis inventory to be sold during the remainder of 2010.
 
Cost of sales for the three-month period ended September 30, 2010 also consisted of $1.0 million in royalty fees based on net sales, $225,000 in amortization of intangible assets, and $67,000 in period costs related to packaging, freight and stability testing. We expect cost of sales for the remainder for the year to be approximately 21% of net Ampyra sales.
 
17
 
 
Zanaflex
 
We recorded cost of sales of $2.3 million for the three-month period ended September 30, 2010 as compared to $2.6 million for the three-month period ended September 30, 2009. Cost of sales for the three-month period ended September 30, 2010 consisted of $1.2 million in inventory costs primarily related to recognized revenues, $799,000 in royalty fees based on net product shipments, $321,000 in amortization of intangible assets, which is unrelated to either the volume of shipments or the amount of revenue recognized, and $39,000 in period costs related to freight and stability testing. Cost of sales for the three-month period ended September 30, 2009 consisted of $1.4 million in inventory costs primarily related to recognized revenues, $878,000 in royalty fees based on net product shipments, $321,000 in amortizati on of intangible assets, which is unrelated to either the volume of shipments or the amount of revenue recognized, and $50,000 in period costs related to packaging, freight, and stability testing. Payments to and interest expense related to the PRF transaction discussed below in the section titled “Liquidity and Capital Resources” do not impact the Company’s cost of sales.
 
Research and Development
 
Research and development expenses for the three-month period ended September 30, 2010 were $8.0 million as compared to $8.2 million for the three-month period ended September 30, 2009, a decrease of approximately $200,000, or 3%. The decrease was primarily attributable to a decrease in regulatory expenses of $1.4 million which were incurred in 2009 related to NDA preparation and support for Ampyra.  The decrease was also related to a reduction in expenses allocated to research and development of $536,000 for Ampyra manufacturing and stability work that was classified as research and development for the three-month period ended September 30, 2009 as it was incurred prior to FDA approval of the drug.
 
The decrease in research and development expenses was partially offset by an increase of $967,000 for clinical costs associated with the close-out of our MS extension study sites and an increase of $711,000 related to work on one of our preclinical pipeline products, GGF2, including an increase in research and development staff and compensation to support this initiative.  The Company’s previous guidance was that R&D expenses would increase in 2010 over 2009. Due to the delay in production of GGF2 clinical study medication announced last quarter as a result of the deficiencies in the vial filling process and the consequent delay in the start of the Phase 1 trial originally targeted for mid-2010, we now expect that R&D expenses will slightly decrease in 2010 over 2009.
 
Selling, General and Administrative
 
Sales and marketing expenses for the three-month period ended September 30, 2010 were $19.0 million compared to $15.6 million for the three-month period ended September 30, 2009, an increase of approximately $3.4 million or 22%. This increase was primarily attributable to an increase in staff and compensation of $4.1 million resulting from the expansion of our field sales staff and the overall commercial department in order to support the launch of Ampyra offset by a decrease of $692,000 primarily in marketing and trade and distribution expenses related to Zanaflex Capsules.
 
General and administrative expenses for the three-month period ended September 30, 2010 were $11.6 million compared to $7.7 million for the three-month period ended September 30, 2009, an increase of approximately $3.9 million, or 51%. This increase was the result of an increase in general and administrative staff and compensation and other expenses of $1.9 million related to supporting the growth of the overall organization, an increase in costs related to Ampyra post-approval regulatory and manufacturing support expenses of $1.0 million, an increase in medical affairs expenses including educational programs of $655,000 and an increase in legal expenses of $275,000.
 
SG&A expenses decreased in the third quarter from the second quarter, but we still expect 2010 SG&A expenses to be substantially higher than in 2009.
 
Other Expense
 
Other expense was $825,000 for the three-month period ended September 30, 2010 compared to $429,000 for the three-month period ended September 30, 2009. Other expense for the three-month period ended September 30, 2010 consisted of interest expense principally related to the PRF revenue interest agreement of $944,000 and interest income of $111,000.  Other expense for the three-month period ended September 30, 2009 consisted of interest expense principally related to the PRF revenue interest agreement of $704,000 and interest income of $314,000.  The decrease in interest expense resulted from lower Zanaflex shipments for the three-month period ended September 30, 2010 as compared to the same period in 2009.  The decrease in interest income for the three-month period ended June 30, 2010 is due to a lower average interest rate than for the same period in 2009.
 
18

Nine-Month Period Ended September 30, 2010 Compared to September 30, 2009
 
Net Revenue
 
Total net revenues are summarized in the following table:
 

 
   
Nine-month
period ended
September 30,
2010
    
Nine-month
period ended
September 30,
2009
  
Gross product sales
            
Ampyra
   $ 85,738,013     $ —  
Zanaflex
     41,146,753       43,834,948  
Total gross product sales
     126,884,766       43,834,948  
                 
Discounts and allowances                                                        
                
Ampyra
     (4,979,432 )     —  
Zanaflex
     (4,771,762 )     (5,959,234 )
Total discounts and allowances
     (9,751,194 )     (5,959,234 )
                 
License revenue                                                        
                
Ampyra
     7,071,428       2,357,144  
Zanaflex
     —       —  
Total license revenue
     7,071,428       2,357,144  
                 
Total net revenue
   $ 124,205,000     $ 40,232,858  

 
Gross Product Sales
 
Ampyra
 
We recognize product sales of Ampyra following shipment of product to a network of specialty pharmacy providers and Kaiser.  We recognized revenue from the sale of Ampyra of $85.7 million for the nine-month period ended September 30, 2010. Third quarter sales were significantly impacted by the large backlog of prescription requests that were submitted earlier in the year and were not all filled until the third quarter. This backlog was eliminated in the third quarter, and fourth quarter sales may be lower than third quarter sales.
 
Zanaflex
 
We recognize product sales of Zanaflex Capsules and Zanaflex tablets using a deferred revenue recognition model where shipments to wholesalers are recorded as deferred revenue and only recognized as revenue when end-user prescriptions of the product are reported. We recognized revenue from the sale of Zanaflex Capsules and Zanaflex tablets of $41.1 million for the nine-month period ended September 30, 2010, as compared to $43.8 million for the nine-month period ended September 30, 2009. The decrease was due to a decrease in both shipments and prescriptions due to increasing managed care pressure, among other factors, partially offset by a 15% price increase for Zanaflex Capsules effective February 1, 2010. As previously projected, we expect sales of Zanaflex Capsules to decline in 2010.
 
Discounts and Allowances
 
Ampyra
 
We recorded discounts and allowances of $5.0 million for the nine-month period ended September 30, 2010, which consists of allowances for customer credits, including estimated rebates, discounts and returns. Discounts and allowances are recorded following shipment of Ampyra tablets to our network of specialty pharmacy providers and Kaiser.  Discounts and allowances may increase as a percentage of sales as we enter into managed care contracts in the future.
 
19
 
Zanaflex
 
We recorded discounts and allowances of $4.8 million for the nine-month period ended September 30, 2010 as compared to $6.0 million for the nine-month period ended September 30, 2009. Adjustments are recorded for estimated chargebacks, rebates, and discounts. Discounts and allowances for the nine-month period ended September 30, 2010 consisted of $1.8 million in fees for services payable to wholesalers, $1.9 million in allowances for chargebacks and rebates, and $1.0 million in cash discounts and patient program rebates. Discounts and allowances for the nine-month period ended September 30, 2009 consisted of $2.8 million in allowances for chargebacks and rebates which includes an adjustment of $865,000, $226,000 related to the first and second quarters of 2009 and $639,000 re lated to 2008. This adjustment resulted from a Department of Defense (DOD) regulation finalized during the three-month period ended March 31, 2009 which purports to require manufacturers to pay rebates to DOD on utilization distributed to TriCare beneficiaries through retail pharmacies retroactive to January 28, 2008. The application of the regulation is currently being challenged in court by a coalition representing a number of manufacturers.  Discounts and allowances for the nine-month period ended September 30, 2009 also included $2.0 million in fees for services payable to wholesalers and $1.1 million in cash discounts and patient program rebates.

Healthcare Reform
 
In March 2010, healthcare reform legislation was enacted in the U.S. This legislation contains several provisions that will affect our business. Although many provisions of the new legislation do not take effect immediately, several provisions became effective in the first quarter of 2010. We do not expect these 2010 changes to have a material impact on our discounts and allowances.
 
Beginning in 2011, the new law requires drug manufacturers to provide a 50% discount to Medicare beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part D coverage gap (i.e., the “donut hole”). Also, beginning in 2011, we will be assessed our share of a new fee (which will not be deductible for tax purposes) payable by all branded prescription drug manufacturers and importers. The manner in which this new legislation will be implemented is still being formulated; therefore we cannot currently quantify the potential impact of this part of the legislation.
 
License Revenue
 
The Company recognized license revenue related to the $110.0 million received from Biogen Idec in 2009 of $7.1 million for the nine-month period ended September 30, 2010 as compared to $2.4 million for the nine-month period ended September 30, 2009. The increase is the result of a full nine months of revenue in 2010 versus a single quarter in 2009.
 
Cost of Sales
 
Ampyra
 
We recorded cost of sales of $15.5 million for the nine-month period ended September 30, 2010. Cost of sales for the nine-month period ended September 30, 2010 consisted of $13.0 million in inventory costs related to recognized revenues. Our launch stock inventory was received in bulk form prior to regulatory approval; therefore the manufacturing cost associated with this inventory was classified as research and development expense as there was no alternative future use prior to regulatory approval. This expensed inventory cost represented approximately 8% of the total cost basis of our launch stock inventory. The remaining packaged portion of the inventory cost was received after regulatory approval and thus capitalized. This reduction to our cost basis effectively reduced our cost of sales related to recognized revenues by approxi mately $1.1 million for the nine-month period ended September 30, 2010.  At September 30, 2010, we are carrying the launch inventory on our balance sheet with a reduction to the cost basis of approximately $191,000.  We expect our reduced cost basis inventory to be depleted during the remainder of the year.
 
Cost of sales for the nine-month period ended September 30, 2010 also consisted of $1.7 million in royalty fees based on net sales, $564,000 in amortization of intangible assets, and $210,000 in period costs related to packaging, freight and stability testing. We expect cost of sales for the remainder for the year to be approximately 21% of net Ampyra sales.
 
Zanaflex
 
We recorded cost of sales of $7.1 million for the nine-month period ended September 30, 2010 as compared to $8.1 million for the nine-month period ended September 30, 2009. Cost of sales for the nine-month period ended September 30, 2010 consisted of $3.6 million in inventory costs primarily related to recognized revenues, $2.4 million in royalty fees based on net product shipments, $962,000 in amortization of intangible assets, which is unrelated to either the volume of shipments or the amount of revenue recognized, and $135,000 in period costs related to freight and stability testing. Cost of sales for the nine-month period ended September 30, 2009 consisted of $4.2 million in inventory costs primarily related to recognized revenues, $2.8 million in royalty fees based on net product shipments, $962,000 in amortizati on of intangible assets, which is unrelated to either the volume of shipments or the amount of revenue recognized, and $152,000 in period costs related to packaging, freight, and stability testing. Payments to and interest expense related to the PRF transaction discussed below in the section titled “Liquidity and Capital Resources” do not impact the Company’s cost of sales.
 
20
 
Research and Development
 
Research and development expenses for the nine-month period ended September 30, 2010 were $22.6 million as compared to $23.9 million for the nine-month period ended September 30, 2009, a decrease of approximately $1.3 million, or 5%. The decrease was primarily attributable to a decrease in regulatory expenses of $3.5 million which were incurred in 2009 related to NDA preparation and support.  The decrease was also related to a reduction in expenses allocated to research and development of $275,000 for Ampyra manufacturing and stability work that was classified as research and development for the three-month period ended September 30, 2009 prior to FDA approval of the drug.
 
The decrease in research and development expenses was partially offset by an increase of $2.2 million related to work on one of our preclinical pipeline products, GGF2, including an increase in overall research and development staff and compensation to support this initiative as well as two milestones expenses recorded during the three-month period ended March 31, 2010 which were related to the filing of the IND for GGF2. One was for $500,000 payable to Paion AG (formerly CeNeS) and one was for $150,000 payable to Brigham and Women’s Hospital. The overall decrease in research and development expense was also offset by a net increase of $274,000 for clinical costs associated with the close-out of our MS extension study sites. The Company’s previous guidance was that R&D expenses would increase in 2010 over 2009. Due t o the delay in production of GGF2 clinical study medication announced last quarter as a result of the deficiencies in the vial filling process and the consequent delay in the start of the Phase 1 trial originally targeted for mid-2010, we now expect that R&D expenses will slightly decrease in 2010 over 2009.
 
Selling, General and Administrative
 
Sales and marketing expenses for the nine-month period ended September 30, 2010 were $59.8 million compared to $44.1 million for the nine-month period ended September 30, 2009, an increase of approximately $15.7million or 36%. This increase was primarily attributable to an increase in staff and compensation of $12.0 million resulting from the expansion of our field sales staff and the overall commercial department in order to support the launch of Ampyra as well as an increase of $3.7 million in marketing, trade and distribution expenses, and various launch activities associated with Ampyra.
 
General and administrative expenses for the nine-month period ended September 30, 2010 were $31.3 million compared to $23.1 million for the nine-month period ended September 30, 2009, an increase of approximately $8.2 million, or 35%. This increase was the result of an increase in medical affairs expenses including educational programs of $3.2 million, an increase in general and administrative staff and compensation and other expenses of $2.8 million related to supporting the overall growth of the organization, and an increase in costs related to Ampyra post-approval regulatory and manufacturing support expenses of $2.4 million.  The overall increase in general and administrative expenses is offset by a decrease in legal expenses of $268,000.SG&A expenses decreased in the third quarter from the second qu arter, but we still expect 2010 SG&A expenses to be substantially higher than in 2009.
 
Other Expense
 
Other expense was $2.9 million for the nine-month period ended September 30, 2010 compared to $2.2 million for the nine-month period ended September 30, 2009, an increase of approximately $652,000 or 29%. The increase was primarily due to a decrease in interest income of $826,000 resulting from a lower average interest rate than for the same period in 2009. The decrease in interest income was partially offset by a $351,000 decrease in interest expense principally related to the PRF revenue interest agreement.
 
Liquidity and Capital Resources
 
We have incurred annual operating losses since inception and, as of September 30, 2010, we had an accumulated deficit of approximately $443.8 million. We have financed our operations primarily through private placements of our securities, public offerings of our common stock, our Collaboration and Licensing Agreement, sales of Zanaflex Capsules and Ampyra, and, to a lesser extent, from loans, government grants and our financing arrangement with PRF.
 
21
 
Financing Arrangements
 
In January 1997, Elan International Services, Ltd. (EIS) loaned us an aggregate of $7.5 million pursuant to two convertible promissory notes to partly fund our research and development activities. On December 23, 2005, EIS transferred these promissory notes to funds affiliated with Saints Capital. As of September 30, 2010, $5.0 million of these promissory notes plus $2.3 million of accrued interest was outstanding. The first of seven annual payments on this note is due on the one year anniversary after Ampyra approval on January 22, 2011.
 
On December 23, 2005, we entered into a revenue interest assignment agreement with PRF, a dedicated healthcare investment fund, pursuant to which we assigned to PRF the right to a portion of our net revenues (as defined in the agreement) from Zanaflex Capsules, Zanaflex tablets and any future Zanaflex products. To secure our obligations to PRF, we also granted PRF a security interest in substantially all of our assets related to Zanaflex. Our agreement with PRF covers all Zanaflex net revenues generated from October 1, 2005 through and including December 31, 2015, unless the agreement terminates earlier. In November 2006, we entered into an amendment to the revenue interest assignment agreement with PRF. Under the terms of the amendment, PRF paid us $5.0 million in November 2006 and an additional $5.0 millio n in February 2007 as our net revenues during the fiscal year 2006 exceeded $25.0 million. Under the terms of the amendment, we were required to pay PRF $5.0 million on December 1, 2009.  This payment was made.  We are required to make an additional $5.0 million payment on December 1, 2010.
 
Under the agreement and the amendment, PRF is entitled to the following portion of Zanaflex net revenues:
 
 
•
with respect to Zanaflex net revenues up to and including $30.0 million for each fiscal year during the term of the agreement, 15% of such net revenues;
 
 
•
with respect to Zanaflex net revenues in excess of $30.0 million but less than and including $60.0 million for each fiscal year during the term of the agreement, 6% of such net revenues; and
 
 
•
with respect to Zanaflex net revenues in excess of $60.0 million for each fiscal year during the term of the agreement, 1% of such net revenues.
 
Notwithstanding the foregoing, once PRF has received and retained payments under the agreement that are at least 2.1 times the aggregate amount PRF has paid us under the agreement, PRF will only be entitled to 1% of Zanaflex net revenues.  In connection with the transaction, we have a liability recorded, referred to as the revenue interest liability, of approximately $11.5 million. We impute interest expense associated with this liability using the effective interest rate method and record a corresponding accrued interest liability. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of Zanaflex sale s. We currently estimate that the imputed interest rate associated with this liability will be approximately 5.7%. Payments made to PRF as a result of Zanaflex sales levels reduce the accrued interest liability and the principal amount of the revenue interest liability.
 
Investment Activities
 
At September 30, 2010, cash and cash equivalents and short-term investments were approximately $245.8 million, as compared to $272.1 million at December 31, 2009. As of September 30, 2010, our cash and cash equivalents consist of highly liquid investments with original maturities of three months or less at date of purchase and consist of time deposits and investments in a Treasury money market fund and high-quality government bonds. Also, we maintain cash balances with financial institutions in excess of insured limits. We do not anticipate any losses with respect to such cash balances. As of September 30, 2010, our cash and cash equivalents were $82.4 million, as compared to $47.3 million as of December 31, 2009. Our short-term investments consist of US Treasury bonds with original maturities greater t han three months and less than one year. The balance of these investments was $163.4 million as of September 30, 2010, as compared to $224.8 million as of December 31, 2009.
 
Net Cash Used in Operations
 
Net cash (used in) provided by operations was $(20.8) million and $51.5 million for the nine-month period ended September 30, 2010 and 2009, respectively. Cash used in operations for the nine-month period ended September 30, 2010 was primarily attributable to a net loss of $15.4 million. It was also attributable to an increase in inventory held by the Company of $19.6 million primarily due to the purchase of Ampyra launch stock and additional Ampyra inventory to meet demand, an increase in accounts receivable of $12.5 million resulting from an increase in gross product sales for Ampyra, and a decrease in the non-current portion of deferred license revenue of $7.1 million due to the amortization of the upfront collaboration payment received during the three-month period ended September 30, 2009.  Cash used in oper ations for the nine-month period ended September 30, 2010 also included a net increase of $15.4 million due to changes in working capital items.  Cash used in operations was partially offset by a non-cash share-based compensation expense of $12.6 million, amortization of net premiums and discounts on short-term investments of $2.9 million, and depreciation and amortization of $2.8 million.
 
Cash provided by operations for the nine-month period ended September 30, 2009 was primarily attributable to a net loss of $61.5 million, an increase in the non-current portion of deferred cost of license revenue of $6.9 million, and a decrease of $2.3 million due to changes in working capital items. Cash used in operations for the nine-month period ended September 30, 2009, was partially offset by an increase in the non-current portion of deferred license revenue of 107.6 million, a non-cash share-based compensation expense of $8.9 million, a decrease in inventory held by the Company of $800,000, amortization of net premiums and discounts on short-term investments of $3.4 million, and depreciation and amortization of $2.1 million.
 
22
 
Net Cash Provided by Investing
 
Net cash provided by investing activities for the nine-month period ended September 30, 2010 was $49.3 million, primarily due to $276.3 million in proceeds of short-term investments which was partially offset by $217.9 million in purchases of short-term investments and $9.1 million in purchases of intangible assets and property and equipment.
 
Net Cash Provided by Financing
 
Net cash provided by financing activities for the nine-month period ended September 30, 2010 was $6.6 million due to $8.0 million in net proceeds from option exercises which was offset by $1.4 million in repayments to PRF.
 
Future Capital Needs
 
Our future capital requirements will depend on a number of factors, including the amount of revenue generated from sales of Zanaflex Capsules and Ampyra, the continued progress of our research and development activities, the timing and outcome of regulatory approvals, the amount and timing of milestone or other payments made or received under collaborative agreements, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights and the acquisition or in-licensing of new products or compounds and development costs relating to those new products or compounds. We may continue to incur losses from operations as we continue to support our sales and marketing infrastructure for the commercialization of Zanaflex Capsules and Ampyra, increase our efforts to s upport launch activities for Ampyra and its commercialization, and continue our clinical development and advance our preclinical programs.
 
To the extent our capital resources are insufficient to meet future operating requirements we will need to raise additional capital, reduce planned expenditures, or incur indebtedness to fund our operations. We may be unable to obtain additional debt or equity financing on acceptable terms, if at all. If adequate funds are not available, we may be required to curtail our sales and marketing efforts, delay, reduce the scope of or eliminate some of our research and development programs or obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.
 
 
Contractual Obligations and Commitments
 
A summary of our minimum contractual obligations related to our major outstanding contractual commitments is included in our Annual Report on Form 10-K for the year ended December 31, 2009. Our long-term contractual obligations include commitments and estimated purchase obligations entered into in the normal course of business. Under certain supply agreements and other agreements with manufacturers and suppliers, we are required to make payments for the manufacture and supply of our clinical and approved products. During the nine-month period ended September 30, 2010, commitments related to the purchase of inventory consistent with our normal course of business increased. As of September 30, 2010, we have inventory-related purchase commitments totaling approximately $21.4 million within the next year.
 
Under certain license agreements, we are required to pay royalties for the use of technologies and products in our R&D activities and in the commercialization of products. The amount and timing of any of the foregoing payments are not known due to the uncertainty surrounding the successful research, development and commercialization of the products.
 
Under certain license agreements, we are also required to pay license fees and milestones for the use of technologies and products in our R&D activities and in the commercialization of products. We have committed to make potential future milestone payments to third parties of up to approximately $32.1 million as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable only upon achievement of certain developmental, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of September 30, 2010, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the succ essful achievement of certain development, regulatory approval and commercial milestones. There is uncertainty regarding the various activities and outcomes needed to reach these milestones, and they may not be achieved.
 
 
23
 
Critical Accounting Policies and Estimates
 
The following discussion of critical accounting policies identifies the accounting policies that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. It is not intended to be a comprehensive list of all of our significant accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by generally accepted accounting principles, with no need for management’s judgment in their application. There are also areas in which the selection of an available alternative policy would not produce a materially different result. We have identified the following as our areas of critical accounting policies: sales r evenue recognition, inventory, research and development, income taxes, and share-based compensation.
 
Revenue Recognition
 
Zanaflex
 
We apply the revenue recognition guidance in Accounting Standards Codification (ASC) 605-15-25, which among other criteria requires that future returns can be reasonably estimated in order to recognize revenue. We have accumulated some sales history with Zanaflex Capsules; however, due to existing and potential generic competition and customer conversion from Zanaflex tablets to Zanaflex Capsules, we cannot reasonably determine a return rate at this time and, thus, are not permitted to recognize revenue based on shipments to wholesalers.  As a result, we account for sales of these products using a deferred revenue recognition model. We continue to accumulate data and when we are able to reasonably estimate product returns based on this data and based on greater certainty regarding generic competition we will then begin to recognize revenue based on shipments of product to our wholesale drug distributors.
 
Under our deferred revenue model, we do not recognize revenue following shipment of Zanaflex Capsules and Zanaflex tablets to our wholesale drug distributors. Instead, we record deferred revenue at gross invoice sales price, and classify the cost basis of the inventory held by the wholesaler as a component of inventory. We recognize revenue when prescriptions are filled to an end-user because once a prescription is filled the product cannot be returned. We use monthly prescription data that we purchase to determine the amount of revenue to be recognized. When we receive the prescription data, we use the number of units of product prescribed to record gross sales. We then reduce deferred revenue and record cost of goods sold.
 
In addition to the prescription data we purchase, we also receive data that we use to monitor trends in sales from wholesalers to their customers. We receive this data from an outside vendor on a monthly basis. This data includes the number of bottles shipped from certain wholesalers to their customers. We also compare our shipments to wholesalers to prescription reports to further assess inventory in the distribution channel on a monthly basis. We use the wholesaler sales trend data and the wholesaler vs. prescription comparison to better understand market conditions, but not as a basis for recognizing revenue.
 
Our net revenues represent total revenues less allowances for customer credits, including estimated discounts, rebates, and chargebacks. These allowances are recorded for cash consideration given by a vendor to a customer that is presumed to be a reduction of the selling prices of the vendor’s products or services and, therefore, should be characterized as a reduction of revenue when recognized in the vendor’s statement of income. Adjustments are recorded for estimated chargebacks, rebates, and discounts. These allowances are established by management as its best estimate based on available information and are adjusted to reflect known changes in the factors that impact such reserves. Allowances for chargebacks, rebates and discounts are established based on the contractual terms with customers, analysis of historical le vels of discounts, chargebacks and rebates, communications with customers and the levels of inventory remaining in the distribution channel, as well as expectations about the market for each product and anticipated introduction of competitive products. Product shipping and handling costs are included in cost of sales.
 
We accept returns of Zanaflex Capsules and Zanaflex tablets for six months prior to and twelve months after their expiration date.  We provide a credit to customers with whom we have a direct relationship or a cash payment to those with whom we do not have a direct relationship. We do not exchange product from inventory for the returned product. Returns of products sold by us are charged directly against deferred revenue, reducing the amount of deferred revenue that we may recognize.  In addition, we record a charge to cost of goods sold for the cost basis of the estimated product returns we believe may ultimately be realized at the time of product shipment to wholesalers. We recognize this charge at the date of shipment since it is probable that we will receive a level of returned products; upon the return of such product we will be unable to resell the product considering its expiration dating; and, we can reasonably estimate a range of returns. This charge represents the cost basis for the low end of the range of the Company’s estimated returns.
 
24
 
Ampyra
 
Ampyra is available only through a network of specialty pharmacy providers that provide the medication to patients by mail and Kaiser Permanente (Kaiser). We recognize revenue by applying the guidance in Staff Accounting Bulletin (SAB) 104 which requires that we do not recognize revenue from product sales until there is persuasive evidence of an arrangement, delivery has occurred, the price is fixed and determinable, the buyer is obligated to pay us, the obligation to pay is not contingent on resale of the product, the buyer has economic substance apart from us, the Company has no obligation to bring about the sale of the product, the amount of returns can be reasonably estimated and collectability is reasonably assured. We recognize product sales of Ampyra following shipment of product to a network of specialty pharmacy providers a nd Kaiser. As of September 30, 2010, inventory levels at specialty pharmacy providers that distribute Ampyra (does not include Kaiser) represented approximately two weeks of their anticipated usage. The specialty pharmacy providers and Kaiser are contractually obligated to hold no more than 30 days of inventory.
 
Our net revenues represent total revenues less allowances for customer credits, including estimated rebates, discounts and returns. These allowances are recorded for cash consideration given by a vendor to a customer that is presumed to be a reduction of the selling prices of the vendor’s products or services and, therefore, are characterized as a reduction of revenue. At the time product is shipped to specialty pharmacies and Kaiser, an adjustment is recorded for estimated chargebacks, rebates, and returns. These allowances are established by management as its best estimate based on available information and will be adjusted to reflect known changes in the factors that impact such reserves. In determining the amounts of certain allowances and accruals, we must make significant judgments and estimates. Allowances for rebates, discounts and returns are established based on the contractual terms with customers, communications with customers and the levels of inventory remaining in the distribution channel, as well as expectations about the market for each product and anticipated introduction of competitive products. Product shipping and handling costs are included in cost of sales.
 
Based on our specialty distribution model where we sell to only 12 specialty pharmacy providers and Kaiser, the data we receive from these distributors, and returns experience of other specialty products with similar selling models, we have been able to make a reasonable estimate for product returns. At September 30, 2010, inventory levels at the specialty pharmacy providers (this does not include Kaiser) represented approximately two weeks of their anticipated usage. The specialty pharmacy providers and Kaiser have contractually agreed to hold no more than 30 days of inventory.  We will accept returns of Ampyra for two months prior to and six months after its expiration date.  We will provide a credit to customers with whom we have a direct relationship. Once our product is prescribed, it cannot be returned . We do not exchange product from inventory for the returned product.
 
Collaborations
 
We recognize collaboration revenues by analyzing each element of the agreement to determine if it shall be accounted for as a separate element or single unit of accounting. If an element shall be treated separately for revenue recognition purposes, the revenue recognition principles most appropriate for that element are applied to determine when revenue shall be recognized. If an element shall not be treated separately for revenue recognition purposes, the revenue recognition principles most appropriate for the bundled group of elements are applied to determine when revenue shall be recognized. Payments received in excess of revenues recognized are recorded as deferred revenue until such time as the revenue recognition criteria have been met.
 
Ampyra Inventory
 
Prior to regulatory approval of Ampyra, the Company incurred expenses for the manufacture of several batches of Ampyra that ultimately became available to support the commercial launch of this drug candidate. Until the necessary initial regulatory approval was received, we charged all such amounts to research and development expenses. As a result, our initial sales of Ampyra will result in higher gross margins than if the inventory costs had not previously been expensed. Upon regulatory approval of Ampyra, the Company began capitalizing the commercial inventory costs associated with manufacturing with Elan and at its second manufacturer, Patheon.
 
The cost of Ampyra inventory manufactured by Elan is based on specified prices calculated as a percentage of net product sales of the product shipped by Elan to Acorda. In the event Elan does not manufacture the products, Elan is entitled to a compensating payment for the quantities of product provided by the alternative manufacturer. This compensating payment is included in our inventory balances.
 
25
 
Research and Development
 
Research and development expenses include the costs associated with our internal research and development activities including, salaries and benefits, occupancy costs, and research and development conducted for us by third parties, such as sponsored university-based research, fees paid to professional service providers for independently monitoring our clinical trials and acquiring and evaluating data from our clinical trials, costs of contract manufacturing services for our preclinical program, costs of materials used in clinical trials and research and development and depreciation of capital resources used to develop our products. In addition, research and development expenses include expenses related to grant revenue, the cost of clinical trial drug supply shipped to our clinical study vendors and the cost of Ampyra inventory rece ived up until regulatory approval. We account for our clinical study costs by estimating the patient cost per visit in each clinical trial and recognizing this cost as visits occur, beginning when the patient enrolls in the trial. This estimated cost includes payments to the trial site and patient-related costs, including laboratory costs related to the conduct of the trial. Cost per patient varies based on the type of clinical trial, the site of the clinical trial, and the length of the treatment period for each patient. As actual costs become known to us, we adjust our accrual; such changes in estimate may be a material change in our clinical study accrual, which could also materially affect our results of operations.  With respect to previously established clinical study accruals in prior periods, for the three and nine-month periods ended September 30, 2010 we did not make any significant adjustments to our clinical study costs. All research and development costs are expensed as incurred except when we are accounting for nonrefundable advance payments for goods or services to be used in future research and development activities. In these cases, these payments are capitalized at the time of payment and expensed when the research and development activity has been performed.
 
Income Taxes
 
As part of the process of preparing our financial statements we are required to estimate our income taxes in each of the jurisdictions in which we operate. We account for income taxes by the asset and liability method. Under this method, deferred income taxes are recognized for tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end, based on enacted laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
 
We have not recorded any tax provision or benefit for the nine-month periods ended September 30, 2010 and 2009. We have provided a valuation allowance for the full amount of our gross deferred tax assets since realization of any future benefit from deductible temporary differences and net operating loss carryforwards cannot be sufficiently assured at September 30, 2010.
 
As of September 30, 2010, we had available net operating loss carryforwards of approximately $270.1 million for federal and state income tax purposes, which are available to offset future federal and state taxable income, if any, and expire between 2019 and 2030 and research and development tax credit carryforwards of approximately $1.6 million for federal income tax reporting purposes which are available to reduce federal income taxes, if any, through 2018. Since our inception, we have incurred substantial losses and expect to incur substantial and recurring losses in future periods. The Internal Revenue Code of 1986, as amended (the “Code”), provides for a limitation of the annual use of net operating loss and research and development tax credit carry forwards (following certain ownership changes, as defined by the Code) that could significantly limit our ability to utilize these carryforwards. We have experienced various ownership changes, as defined by the Code, as a result of past financings. Accordingly, our ability to utilize the aforementioned carry- forwards may be limited. Additionally, because U.S. tax laws limit the time during which these carryforwards may be applied against future taxes we may not be able to take full advantage of these attributes for federal income tax purposes.
 
Share-based Compensation
 
We account for stock options and restricted stock granted to employees and non-employees by recognizing the costs resulting from all share-based payment transactions in the financial statements at their fair values.  We estimate the fair value of each option on the date of grant using the Black-Scholes closed-form option-pricing model based on assumptions for the expected term of the stock options, expected volatility of our common stock, prevailing interest rates, and an estimated forfeiture rate.
 
 
26
 
We have based our current assumptions on the following:
 
Assumption
Method of estimating
•Estimated expected term of options
•Based on the 50th percentile of our peer companies
•Expected volatility
•Combination of historic volatility of our common stock since October 1, 2006 and the historic volatility of the stock of our peer companies
•Risk-free interest rate
•Yields of U.S. Treasury securities corresponding with the expected life of option grants
•Forfeiture rates
•Historical forfeiture data
 
Of these assumptions, the expected term of the option and expected volatility of our common stock are the most difficult to estimate since they are based on the exercise behavior of the employees and expected performance of our common stock. Increases in the term and the volatility of our common stock will generally cause an increase in compensation expense.
 
Item 3.  Quantitative and Qualitative Disclosures About Market Risk
 
Our financial instruments consist of cash equivalents, short-term investments, grants receivable, convertible notes payable, accounts payable, and put/call liability. The estimated fair values of all of our financial instruments approximate their carrying amounts at September 30, 2010.
 
We have cash equivalents and short-term investments at September 30, 2010, which are exposed to the impact of interest rate changes and our interest income fluctuates as our interest rates change. Due to the short-term nature of our investments in money market funds and US Treasury bonds, the carrying value of our cash equivalents and short-term investments approximate their fair value at September 30, 2010. At September 30, 2010, we held $245.8 million in cash and cash equivalents and short-term investments which had an average interest rate of approximately 0.1%.
 
We maintain an investment portfolio in accordance with our investment policy. The primary objectives of our investment policy are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. Although our investments are subject to credit risk, our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure from any single issue, issuer or type of investment. Our investments are also subject to interest rate risk and will decrease in value if market interest rates increase. However, due to the conservative nature of our investments and relatively short duration, interest rate risk is mitigated. We do not own derivative financial instruments. Accordingly, we do not believe that there is any material market risk exposure with respect to derivative or other financial instruments.
 
Item 4.  Controls and Procedures
 
Evaluation of disclosure controls and procedures
 
As required by Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”) we carried out an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this report. This evaluation was carried out under the supervision and with the participation of our management, including our chief executive officer and our chief financial officer. Based on that evaluation, these officers have concluded that, as of September 30, 2010, our disclosure controls and procedures were effective.
 
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding disclosure.
 
27
 
Change in internal control over financial reporting
 
In connection with the evaluation required by Exchange Act Rule 13a-15(d), our management, including our chief executive officer and chief financial officer, concluded that there were no changes in our internal control over financial reporting during the quarter ended September 30, 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
Limitations on the effectiveness of controls
 
Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.
 
28

PART II—OTHER INFORMATION
 
 
In August 2007, the Company received a Paragraph IV Certification Notice from Apotex Inc. advising that it had submitted an ANDA to the FDA seeking marketing approval for generic versions of Zanaflex Capsules.  In October 2007, the Company filed a lawsuit against Apotex Corp. and Apotex Inc. (collectively, Apotex) for patent infringement in relation to the filing of the ANDA by Apotex. The defendants answered the Company’s complaint, asserting patent invalidity and non-infringement and counterclaiming, seeking a declaratory judgment of patent invalidity and non-infringement. The Company denied those counterclaims.  In March 2008, Apotex filed a motion, which the Company opposed, for partial judgment on the pleadings dismissing the Company’s request for relief on the ground that the case is “exceptional” under U.S.C. §§ 271(e)(4) or 285. The court ruled in the Company’s favor and denied Apotex’s motion in December 2008. Fact discovery in the case has been completed. On July 2, 2010, the U.S. District Court held a Markman hearing to determine the interpretation of certain terms in the Company’s Zanaflex Capsules patent that is at issue in this litigation. The Court ruled favorably on a number of those terms, and the case is proceeding, with expert discovery scheduled to be completed by early January 2011.
 
Our timely filing of a lawsuit against Apotex in October 2007 triggered an automatic stay on FDA approval of the Apotex ANDA for 30 months. That stay expired in March 2010. Consequently, Apotex will be able to receive FDA approval of its ANDA, if Apotex is able otherwise to satisfy FDA's review requirements for ANDAs, at which time it could begin selling a generic tizanidine hydrochloride capsule in competition with Zanaflex Capsules and Zanaflex tablets, even if our patent litigation remains pending. If Apotex begins selling its product before it is successful in challenging the validity, infringement, or enforceability of our patent, Apotex would be selling at the risk of our ultimately prevailing on our patent infringement claims and its being held liable for damages for patent infringement.
 
 
In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2009 and Part II, Item 1A of our Form 10-Q for the quarter ended June 30, 2010,  all of which could materially affect our business, financial condition or future results. The risks described or referred to herein are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.
 
 
31.1
Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
31.2
Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
32.1
Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2
Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*
XBRL Instance Document
101.SCH*
XBRL Taxonomy Extension Schema Document
101.CAL*
XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*
XBRL Taxonomy Extension Label Linkbase Document
101.PRE*
XBRL Taxonomy Extension Presentation Linkbase Document
   

 
* In accordance with Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall be deemed to be “furnished” and not “filed.”
 
29

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
Acorda Therapeutics, Inc.
 
By:
/s/ Ron Cohen
 
 
Date:  November 9, 2010
  
Ron Cohen, M.D.
President, Chief Executive Officer and Director
(Principal Executive Officer)


   
 
By:
/s/ David Lawrence
 
 
Date:  November 9, 2010
  
David Lawrence, M.B.A.
Chief Financial Officer
(Principal Financial and Accounting Officer)
 
 
 
 
 
30

Exhibit Index
 
Exhibit No.
Description
   
Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
Certification by the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*
XBRL Instance Document
101.SCH*
XBRL Taxonomy Extension Schema Document
101.CAL*
XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*
XBRL Taxonomy Extension Label Linkbase Document
101.PRE*
XBRL Taxonomy Extension Presentation Linkbase Document
   
 
* In accordance with Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall be deemed to be “furnished” and not “filed.”
 
 
 
 

 

EX-31.1 2 exhibit311ceo.htm exhibit311ceo.htm
    EXHIBIT 31.1
 
 
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO
RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Ron Cohen, certify that:
 
1.
I have reviewed this report on Form 10-Q of Acorda Therapeutics, Inc.;
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
 
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
 
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: November 9, 2010
 
/s/ Ron Cohen
  
Ron Cohen
Chief Executive Officer
(Principal Executive Officer)
 
  
EX-31.2 3 exhibit312cfo.htm exhibit312cfo.htm
Exhibit 31.2
 
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO
RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
I, David Lawrence, certify that:
 
1.
I have reviewed this report on Form 10-Q of Acorda Therapeutics, Inc.;
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
 
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
 
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: November 9, 2010
 
/s/ David Lawrence
  
David Lawrence
Chief Financial Officer
(Principal Financial Officer)
  
EX-32.1 4 exhibit321ceo.htm exhibit321ceo.htm
EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Acorda Therapeutics, Inc. (the “Company”) for the fiscal quarter ended September 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Form 10-Q”), I, Ron Cohen, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 
(1)    The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 
(2)    The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:  November 9, 2010
   /s/RON COHEN
   
Ron Cohen, Chief Executive Officer
   
(Principal Executive Officer)

 
[A signed original of this written statement required by Section 906 has been provided to Acorda Therapeutics, Inc. and will be retained by Acorda Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.]
 EX-32.2 5 exhibit322cfo.htm exhibit322cfo.htm
EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Acorda Therapeutics, Inc. (the “Company”) for the fiscal quarter ended September 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Form 10-Q”), I, David Lawrence, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 
(1)  The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 
(2)  The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 9, 2010
   /s/DAVID LAWRENCE
   
David Lawrence
   
Chief Financial Officer
   
(Principal Financial Officer)

 
[A signed original of this written statement required by Section 906 has been provided to Acorda Therapeutics, Inc. and will be retained by Acorda Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.]

 EX-101.INS 6 acor-20100930.xml 0001008848 2009-01-01 2009-09-30 0001008848 2009-01-01 2009-12-31 0001008848 2008-12-31 0001008848 2009-12-31 0001008848 2009-09-30 0001008848 2010-09-30 0001008848 2010-01-01 2010-09-30 0001008848 2010-07-01 2010-09-30 0001008848 2009-07-01 2009-09-30 0001008848 2010-10-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares Q3 No <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(8) Biogen Collaboration Agreement</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June&#160;30, 2009, the Company entered into an exclusive collaboration and license agreement with Biogen Idec International&#160;GmbH (Biogen Idec) to develop and commercialize Ampyra (known as fampridine outside the U.S.) in markets outside the United States (the &#8220;Collaboration Agreement&#8221;). Under the Collaboration Agreement, Biogen Idec was granted the exclusive right to commercialize Ampyra and other products containing aminopyridines developed under that agreement in all countries outside of the United States, which grant includes a sublicense of the Company&#8217;s rights under an existing license agreement between the Company and Elan Pharma International Limited, a subsidiary of Elan Corporation&#160;plc (Elan). Biogen Idec will have responsibility for regulatory activities and future clinical development of Ampyra in ex-U.S. markets worldwide. The Company also entered into a related supply agreement with Biogen Idec (the &#8220;Supply Agreement&#8221;), pursuant to which the Company will supply Biogen Idec with its requirements for the licensed products through the Company&#8217;s existing supply agreement with Elan.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGI N-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under the Collaboration Agreement, the Company was entitled to an upfront payment of $110.0&#160;million as of June&#160;30, 2009, which was received on July&#160;1, 2009, and will be entitled to receive additional payments of up to approximately $400&#160;million based on the successful achievement of future regulatory and sales milestones. Due to the uncertainty surrounding the achievement of the future regulatory and sales milestones, these payments will not be recognized as revenue unless and until they are earned. The Company is not able to reasonably predict if and when the milestones will be achieved. Under the Collaboration Agreement, Biogen Idec will be required to make double-digit tiered royalty payments to the Company on ex-U.S. sales. In addition, the consideration that Biogen Idec will pay for licensed products under the Suppl y Agreement will reflect the price owed to the Company&#8217;s suppliers under its supply arrangements with Elan or other suppliers for ex-U.S. sales, including manufacturing costs and royalties owed. The Company and Biogen Idec may also carry out future joint development activities regarding licensed product under a cost-sharing arrangement. Under the terms of the Collaboration Agreement, the Company, in part through its participation in joint committees with Biogen Idec, will participate in overseeing the development and commercialization of Ampyra and other licensed products in markets outside the United States pursuant to that agreement. Acorda will continue to develop and commercialize Ampyra independently in the United States.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style= "DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of June&#160;30, 2009, the Company recorded a license receivable and deferred revenue of $110.0&#160;million for the upfront payment due to the Company from Biogen Idec under the Collaboration Agreement. Also, as a result of such payment to Acorda, a payment of $7.7&#160;million became payable by Acorda to Elan and was recorded as a cost of license payable and deferred expense. The payment of $110.0&#160;million was received from Biogen Idec on July&#160;1, 2009 and the payment of $7.7&#160;million was made to Elan on July&#160;7, 2009.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">T he Company considered the following deliverables with respect to the revenue recognition of the $110.0 million upfront payment:&#160;&#160;(1) the license to use the Company&#8217;s technology, (2) the Collaboration Agreement to develop and commercialize licensed product in all countries outside the U.S., and (3) the supply agreement. The Company has determined that the identified deliverables would have no value on a standalone basis if they were sold separately by a vendor and the customer could not resell the delivered items on a standalone basis, nor does the Company have objective and reliable evidence of fair value for the deliverables.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline">Accordingly, the deliverables are treated as one unit of accounting.&#160;&#160;</font>As a result, the Company will recognize the non-refundable upfront payment from Biogen Idec as revenue and the associated payment to El an as expense ratably over the estimated term of regulatory exclusivity for the licensed products under the Collaboration Agreement as we had determined this was the most probable expected benefit period. The Company recognized $7.1&#160;million in license revenue, a portion of the $110.0&#160;million received from Biogen Idec and $495,000 in cost of license revenue, a portion of the $7.7&#160;million paid to Elan during the nine-month period ended September 30, 2010. The Company currently estimates the recognition period to be approximately 12&#160;years from the date of the Collaboration Agreement.</font></div> 35090415 -3904938 276250000 224650000 2891356 3399860 12557768 8885986 39987644 37749920 38260608 37700747 8132 0 8132 5365 6215001 6710001 false 0.31 -0.51 -0.40 -1.63 11666020 2602064 22573938 8112490 63622042 15214321 124205000 40232858 2357143 2357144 7071428 2357144 88785714 95857142 20617977 21489081 3320957 1891321 301848 301160 Yes <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(7) Short-Term Investments</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has determined that all of its short-term investments are classified as available-for-sale. Available-for-sale securities are carried at fair value with interest on these securities included in interest income. Available-for-sale securities consisted of the following:</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0p t" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" width="39%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amortized</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cost</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"& gt;&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gross</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">unrealized</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">gains</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td> ;<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gross</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">unrealized</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">losses</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Estimated</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">fair</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">value</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" align="left" width="39%"><div style="DISPLAY: b lock; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2010</font></div></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align="left" width="39%"><div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">US Treasury bonds</font></div></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$163,390,222</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$24,182</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(2,044)</font></div></td><td valign="bottom" align="right" width="12 %"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$163,412,360</font></div></td></tr><tr><td valign="top" align="left" width="39%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31, 2009</font></div></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td ><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align="left" width="39%"><div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">US Treasury bonds</font></div></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">224,669,409</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">126,169</font></div&g t;</td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(17,556)</font></div></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">224,778,023</font></div></td></tr></table></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The contractual maturities of available-for-sale debt securities at September 30, 2010 and De cember&#160;31, 2009 are within one year. The Company has determined that there were no other-than-temporary declines in the fair values of its short term investments as of September 30, 2010. Short-term investments with maturity of three months or less from date of purchase have been classified as cash equivalents, and amounted to $76,104,201 and $43,471,757 as of September 30, 2010 and December&#160;31, 2009, respectively.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1) Organization and Business Activities</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Acorda Therapeutics,&#160;Inc. (&#8220;Acorda&#8221; or the &#8220;Company&#8221;) is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injur y (SCI) and other disorders of the central nervous system (CNS).</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The management of the Company is responsible for the accompanying unaudited interim consolidated financial statements and the related information included in the notes to the consolidated financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, including normal recurring adjustments necessary for the fair presentation of the Company&#8217;s financial position and results of operations and cash flows for the periods presented. Results of operations for interim periods are not necessarily indicative of the results to be expected for the entire year.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December&#160;31, 2009 included in the Company&#8217;s Annual Report on Form&#160;10-K for such year, as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FON T-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company finances its operations through a combination of issuance of equity securities, revenues from Zanaflex Capsules and Ampyra, loans, collaborations, and, to a lesser extent, grants. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed to fund its development and commercialization efforts. To the extent the Company&#8217;s capital resources are insufficient to meet future operating requirements, the Company will need to raise additional capital, reduce planned expenditures, or incur indebtedness to fund its operations. The Company may be unable to obtain additional debt or equity financing on acceptable terms, if at all. If adequate funds are not available, the Company may be required to curtail its sales and marketing efforts, delay, reduce the scope of or eliminate some of its research and development programs or obtain funds through arrangements with collaborative partners or others that m ay require us to relinquish rights to certain product candidates that it might otherwise seek to develop or commercialize independently.</font></div> 2207442 1903764 580 6279 -319000 75000 10-Q 47314412 29612916 82404827 25707978 7998120 2277073 38449917 37749920 38260608 37700747 38568369 37935075 163412360 224778023 Yes 0001008848 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2) Summary of Significant Accounting Policies</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Principles of Consolidation</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 1 0pt; FONT-FAMILY: Times New Roman">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America and include the results of operations of the Company and its majority owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Use of Estimates</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font st yle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include research and development and share-based compensation accounting, which are largely dependent on the fair value of the Company&#8217;s equity securities. In addition, the Company recognizes Zanaflex revenue based on estimated prescriptions filled. The Company adjusts its Zanaflex inventory value based on an estimate of inventory that may be returned. Actual results could differ from those estimates.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGH T: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Revenue Recognition</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Zanaflex</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company applies the reve nue recognition guidance in Accounting Standards Codification (ASC) 605-15-25, which among other criteria requires that future returns can be reasonably estimated in order to recognize revenue. The amount of future tablet returns is uncertain due to generic competition and customer conversion to Zanaflex Capsules. The Company has accumulated some sales history with Zanaflex Capsules; however, due to existing and potential generic competition and customer conversion from Zanaflex tablets to Zanaflex Capsules, we do not believe we can reasonably determine a return rate at this time. As a result, the Company accounts for these product shipments using a deferred revenue recognition model. Under the deferred revenue model, the Company does not recognize revenue upon product shipment. For these product shipments, the Company invoices the wholesaler, records deferred revenue at gross invoice sales price, and classifies the cost basis of the product held by the wholesaler as a component of inventory. The Company rec ognizes revenue when prescribed to the end-user, on a first-in first-out (FIFO) basis. The Company&#8217;s revenue to be recognized is based on (1)&#160;the estimated prescription demand, based on pharmacy sales for its products; and (2)&#160;the Company&#8217;s analysis of third-party information, including third-party market research data. The Company&#8217;s estimates are subject to the inherent limitations of estimates that rely on third-party data, as certain third-party information was itself in the form of estimates, and reflect other limitations. The Company&#8217;s sales and revenue recognition reflects the Company&#8217;s estimates of actual product prescribed to the end-user. The Company expects to be able to apply a more traditional revenue recognition policy such that revenue is recognized following shipment to the customer when it believes it has sufficient data to develop reasonable estimates of expected returns based upon historical returns and greater certainty re garding generic competition.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s net revenues represent total revenues less allowances for customer credits, including estimated discounts, rebates, and chargebacks. These allowances are recorded for cash consideration given by a vendor to a customer that is presumed to be a reduction of the selling prices of the vendor&#8217;s products or services and, therefore, should be characterized as a reduction of revenue when recognized in the vendor&#8217;s statement of operations. Adjustments are recorded for estimated chargebacks, rebates, and discounts. These allowances are established by management as its best estimate based on available information and are adjusted to reflect known changes in the factors that impact such allowances. Allowances for chargebacks, rebates and discounts are established based on the contractual terms with customers, analysis of historical levels of discounts, chargebacks and rebates, communications with customers and the levels of inventory remaining in the distribution channel, as well as expectations about the market for each product and anticipated introduction of competitive products. In addition, the Company records a charge to cost of goods sold for the cost basis of the estimated product returns the Company believes may ultimately be realized at the time of product shipment to wholesalers. The Company has recognized this charge at the date of shipment since it is probable that it will receive a level of returned products; upon the return of such product it will be unable to resell the product considering its expiration dating; and it can reasonably estimate a range of returns. This charge represents the cost basis for th e low end of the range of the Company&#8217;s estimated returns. Product shipping and handling costs are included in cost of sales.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Ampyra</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ampyra is available only through a network of specialty pharmacy providers that provide the medication to patients by mail and Kaiser Permanente (&#8220;Kaiser&#8221;). Ampyra wil l not be available in retail pharmacies. The Company applies the revenue recognition guidance in Staff Accounting Bulletin (SAB) 104 and does not recognize revenue from product sales until there is persuasive evidence of an arrangement, delivery has occurred, the price is fixed and determinable, the buyer is obligated to pay the Company, the obligation to pay is not contingent on resale of the product, the buyer has economic substance apart from the Company, the Company has no obligation to bring about the sale of the product, the amount of returns can be reasonably estimated and collectability is reasonably assured. The Company recognizes product sales of Ampyra following shipment of product to a network of specialty pharmacy providers and Kaiser. As of September 30, 2010, inventory levels at specialty pharmacy providers that distribute Ampyra (excluding Kaiser) represented approximately two weeks of their anticipated usage. The specialty pharmacy providers and Kaiser are contractually obligated to hold no more than 30 days of inventory.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s net revenues represent total revenues less allowances for customer credits, including estimated rebates, discounts and returns. These allowances are recorded for cash consideration given by a vendor to a customer that is presumed to be a reduction of the selling prices of the vendor&#8217;s products or services and, therefore, are characterized as a reduction of revenue. At the time product is shipped to specialty pharmacies and Kaiser, an adjustment is recorded for estimated rebates, discounts and returns. These allowances are established by management as its best estimate based on available information and will be ad justed to reflect known changes in the factors that impact such allowances. Allowances for rebates, discounts and returns are established based on the contractual terms with customers, communications with customers and the levels of inventory remaining in the distribution channel, as well as expectations about the market for the product and anticipated introduction of competitive products.&#160;&#160;Product shipping and handling costs are included in cost of sales.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on the Company&#8217;s specialty distribution model where it sells to only 12 specialty pharmacies and Kaiser, the inventory and prescription data it receives from these distributors, and returns e xperience of other specialty products with similar selling models, the Company has been able to make a reasonable estimate for product returns. At September 30, 2010, inventory levels at the specialty pharmacies (excluding Kaiser) represented approximately two weeks of their anticipated usage. The specialty pharmacy providers and Kaiser have contractually agreed to hold no more than 30 days inventory. The Company will accept returns of Ampyra for two months prior to and six months after the product expiration date. The Company will provide a credit for such returns to customers with whom we have a direct relationship. Once product is prescribed, it cannot be returned. The Company does not exchange product from inventory for the returned product.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: ita lic; FONT-FAMILY: Times New Roman">Milestones and royalties</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenue from milestones is recognized when earned, as evidenced by written acknowledgement from the other party to a contract, provided that (i)&#160;the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, and the Company has no further performance obligations relating to that event, and (ii)&#160;collectability is reasonably assured. If these criteria are not met, the milestone payment is recognized over the remaining period of our performance obligations under the arrangement. Royalties are recognized as earned in accordance with the terms of various research and collaboration agreements. </fon t></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Collaborations</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recognizes collaboration revenues and expenses by analyzing each element of the agreement to determine if it shall be accounted for as a separate element or single unit of accounting. If an element shall be treated separately for revenue recognition purposes, the revenue recognition principles most appropriate for that element are applied t o determine when revenue shall be recognized. If an element shall not be treated separately for revenue recognition purposes, the revenue recognition principles most appropriate for the bundled group of elements are applied to determine when revenue shall be recognized. Payments received in excess of revenues recognized are recorded as deferred revenue until such time as the revenue recognition criteria have been met.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Ampyra Inventory</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDE NT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior to regulatory approval of Ampyra, the Company incurred expenses for the manufacture of bulk, unpackaged product of Ampyra that ultimately became available to support the commercial launch of this drug candidate. Until the necessary initial regulatory approval was received, we charged all such amounts to research and development expenses as there was no alternative future use prior to regulatory approval. As a result, our initial sales of Ampyra will result in higher gross margins than if the inventory costs had not previously been expensed. Upon regulatory approval of Ampyra, the Company began capitalizing the commercial inventory costs associated with manufacturing with Elan and its second manufacturer, Patheon.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style=" DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Concentration of Risk</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of investments in cash and cash equivalents, restricted cash and accounts receivable. The Company maintains cash and cash equivalents and restricted cash with approved financial institutions. The Company is exposed to credit risks and liquidity risks in the event of default by the financial institutions or issuers of investments in excess of FDIC insured limits. The Company performs periodic evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any institution.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Segment Information</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is managed and operated as one business. The entire business is managed by a single mana gement team that reports to the chief executive officer. The Company does not operate separate lines of business with respect to any of its product candidates. Accordingly, the Company does not prepare discrete financial information with respect to separate product candidates or by location and does not have separately reportable segments.</font></div> 6606888 696773 217862168 278897068 -505677 335887 -727800 -3648754 66188194 14463303 126884766 43834948 25803985 14975794 ACORDA THERAPEUTICS INC --12-31 337487 48675 495000 -6875001 80693 78242 13262505 -19000664 -12545827 -59224176 142361917 137332768 9428571 9428571 17363236 11613434 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(9) Commitments and Contingencies</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of the Company&#8217;s commitments and contingencies was included in the Company&#8217;s Annual Report on Form 10-K for the twelve-month period ended December 31, 2009. The Company&#8217;s long-term contractual obligations include commitments and estimated purchase obligations entered into in the normal course of business.</font></div> ;<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when information available indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated. The Company believes that the ultimate resolution of these matters will not have a material adverse effect on the Company&#8217;s financial condition or liquidity. However, adjustments, if any, to the Company&#8217;s estimates could be material to operating results for the periods in which adjustments to the liability are recorded.</font></div> 2850437 3158931 7970073 8197789 22627938 23982123 38568369 37935075 1144275 0 -20802949 51549121 110528 314000 449736 1478996 586058355 565503101 4374627 5630862 5722357 4274625 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(10) Intangible Assets</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company acquired all of Elan's U.S. sales, marketing and distribution rights to Zanaflex Capsules and Zanaflex tablets in July 2004 for $2.0 million plus $675,000 for finished goods inventory. The Company was also responsible for up to $19.5 million in future contingent milestone payments based on cumulative gross sales of Zanaflex tablets and Zanaflex Capsules. As of December 31, 2009 , the Company made $19.5 million of these milestone payments which were recorded as intangible assets in the consolidated financial statements.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with this transaction, the Company acquired the rights to the trade name "Zanaflex&#174;", one issued U.S. patent and two patent applications related to Zanaflex Capsules, and the remaining tablet inventory on hand with Elan. Additionally, the Company assumed Elan's existing contract with Novartis to manufacture Zanaflex tablets and entered into a separate contract with Elan to manufacture Zanaflex Capsules. The Company separately launched Zanaflex Capsules in April 2005. The Company did not acquire any receivables, em ployees, facilities or fixed assets. The Company allocated, on a relative fair value basis, the initial and milestone payments made to Elan to the assets acquired, principally the Zanaflex trade name and the capsules patent. There is no expected residual value of these intangible assets. The Company amortizes the allocated fair value of the trade name and patent over their estimated future economic benefit to be achieved. The Zanaflex trade name was fully amortized as of December 31, 2008.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January&#160;22, 2010, the Company received marketing approval from the FDA for Ampyra triggering two milestone payments of $2.5 million to Elan and $750,000 to Rush-Presbyterian St.&a mp;#160;Luke&#8217;s Medical Center (Rush).&#160;&#160;As of September 30, 2010, the Company made or accrued these milestone payments totaling $3.25 million and they were recorded as intangible assets in the consolidated financial statements. The payment to Elan was made during the three-months ended June 30, 2010.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In 1990, Elan licensed from Rush know-how relating to dalfampridine (4-aminopyridine, 4-AP, the formulation used in Ampyra), for the treatment of MS. The Company subsequently licensed this know-how from Elan. In September 2003, the Company entered into an agreement with Rush and Elan terminating the Rush license to Elan and providing for mutual releases. The Company also entered into a license agreement with Rush in 2003 in which Rush granted the Company an exclusive worldwide license to its know-how relating to dalfampridine for the treatment of MS. Rush has also assigned to the Company its Orphan Drug Designation for dalfampridine for the relief of symptoms of MS.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company agreed to pay Rush a license fee, milestone payments of up to $850,000 and royalties based on net sales of the product for neurological indications. As of December 31, 2009, the Company had made an aggregate of $100,000 in payments under this agreement.&#160;&#160;The FDA approval of Ampyra triggered the final milestone of $750,000 which was paid during the three-months ended March 31, 2010.&#160;&#160;As of September 30, 2010, the Company made or accrued royalty payments totaling $1.6 million.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In August 2003, the Company entered into an Amended and Restated License Agreement with the Canadian Spinal Research Organization (CSRO). Under this agreement, the Company was granted an exclusive and worldwide license under certain patent assets and know-how of CSRO relating to the use of dalfampridine in the reduction of chronic pain and spasticity in a spinal cord injured subject.&#160;&#160;The agreement required the Company to pay to CSRO royalties based on a percentage of net sales of any product incorporat ing the licensed rights, including royalties on the sale of Ampyra and on the sale of dalfampridine for any other indication. No royalty payments have been made to date. During the three-month period ended March 31, 2010, the Company purchased CSRO&#8217;s rights to all royalty payments under the agreement with CSRO for $3.0 million.&#160;&#160;This payment was recorded as an intangible asset in the consolidated financial statements.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intangible assets also include certain website development costs which have been capitalized. The Company has developed several websites, each with its own purpose, including the general corporate website, product information websites a nd websites focused on the MS community.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its intangible assets may warrant revision or that the carrying value of these assets may be impaired. The Company evaluates the realizability of its intangible assets based on profitability and cash flow expectations for the related assets. As of September 30, 2010, the Company does not believe that there are any facts or circumstances that would indicate a need for changing the estimated useful life of the Zanaflex or Ampyra patents.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intangible assets consisted of the following:</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"& gt;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: i nline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Estimated</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">remaining</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FO NT-FAMILY: times new roman">useful lives as of</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2010</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Zanaflex patents<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$19,3 50,000</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$19,350,000</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11&#160;years</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Zanaflex trade name<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width ="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,150,000</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,150,000</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0&#160;years</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FO NT-SIZE: 10pt; FONT-FAMILY: times new roman">Ampyra milestones<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,250,000</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7&#160;years</font></div></td></tr>&l t;tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CSRO Royalty Buyout<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,000,000</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT - -INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;7&#160;years</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Website development costs(1)<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,871,195</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DI SPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,444,749</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3&#160;years</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Website development costs &#8211; in process websites (2)</font></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">782,531</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3&#160;years</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt ; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div></td></tr><tr><td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30,621,195</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23,727,280</font></div></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign=" top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less accumulated amortization<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,607,764</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN - -LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,578,649</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$22,013,431</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$17,148,631</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; M ARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>(1)&#160;&#160;Represents capitalized website development costs for fully developed and launched websites.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><tr valign="top"><td style="WIDTH: 38.5pt"><div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div></td><td><div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;Represents websites in development which had not been completed and therefore had not been launched as o f December 31, 2009.</font></div></td></tr></table></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recorded $2,029,115 and $794,513 in amortization expense related to these intangible assets in the nine-month periods ended September 30, 2010 and 2009, respectively.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Estimated future amortization expense for these intangible assets subsequent to December&#160;31, 2009 for the next five years is as follows:</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$2,700,347</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style= "DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,127,212</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-R IGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,801,439</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2013<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,410,262</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2014<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,182,817</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" a lign="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$13,222,077</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> 6381187 6178697 299512755 293280347 24079937 4497533 18228831 5739013 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(4) Earnings Per Share</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table sets forth the computation of basic and diluted earnings per share for the three and nine-month periods ended September&#160;30, 2010 and 2009:</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspac ing="0" cellpadding="0" width="100%"><tr><td valign="bottom" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three-month</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">period ended</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three-month</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> ;period ended</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine-month</font></div>&l t;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">period ended</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LE FT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine-month</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">period ended</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td>< ;/tr><tr><td valign="top" align="left" width="32%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Basic and diluted</font></div></td><td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align="left" width="32%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss)<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$12,437,191</font></div></td><td valign="bottom" align="right" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(19,429,807)</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align ="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(15,440,264)</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(61,466,881)</font></div></td></tr><tr><td valign="top" align="left" width="32%"><div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average common shares outstanding used in computing net income (loss) per share&#8212;basic</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE : 10pt; FONT-FAMILY: times new roman">38,449,917</font></div></td><td valign="bottom" align="right" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,749,920</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,260,608</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,700,747</font></div></td></tr><tr><td valign="top" align="left" width="32%"><div style=" DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Plus: net effect of dilutive stock options and restricted common shares</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,537,727</font></div></td><td valign="bottom" align="right" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISP LAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td></tr><tr><td valign="top" align="left" width="32%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average common shares outstanding used in computing net income (loss) per share&#8212;diluted</font></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0 pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,987,644</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,749,920</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style= "DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,260,608</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,700,747</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" align="left" width="32%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss) per share&#8212;basic</font></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$0.32</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(0.51)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width=" 13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(0.40)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(1.63)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" align="left" width="32%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss) per share&#8212;diluted</font></div></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$0.31</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(0.51)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(0.40)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(1.63)</font></div><div styl e="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>The difference between basic and diluted shares is that diluted shares include the dilutive effect of the assumed exercise of outstanding securities. The Company&#8217;s stock options and unvested shares of restricted common stock could have the most significant impact on diluted shares.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DIS PLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>Securities that could potentially be dilutive are excluded from the computation of diluted earnings per share when a loss from continuing operations exists or when the exercise price exceeds the average closing price of the Company&#8217;s common stock during the period, because their inclusion would result in an anti-dilutive effect on per share amounts.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>For the three months ended September&#160;30, 2010 a nd 2009, options to purchase 2,841,156 shares and 3,720,272 shares, respectively, of common stock that could potentially dilute basic earnings per share in the future were excluded from the calculation of diluted earnings per share as their effect would have been anti-dilutive because their exercise price was in excess of the average closing price of the common stock during the period. For the nine months ended September&#160;30, 2010 and 2009, options to purchase 4,080,052 shares and 3,562,639 shares, respectively, of common stock that could potentially dilute basic earnings per share in the future were excluded from the calculation of diluted earnings per share as their effect would have been anti-dilutive.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10p t; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>For the three months ended September&#160;30, 2010 and 2009, 371,945 and 332,074 shares, respectively, of unvested restricted stock that could potentially dilute basic earnings per share in the future were excluded from the calculation of diluted earnings per common share as their effect would have been anti-dilutive. For the nine months ended September&#160;30, 2010 and 2009, 406,847 and 287,803 shares, respectively, of unvested restricted stock that could potentially dilute basic earnings per share in the future were excluded from the calculation of diluted earnings per common share as their effect would have been anti-dilutive.</font></div> 1391232 1580300 -12489818 376637 0.32 -0.51 -0.40 -1.63 -825315 -429143 -2894437 -2242705 2010-09-30 49286476 -56150832 -871104 2486481 50359537 34214985 136750827 99457034 30723444 23415132 91548951 67362421 38569 37935 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3) Share-based Compensation</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the three-month periods ended September 30, 2010 and 2009, the Company recognized share-based compensation expense of $4.8&#160;million and $3.2&#160;million, respectively. During the nine-month periods ended September 30, 2010 and 2009, the Company recognized share-based compensation expense of $12.6 million and $8.9 million, re spectively. Activity in options and restricted stock during the nine-month period ended September 30, 2010 and related balances outstanding as of that date are reflected below. The weighted average fair value per share of options granted to employees for the three-month periods ended September 30, 2010 and 2009 were approximately $19.75 and $16.75, respectively.&#160;&#160;The weighted average fair value per share of options granted to employees for the nine-month periods ended September 30, 2010 and 2009 were approximately $19.37 and $17.59, respectively.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes share-based compensation expense included within our consolidated statements of operations:</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="TEXT-ALIGN: left" align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left" cellspacing="0" cellpadding="0" width="100%"><tr style="TEXT-ALIGN: left"><td style="TEXT-ALIGN: left" valign="bottom" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="TEXT-ALIGN: center" valign="bottom" width="23%" colspan="7"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For the three-month</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-W EIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: center" valign="bottom" width="23%" colspan="7"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For the nine-month</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr><tr><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="23%" colspan="7"><div style="DISPLAY: block; MARGI N-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">period ended September&#160;30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="23%" colspan="7"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">period ended September&#160;30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr><tr><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="30%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(In millions)</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="11%" colspan="3"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="11%" colspan="3"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="11%" colspan="3"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="11%" colspan="3"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr><tr><td style="TEXT-ALIGN: left" valign="bottom" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>&l t;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr><tr><td style="TEXT-ALIGN: left" valign="bottom" width="30%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> 1.4</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.9</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLA Y: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.6</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign=" bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.5</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr><tr><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="30%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Selling, general and administrative</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FO NT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.4</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style ="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.3</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9.0</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%" ><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.4</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr><tr><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: le ft" valign="bottom" width="30%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;Total</font></div></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.8</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT- SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FON T-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12.6</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="PADDING-BOTTOM: 4px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RI GHT: 0pt; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.9</font></td><td style="PADDING-BOTTOM: 4px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; M ARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of share-based compensation activity for the nine-month period ended September 30, 2010 is presented below:</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stock Option Activity</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="TEXT-ALIGN: left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left" cellspacing="0" cellpadding="0" width="91%"><tr style="TEXT-ALIGN: left"><td s tyle="TEXT-ALIGN: left" valign="bottom" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of Shares</font></div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt ; FONT-FAMILY: times new roman">Weighted Average</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise Price</font></div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="19%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted Average</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Remaining</font>&l t;/div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contractual</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Term</font></div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="15%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intrinsic Value</font></div></div></td></tr><tr><td style="TE XT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at January&#160;1, 2010</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,711,778</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$15.25</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; F ONT-FAMILY: times new roman">&#160; </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,098,169</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LE FT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.61</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cancelled<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="18%"><div style="DISPLAY: block; MA RGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(88,289)</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24.89</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RI GHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(623,294)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12.92</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at September 30, 2010</font></div></td><td style="BORDER-BOTT OM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,098,364</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$20.05</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>< /div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="19%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7.1</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="15%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$53,896,144</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&am p;#160;</div></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested and expected to vest at September 30, 2010</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,008,207</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="20%">&l t;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$19.83</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="19%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7.1</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="15%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$53,588,108</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested and exercisable at September 30, 2010</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISP LAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,278,343</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$14.12</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="19%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left "><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.9</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="15%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$43,143,212</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr></table></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Restricted Stock Activity</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="TEXT-ALIGN: left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left" cellspacing="0" cellpadding="0" width="74%"><tr style="TEXT-ALIGN: left"><td style="TEXT-ALIGN: left" valign="bottom" width="58%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; BORDER-BOTTOM: 1pt double; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">Restrict ed Stock</font></div></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="16%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; BORDER-BOTTOM: 1pt double; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">Number of Shares</font></div></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="58%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nonvested at January&#160;1, 2010</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="16%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-I NDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">203,776</font></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="58%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="16%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">334,178</font></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="58%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FO NT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="16%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(10,000)</font></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="58%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Forfeited</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="16%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&l t;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(12,185)</font></div></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="58%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nonvested at September 30, 2010</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="16%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">515,769</font></div></div></td></tr></table></div> -688 -2860 61264899 12857177 117133572 37875714 359045 440318 2010 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(5) Income Taxes</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>The Company had available net operating loss carryforwards (NOL) of approximately $270.1&#160;million and $249.5&#160;million as of September 30, 2010 and December&#160;31, 2009, respectively, for federal and state income tax purposes, which are available to offset future federal and state taxable income, if any, and expire between 2019 and 2030. The Company also has research and development tax credit carryforwards of approximately $1.6&#160;million as of both September 30, 2010 and December&#160;31, 2009, for federal income tax reporting purposes that are available to reduce federal income taxes, if any, and expire in future years beginning in 2020.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>At September 30, 2010 and December&#160;31, 2009, the Company had a deferred tax asset of $160.7&#160;million and $147.2&#160;million, respectively, offset by a full valuation allowance. Since inception, the Company has incurred substantial losses and expects to incur substantial losses in future p eriods. The Tax Reform Act of 1986 (the &#8220;Act&#8221;) provides for a limitation of the annual use of NOL and research and development tax credit carryforwards (following certain ownership changes, as defined by the Act) that could significantly limit the Company&#8217;s ability to utilize these carryforwards. The Company has experienced various ownership changes as a result of past financings. Accordingly, the Company&#8217;s ability to utilize the aforementioned carryforwards may be limited. Additionally, because U.S. tax laws limit the time during which these carryforwards may be applied against future taxes, the Company may not be able to take full advantage of these attributes for federal income tax purposes. Because of the above mentioned factors, the Company has not recognized its gross deferred tax assets as of and for all periods presented. As of September 30, 2010, management believes that it is more likely than not that the gross deferred tax assets will not be realized based o n future operations and reversal of deferred tax liabilities. Accordingly, the Company has provided a full valuation allowance against its gross deferred tax assets and no tax benefit has been recognized relative to its pretax losses.</font></div> 16731204 -2826805 943975 704229 3352305 3703552 80000000 80000000 0.001 0.001 -443757145 -428316881 6132134 7112027 318500 637500 8709065 9214742 293054 111871 -19582404 823951 12437190 -19429807 -15440264 -61466881 0 -38914 0 -23514 6893914 0 331421188 319470618 -7071428 107642856 2818092 2074183 331421188 319470618 22013430 17148631 3260669 3980601 Large Accelerated Filer 39079688 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(6) Fair Value Measurements</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table presents information about our assets and liabilities measured at fair value on a recurring basis as of September 30, 2010 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value. In general, fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level&#160;2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level&#160;3 inputs utilize unobservable data points for the asset or liability. The Company&#8217;s Level&#160;1 assets consist of time deposits and investments in a Treasury money market fund and high-quality government bonds. The Company&#8217;s Level&#160;3 liability represents our put/call liability related to the Paul Royalty Fund (PRF) transaction. No changes in valuation techniques or inputs occurred during the three months ended September 30, 2010. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the nine-month period ended September 30, 2010.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" width="54%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level&#160;1</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="cen ter"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level&#160;2</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level&#160;3</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" align="left" width="54%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Assets Carried at Fair Value:</font></div></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align="left" width="54%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash equivalents<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$76,104,201</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$&#8212;</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$&#8212;</font></div></td></tr><tr><td valign="top" align="left" width="54%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Short-term investments<fo nt style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">163,412,360</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td></tr><tr><td valign="top" align="left" width="54%"><div style="DIS PLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liabilities Carried at Fair Value:</font></div></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align="left" width="54%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Put/call liability<font style="MARGI N-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">318,500</font></div></td></tr></table></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MA RGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table presents additional information about assets and/or liabilities measured at fair value on a recurring basis and for which the Company utilizes Level&#160;3 inputs to determine fair value.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="17%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; T EXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance as of</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31, 2009</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Realized (gain s)</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">losses included</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">in net loss</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unrealized</font></div>< div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(gains) losses included</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">in other</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">comprehensive</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">loss</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&am p;#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance as of</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></t d></tr><tr><td valign="top" align="left" width="23%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liabilities Carried at Fair Value:</font></div></td><td valign="bottom" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="18%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align=" left" width="23%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Put/call liability</font></div></td><td valign="bottom" align="right" width="17%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$637,500</font></div></td><td valign="bottom" align="right" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">($319,000)</font></div></td><td valign="bottom" align="right" width="15%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-S IZE: 10pt; FONT-FAMILY: times new roman">$&#8212;</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$318,500</font></div></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We estimate the fair value of our put/call liability using a discounted cash flow valuation technique. Using this approach, expected future cash flows are calculated over the expected life of the PRF agreement, are discount ed to a single present value and then exercise scenario probabilities are applied. Some of the more significant assumptions made in the present value calculations include (i)&#160;the estimated Zanaflex revenue forecast and (ii)&#160;the likelihood of put/call exercise trigger events. Realized gain and losses are included in sales, general and administrative expenses.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our put/call liability has been classified as a Level&#160;3 asset as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market due to the lack of trading in the security. If different assumptions were used for the various inputs to the valuat ion approach including, but not limited to, assumptions involving the estimated Zanaflex revenue forecast and the likelihood of trigger events, the estimated fair value of these investments could be significantly higher or lower than the fair value we determined. We may be required to record losses in future periods.</font></div> 4923295 1606126 9751194 5959234 22138 108613 89448296 72900319 2101926 2394980 EX-101.SCH 7 acor-20100930.xsd 001000 - Statement - Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 002000 - Statement - Consolidated Statements Of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 003000 - Statement - Consolidated Statements Of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 006010 - Disclosure - Organization and Business Activities link:presentationLink link:calculationLink link:definitionLink 006020 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 006030 - Disclosure - Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 006050 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 006060 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 006070 - Disclosure - Short-Term Investments link:presentationLink link:calculationLink link:definitionLink 006080 - Disclosure - Collaboration Agreement link:presentationLink link:calculationLink link:definitionLink 006090 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 006100 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 001010 - Statement - Consolidated Balance Sheets (unaudited) (parenthetical) link:presentationLink link:calculationLink link:definitionLink 006040 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 acor-20100930_cal.xml EX-101.LAB 9 acor-20100930_lab.xml Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Restricted cash Restricted Cash And Cash Equivalents Short-term investments Trade accounts receivable, net Prepaid expenses Finished goods inventory held by the Company Finished goods inventory held by others Other current assets Total current assets Total current assets Property and equipment, net of accumulated depreciation Intangible assets, net of accumulated amortization Non-current portion of deferred cost of license revenue Other assets Total assets Total assets Liabilities and Stockholders' Equity Current liabilities: Accounts payable Accrued expenses and other current liabilities Deferred product revenue-Zanaflex tablets Amount of deferred revenue as of balance sheet date relating to product one. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Deferred Product Revenue Current Product One Deferred product revenue-Zanaflex Capsules Amount of deferred revenue as of balance sheet date relating to product two. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Deferred Product Revenue Current Product Two Current portion of deferred license revenue Current portion of revenue interest liability Current portion of convertible notes payable Total current liabilities Total current liabilities Non-current portion of deferred license revenue Put/call liability Non-current portion of revenue interest liability Non-current portion of convertible notes payable Commitments and contingencies Stockholders' equity: Common stock, $0.001 par value. Authorized 80,000,000 shares at September 30, 2010 and December 31, 2009; issued and outstanding 38,568,369 and 37,935,075 shares as of September 30, 2010 and December 31, 2009, respectively Additional paid-in capital Accumulated deficit Accumulated other comprehensive income Total stockholders' equity Total stockholders' equity Total liabilities and stockholders' equity Total liabilities and stockholders' equity Common stock, par value (In dollars per share) Common stock, Authorized shares (In shares) Common stock, issued (In shares) Common stock, outstanding (In shares) Income Statement [Abstract] Revenues: Gross product sales Less: discounts and allowances Aggregate allowances for customer credits, including estimated discounts, returns, rebates, and chargebacks given by the entity for goods sold to customers. Discounts and allowance are a deduction from gross revenue in arriving at net revenue. Less: discounts and allowances Sales Discounts And Allowances Net sales Net sales License revenue Total net revenues Total net revenues Costs and expenses: Cost of sales Research and development Selling, general and administrative Total operating expenses Total operating expenses Operating loss Operating income (loss) Other expense (net): Interest and amortization of debt discount expense Interest and amortization of debt discount expense Interest income Loss on disposal of property and equipment Loss on disposal of property and equipment Total other expense (net) Total other expense (net) Net loss Net income (loss) Net loss per share-basic and diluted The amount of net income or loss for the period per each share of common stock and dilutive common stock equivalents outstanding during the reporting period. Earnings Per Share Basic Diluted Weighted average common shares outstanding used in computing net income (loss) per share-diluted (In shares) Number of [basic] shares, after adjustment for contingently issuable shares and other shares not deemed outstanding, determined by relating the portion of time within a reporting period that common shares have been outstanding to the total time in that period and the average number of [diluted] shares issued and outstanding that are used in calculating diluted EPS, determined based on the timing of issuance of shares in the period. Weighted Average Number Of Shares Outstanding Basic Diluted Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash provided by operating activities: Share-based compensation expense Amortization of net premiums and discounts on short-term investments Amortization of revenue interest issuance cost Depreciation and amortization expense Changes in assets and liabilities: Increase Decrease In Accounts Receivable (Increase) decrease in accounts receivable Increase in prepaid expenses and other current assets (Increase) decrease in inventory held by the Company Decrease in inventory held by others The net change during the reporting period in the book value of inventories of a nature not otherwise specified in the taxonomy. Increase Decrease In Other Inventories Decrease (increase) in non-current portion of deferred cost of license revenue The net change during the reporting period, excluding the portion taken into expense, in the non current deferred cost reflecting the cost of license revenue yet to be incurred by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable. Increase Decrease In Non Current Deferred Revenue (Increase) decrease in other assets Decrease in other assets Increase (decrease) in accounts payable, accrued expenses, other current liabilities Increase in revenue interest liability interest payable (Decrease) increase in non-current portion of deferred license revenue Increase Decrease In Deferred Revenue Product One The net change during the reporting period, excluding the portion taken into income, in the liability of revenue relating to product one reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable. (Decrease) increase in deferred product revenue-Zanaflex tablets (Decrease) increase in deferred product revenue-Zanaflex Capsules The net change during the reporting period, excluding the portion taken into income, in the liability of revenue relating to product two reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable. Increase Decrease In Deferred Revenue Product Two Restricted cash Increase Decrease In Restricted Cash For Operating Activities Net cash used in operating activities Net cash (used in) provided by operating activities Cash flows from investing activities: Purchases of property and equipment Purchases of property and equipment Purchases of intangible assets Purchases of intangible assets Purchases of short-term investments Purchases of short-term investments Proceeds from maturities of short-term investments Proceeds From Sale And Maturity Of Marketable Securities Net cash provided by investing activities Net cash provided by (used in) investing activities Cash flows from financing activities: Proceeds from issuance of common stock and option exercises Repayments of revenue interest liability Repayments of revenue interest liability Net cash provided by financing activities Net cash provided by financing activities Net increase in cash and cash equivalents Net increase (decrease) in cash and cash equivalents Supplemental disclosure: Cash paid for interest Notes To Financial Statements [Abstract] Organization and Business Activities Summary of Significant Accounting Policies Share-based Compensation Income Taxes Fair Value Measurements Short-Term Investments Collaboration Agreement Commitments and Contingencies Intangible Assets Document Information [Text Block] Document Type Amendment Flag Amendment Description Document Period End Date Entity [Text Block] Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Other income (Gain) loss on put/call liability Net income (loss) per share-basic (In dollars per share) Net income (loss) per share-diluted (In dollars per share) Weighted average common shares outstanding used in computing net income (loss) per share-basic (In shares) Weighted average common shares outstanding used in computing net income (loss) per share-diluted (In shares) Earnings Per Share [Text Block] Earnings Per Share EX-101.PRE 10 acor-20100930_pre.xml XML 11 R11.xml IDEA: Short-Term Investments  2.2.0.7 false Short-Term Investments 006070 - Disclosure - Short-Term Investments true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 0 acor_NotesToFinancialStatementsAbstract acor false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 1 us-gaap_AvailableForSaleSecuritiesTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(7) Short-Term Investments</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has determined that all of its short-term investments are classified as available-for-sale. Available-for-sale securities are carried at fair value with interest on these securities included in interest income. Available-for-sale securities consisted of the following:</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div ><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" width="39%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amortized</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cost</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div>< ;/td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gross</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">unrealized</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">gains</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gross</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">unrealized</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">losses</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Estimated</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">fair</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">value</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" align="left" width="39%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -1 8pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2010</font></div></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align="left" width="39%"><div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt ; FONT-FAMILY: times new roman">US Treasury bonds</font></div></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$163,390,222</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$24,182</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(2,044)</font></div></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MAR GIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$163,412,360</font></div></td></tr><tr><td valign="top" align="left" width="39%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31, 2009</font></div></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="12%"&g t;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align="left" width="39%"><div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">US Treasury bonds</font></div></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">224,669,409</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">126,169</font></div></td><td valign="bottom" alig n="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(17,556)</font></div></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">224,778,023</font></div></td></tr></table></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The contractual maturities of available-for-sale debt securities at September 30, 2010 and December&#160;31, 2009 are within one year. The Company has determined that there were no other-than-temporary declines in the fair values of its short term investments as of September 30, 2010. Short-term investments with maturity of three months or less from date of purchase have been classified as cash equivalents, and amounted to $76,104,201 and $43,471,757 as of September 30, 2010 and December&#160;31, 2009, respectively.</font></div> (7) Short-Term Investments&#160;The Company has determined that all of its short-term investments are classified as available-for-sale. Available-for-sale false false false us-types:textBlockItemType textblock This item represents the entire disclosure related to Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 03-1 -Paragraph 21 -Subparagraph a, b Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number FAS115-1/124-1 -Paragraph 17 -Subparagraph a, b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 115 -Paragraph 19, 20, 21 false 1 2 false UnKnown UnKnown UnKnown false true XML 12 R10.xml IDEA: Fair Value Measurements  2.2.0.7 false Fair Value Measurements 006060 - Disclosure - Fair Value Measurements true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 0 acor_NotesToFinancialStatementsAbstract acor false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 1 us-gaap_FairValueMeasurementInputsDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(6) Fair Value Measurements</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table presents information about our assets and liabilities measured at fair value on a recurring basis as of September 30, 2010 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value. In general, fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level&#160;2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level&#160;3 inputs utilize unobservable data points for the asset or liability. The Company&#8217;s Level&#160;1 assets consist of time deposits and investments in a Treasury money market fund and high-quality government bonds. The Company&#8217;s Level&#160;3 liability represents our put/call liability related to the Paul Royalty Fund (PRF) transaction. No changes in valuation techniques or inputs occurred during the three months ended September 30, 2010. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the nine-month period ended September 30, 2010.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing=" 0" cellpadding="0" width="100%"><tr><td valign="bottom" width="54%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level&#160;1</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIG HT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level&#160;2</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level&#160;3</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" align="left" width="54%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Assets Carried at Fair Value:</font& gt;</div></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align="left" width="54%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash equivalents<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style ="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$76,104,201</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$&#8212;</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$&#8212;</font></div></td></tr><tr><td valign="top" align="left" width="54%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Short-term investments<font style="MARGIN-LEFT: 12pt"></font></ font></div></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">163,412,360</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td></tr><tr><td valign="top" align="left" width="54%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt ; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liabilities Carried at Fair Value:</font></div></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align="left" width="54%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Put/call liability<font style="MARGIN-LEFT: 12pt"></font></font></di v></td><td valign="bottom" align="right" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">318,500</font></div></td></tr></table></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;< /div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table presents additional information about assets and/or liabilities measured at fair value on a recurring basis and for which the Company utilizes Level&#160;3 inputs to determine fair value.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="17%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div sty le="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance as of</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31, 2009</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Realized (gains)</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">losses included</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">in net loss</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unrealized</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT- INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(gains) losses included</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">in other</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">comprehensive</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">loss</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td s tyle="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance as of</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" alig n="left" width="23%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liabilities Carried at Fair Value:</font></div></td><td valign="bottom" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="18%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align="left" width="23%"><div style="DISPLAY: block ; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Put/call liability</font></div></td><td valign="bottom" align="right" width="17%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$637,500</font></div></td><td valign="bottom" align="right" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">($319,000)</font></div></td><td valign="bottom" align="right" width="15%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$& #8212;</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$318,500</font></div></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We estimate the fair value of our put/call liability using a discounted cash flow valuation technique. Using this approach, expected future cash flows are calculated over the expected life of the PRF agreement, are discounted to a single present value and then exercise sce nario probabilities are applied. Some of the more significant assumptions made in the present value calculations include (i)&#160;the estimated Zanaflex revenue forecast and (ii)&#160;the likelihood of put/call exercise trigger events. Realized gain and losses are included in sales, general and administrative expenses.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our put/call liability has been classified as a Level&#160;3 asset as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market due to the lack of trading in the security. If different assumptions were used for the various inputs to the valuation approach including, but not limited to, assump tions involving the estimated Zanaflex revenue forecast and the likelihood of trigger events, the estimated fair value of these investments could be significantly higher or lower than the fair value we determined. We may be required to record losses in future periods.</font></div> (6) Fair Value Measurements&#160;The following table presents information about our assets and liabilities measured at fair value on a recurring basis as of false false false us-types:textBlockItemType textblock This element represents the disclosure related to the fair value measurement of assets and liabilities which includes [financial] instruments measured at fair value that are classified in stockholders' equity. Such assets and liabilities may be measured on a recurring or nonrecurring basis. The disclosures which may be required or desired include: (1) for assets and liabilities measured on a recurring basis, disclosure may include: (a) the fair value measurements at the reporting date; (b) the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3); (c) for fair value measurements using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period a ttributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (ii) purchases, sales, issuances, and settlements (net); (iii) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs); (d) the amount of the total gains or losses for the period in subparagraph (c) (i) above included in earnings (or changes in net assets) that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date and a description of where those unrealized gains or losses are reported in the statement of income (or activities); (e) the valuation technique(s) used to measure fair value and a discussion of changes in valuation techni ques, if any, during the period and (2) for assets and liabilities that are measured at fair value on a nonrecurring basis (for example, impaired assets) disclosure may include, in addition to (a) above: (a) the reasons for the fair value measurements recorded; (b) the same as (b) above; (c) for fair value measurements using significant unobservable inputs (Level 3), a description of the inputs and the information used to develop the inputs; and (d) the valuation technique(s) used to measure fair value and a discussion of changes, if any, in the valuation technique(s) used to measure similar assets and/or liabilities in prior periods. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 157 -Paragraph 32 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 157 -Paragraph 33 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 157 -Paragraph 6 -Footnote 4 false 1 2 false UnKnown UnKnown UnKnown false true XML 13 R8.xml IDEA: Earnings Per Share  2.2.0.7 false Earnings Per Share 006040 - Disclosure - Earnings Per Share true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 0 acor_NotesToFinancialStatementsAbstract acor false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 1 us-gaap_EarningsPerShareTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false terselabel false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(4) Earnings Per Share</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table sets forth the computation of basic and diluted earnings per share for the three and nine-month periods ended September&#160;30, 2010 and 2009:</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width= "100%"><tr><td valign="bottom" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three-month</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">period ended</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three-month</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">period ended</font>< /div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine-month</font></div><div style="DISPLAY: block; M ARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">period ended</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MAR GIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine-month</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">period ended</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valig n="top" align="left" width="32%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Basic and diluted</font></div></td><td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align="left" width="32%"><div style= "DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss)<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$12,437,191</font></div></td><td valign="bottom" align="right" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(19,429,807)</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DI SPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(15,440,264)</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(61,466,881)</font></div></td></tr><tr><td valign="top" align="left" width="32%"><div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average common shares outstanding used in computing net income (loss) per share&#8212;basic</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,449,917</font></div></td><td valign="bottom" align="right" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,749,920</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,260,608</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,700,747</font></div></td></tr><tr><td valign="top" align="left" width="32%"><div style="DISPLAY: block; MARGIN-LEFT: 1 8pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Plus: net effect of dilutive stock options and restricted common shares</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,537,727</font></div></td><td valign="bottom" align="right" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td></tr><tr><td valign="top" align="left" width="32%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average common shares outstanding used in computing net income (loss) per share&#8212;diluted</font></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align=" right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,987,644</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,749,920</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 1 0pt; FONT-FAMILY: times new roman">38,260,608</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,700,747</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" align="left" width="32%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss) per share&#8212;basic</font></div></td><td style="BORDER-BOTTOM: black 2 px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$0.32</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(0.51)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY : block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(0.40)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(1.63)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" align="left" width="32%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align ="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss) per share&#8212;diluted</font></div></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$0.31</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(0.51)</fon t></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(0.40)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$(1.63)</font></div><div style="DISPLAY: block; TEXT-INDENT : 0pt">&#160;</div></div></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>The difference between basic and diluted shares is that diluted shares include the dilutive effect of the assumed exercise of outstanding securities. The Company&#8217;s stock options and unvested shares of restricted common stock could have the most significant impact on diluted shares.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>Securities that could potentially be dilutive are excluded from the computation of diluted earnings per share when a loss from continuing operations exists or when the exercise price exceeds the average closing price of the Company&#8217;s common stock during the period, because their inclusion would result in an anti-dilutive effect on per share amounts.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>For the three months ended September&#160;30, 2010 and 2009, options to purchase 2 ,841,156 shares and 3,720,272 shares, respectively, of common stock that could potentially dilute basic earnings per share in the future were excluded from the calculation of diluted earnings per share as their effect would have been anti-dilutive because their exercise price was in excess of the average closing price of the common stock during the period. For the nine months ended September&#160;30, 2010 and 2009, options to purchase 4,080,052 shares and 3,562,639 shares, respectively, of common stock that could potentially dilute basic earnings per share in the future were excluded from the calculation of diluted earnings per share as their effect would have been anti-dilutive.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roma n"><font style="MARGIN-LEFT: 36pt"></font>For the three months ended September&#160;30, 2010 and 2009, 371,945 and 332,074 shares, respectively, of unvested restricted stock that could potentially dilute basic earnings per share in the future were excluded from the calculation of diluted earnings per common share as their effect would have been anti-dilutive. For the nine months ended September&#160;30, 2010 and 2009, 406,847 and 287,803 shares, respectively, of unvested restricted stock that could potentially dilute basic earnings per share in the future were excluded from the calculation of diluted earnings per common share as their effect would have been anti-dilutive.</font></div> (4) Earnings Per Share&#160;The following table sets forth the computation of basic and diluted earnings per share for the three and nine-month periods ended false false false us-types:textBlockItemType textblock This element may be used to capture the complete disclosure pertaining to an entity's earnings per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 false 1 2 false UnKnown UnKnown UnKnown false true ZIP 14 0001008848-10-000036-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001008848-10-000036-xbrl.zip M4$L#!!0````(``Z$:3T^FW8P$5<``/`J`P`1`!P`86-O[ M9==),DD]*#E.MAS;R?HFL;.Q9V=WOU$D)&%"D3R"M*W]]=?=`%\B)4M._$CB MJ:D9F03ZA48_`+!Q^)?;N<^N>2Q%&+S>,3O&#N.!&WHBF+[>^>WJ77NX\YO#_Z+/[-XW\<,'86R,0)7,Z\T$WG/$C8E`<\=A+NL?&"%6U;&6S6 M[?0[W8[1;K\YO!W'/@.\@7R],TN2Z&!__^;FIH./.V$\W;<,H[LO-(H=U?+` M%\&7-?/;6ON;+K4V1Z/1/KW-FTK1U!#`FOO_^/CATIWQN=->I@?1 MBRWH=TI8'#>,/:?CAG-H:QJF:8S*8+VB91GF8%^]S)H*&?8LTUY'@VJ1=4AE M>^HX415X*O?U<^PS:AMFNVOF1`.AJZ@V1ETC:^=Q48,*S\H0W_SG?S!VB'(_ MD"31SWS":!P.DD7$7^](,8]\%!<]F\5\\GH'4;8S9)U;Z>WL*SAN&"3\-F'" M>[WC&OB/0@"O0!M%LM!_P=_"PR<3P6-&B'E%8)*[G6EXO7]\]NO.&P`#J(;# MWO!PO^B6`=ZO0#Z,>"Q"K\`#PQTG)S`%WF1<&^;A?O$T;\@#K]1LU.X:"-HK M-3K<+P$_W-?,KN#<_$XY-RU0BZ_BW'IRSM4D3Y"A8<90]NP>#'6?$T.C;\!0 M[WDQI"?;5S#4?T8,F<8W8&CPY`R5K0>RM('U*#C_"NMA/SO.[4?B?/BL.,=Y MN0'GW\17CIZ<\\KTA7^W,[!I(!0W:3GBF7-'IC%_H\.]@]\N3P[WLX<*"G:L M@S!K("BJ/9`S)^9R,QB%$_;$-8BC8!5;G4-V`&E!&.>/-Z%7B:&Y/X$]X4$X M%\$JP*NY*"#701SNES@HLPO9STF6Y[P3TG5\]HF&B+V#QQ)2&FH&`>]!UDXU M4ZVH$=/C^!G#VLSR_JU[N+^V5X[_E)2*_3WTTP!FR0+H\"&Q*J-63?(6JD$C MVO-0H6WLD:,\#GW?&8<@?4S?CJ8QYTACAE(G#0>E9M?\*(Z=8$KM3H`7/T3! M7P'^MW[H?FDDYL]^\@KDSF2R\&'2G9Q=?OIP],\#-L8>K]C'H\_OS\[;'T[? M71TP(TI>L:O3?URUS\Y/3L^S)[K-Y[/W?ZTT.OIP]O[\@/E\DNS\>9J\0E03 M(*&&2P20<_!7[-W%^57[]U,%9QSZGGYT>?:OTP-F$F1Z\.[HX]D'Z'@EYERR M\X7+`\F9DPT>NQ')+!O@,X^[[`S!!=3%\0O<[^?CO[+=4L,] M!N@\?LW],"+8D$F#=7.%XXM_ M.$$EK\;FK0KW-T#I%&8]HL5.A3!C,9TER',CGRB`$#K$+(I#+W439:L<$8A@ MRAPPS2&T(_9E)C5`D6KJG*0T)"`,Q_>A/QBR6/!").&D+I46NYD)=Z:(AJY` MK@=='";3<3;:NI]6F$P^IOU**JZDIH.41\@$2:YKRI@G-QSD5-8]9/O4AWZ? MP#O-G:KRL`]BCI2V%#7`@D!;#]10E^,PCO1H%&H6^2[;Q=G)4_\`!UZ M\`3RW49-S+7P)HQ][P:$WF%797Y]&2Y-.,#NTTJA3*/(7ZR;6LL*?*EZ-&IN MBT5I+%,<5,"BQK@L>1*(1ED5%"`5P$',_R\5,<&5)"7LK4?5*[0TF<5A.IVM M5)!<(9K9PZ'JO'B`!_(`&QBOBDZ`\:)XW4?K18QV&VP+A'LP.0+9!BG1`9V7$P`T('R$`<,#%G3C@7M4N M"4G0G+'/E9P="=(=@_PBL%3"!<\P4:,RTQ:\("X?*M[W3U`"TR:&AGCM? M<#\%G!!O>V(*&18897P7APO'!^'FLM""SU@)"V-,8NR`4\D51NF[B_;?XYHH M\IXU<@`\6;VZQ4MSYI;MK^H9\XG/06+8`B(6%_SGC>)IE8TDTR@P/U&PT?QF MYK)((61A,1D0IJ*%HBL26V&\I;TY:A\8A'0"OBV-\2\WE(E2#25,BA%NEG4" MWY?%,G>T_W*!J`4&%9GV_A&"NE=\8\F-@FH[L5<*"7)19E$#T=/&_)1BG8+C MLB*!RYS+(A*YVYHA^S"*<9*[*!0K/A"NB%1/:*%HQYA,)`GGLN9U6YD^9!TY M=@MQ(X_S;&97>%^*916J(EHH0KVZ;FT4QY8=>S7TZ[`CVI52)&,`*0)EFNX, MM`5(.N(!+N"`VHF@CO?%33^4FSY:ZSG+Q@UM?>RAI<\#;.43R7+CX'I\PF.R MD]H1K/'8652W[.2]PIUEB*'!O&(-TKM,/.@B&(L6^B2,<67JD],#9SO+$0$2 MI;`8XI=##+MC-SAM[CIS%,EC`T\HKPYX['<]YJ(&T%\F56/M2LO`,DM2G[ MRRRJT)G_!*9%>(,.PN,^J$F,2J?="^:@%"*H299-51W)9?X"7RG]8YE:+,W4 M@Y+@\U^[YEXY5T,DJ>0K@X^$N[,@],,I>,Q=:V_=E%[O2&KN?>4Z1+9NHP+] MW>Z>#L.K"6(U&IDYN.Z!40#(WE-^#WOE6P[>DIS#U/=4QA^$[-KQT10&N)*0 M`%+'A\@5LP`(?,5$Q<8W,'1,AM!+,,"]Q1*QYRFQXF?FZ3=AF:C3-Z`UA*6_FHO4%Q?<7K1IIE($DD%\DRCRC M1&C_!+AR7%(5Z-EITNL*(4>%5UG*854(KE,B>A6$01N"SWJ4L M*AMR1\H0]!R)+ODNY71DYCP8Z`SE3!@ZE'XBCR6$KUL:3!;A6I> M7[G3SR(!-QQ4QZO.#]!L="*4JZ$'!(ACI4BW:'OP:!H/^`1$KS;8JM.ME%2" M@S+K#@HF=Q&!D+#(AX=QW7K5.Z_VG"CP7WJC?LLP#,2Q[+S7X&KTHY$CO'RH M/)7^D$Z`E-IS4(.99I]A[`NA+H]@UHY!Y"H``_HKM+O`YJ@[_$H^/\6AR[FG ME0M4#_1>)?D0?\]@VK3)'(G@&I1XWL1E!N$=`+@$G$#"1P5F<3'Y2!DJVI)+ M[F:@MQU2RQY8??Q=\+HUTN^'81A;R^H-OAG#1W,T?L720L#1P/.Y2.=J8<># MZ8[.E.*/S410AGDQ.>%CLAD(Y)."O/T8#T=FMS\H&+X3Q??$((QIMSL:#0?& M?1B\Q.,8>AT:XF@,(!2S.IA8)I[:O\7FQ^76VPZ):?7[MCTH69AFP$]*)TAV M.!SV0;0;D_D[QXU(C"DQTIQRRDU(,_#4"V4>&(*C^T\E[;T1-REM307*+T!, MSW;!1\H]=.&J:]L3?HIP=\\R8'O++&>XCQ3J\Q3C!QA]U9,(EQ=E`DJR,.^2 MA0U:!DIF#WJ]0AA;8OSQI30$*=EV;S2RC!NV#3.O M9W^]E"YHH5^QNLP%O3M34MC*/H)-&)I=JZ"N!.EA,<,\,YX`[>#)&`9EZ'<' M_?68S\.@K1/#VXK,OL[;P:6">&E65!:`?>,:.T" MK;9I;$#K$81QGCIGZCO3\NG._`V^:-27">#GZF!GI?%R,GBG"?(PH89$/7]; MLT:G3HRGM#`K(T.@C4)%*M8&<]KH=$LB60'UN=(/EJ%M=/K?+P,#8J!G?+<, MX/J!V1ET-V?@6,]U.BY0/\DLDXO)^S#TY"4NBF_KH4QS,!@8Y7AL">(CD`%* M:2$-@]Y34H&9L-6WN]6%G4H7\K%[B M1-A6/0;=@649O9)/7X+X6+2`CIA]R^QU+?/)::$$O6<9_P/[Z;EP_IP0;_.>FZM+5:W;\,0%70L`7P4.H89';VGI0.TQ#:`#&OXM'08 M6\CCKK!SPW`ST[PPR(!M&R8/A_80::['GC78SXQXB)M'?:+=VH;XK$6^+9]1 M^2\G<"8^OV7'3B33DK?!,@,YX$^JEX9_K(#KAU!1SW((&Y6O8 MO"`PGWPG2(X"[S2#M+7-[^.:MF6,^J6ECW70GR\G,#@F;C^4O?I&G'SF,HD% M;9#C7N`RA<7KYJVY[>5MF/3M[*8(GH;0+A%JEO*KG"OZ&S-7M&U(WS< M?'L7QACS%'MPC__]Y@YS?#$-7N\\]J>;]AYKEM:CGCG,V?\CE8F8+![[Q.%] MQ;^5K.\ZZH8'Z<".TIN:=E/VJ?/:%D_^@F-?@"C']/H,Q<,EHPKO"#]8T7_?""^9 MO=XQ#>-/N?8E? M3TX_M]]>7%U=?,1!VY0!)V%47:UIRH4W'1%S6!N2MGKV\$M$3?*O?YJT=C"J1G`# MZ_9D:P0;A%(OM'U/8_JHT]2RG]V27<548W,!IC;PU@=`ZT=4_TE%UAXG M(JFB?"`1_6(.NJWNR&A9EO7-I?.0"=CC2,?JM"=!H*SSUAN<^`,ZS7 MLU%-,NR&_PE"5>>S#2^"-B#'"TC3!9T@.['-EMVW5[)PQV"TLIIYXIK[ MBTT*(6UP@K/X=#B>.D%6;83JWJ821TBRH[R0;>V3XE*?XS"@723ZXRCP/F$] MN"#194#>B<`)L$H>U5&E@7G*ZT">[#BIN<DJ=V=4*DGBC0-81-PIU83$HH=3L"`B MC.AR!Y2!FY6]CGB8>3K8ZWSU$\$_@5SDL[1Z?7^X] M;JW6GT*UT1W#;V=:J:I?*FN?7_?A%[4RL=`D-5"U09S4HS+7=&I9S.DXLK+F M6*$P,]ZHSMIZYV4ALZL[1`"@YUE-\>(6X:@>UK# M"_Y:^HJ![2G.BM+C.7+'0XV8*]]=U(@/D`6JG9G&JA)[T0[4&:](P.@E$R)% M+5')T:V[)J:@*8+YE5M_5<"3Y@Y^F4-@9%&&;^*'-\7=(ZJLHLQP8KGZSXW] ML4,FF:R30_%8DO,AJ,@YV1^LM*I)S^A1I1OS0ID9!6B=8AT(ODSE!YC*\G[* M#=$R%N*E&R0<76D(S+6V]F3C:=IKP'<#7#(C*F:E^X"T)J`*Z(JA:Q*(95/0 M-#..@@`SFL\D6 M(OA@2@CG0M*%X[6[@TZ/*Q==O>CS0W[2H[0,4S[4KL)495=34-PT%D%N2&'4 M4D=7>\9<"V^3R0>YE7_PKU*WVK>OI`7J8H<6\T,G@"Z5R]Q4TM:BZW(H!^1X M>4A"+H9N`I.4Z8*Q4X83"R"GL6(A+[U=*;D\KMRC@RGS.+^]#.]?`28PP?0Q MI*,2UFK>42TP[JD8$$LTDX3N#OSX!"8%41GJ>]82*LJ\8I:Y$!LFY-QD"/FM M_M1)!#*=0+@I=#WG.>?YG29ZD("^\D58#;6FD7RZ,\<1LG(SD<:)@^6E,)*1 M[P1!=M4`M`(L`(]\%0PL7<`Q!HM$V5!9&(6Z5%^6Z&Z5%EWQ0Q$"!"&38LB0D,*!YHLM55%H8LHW^`!3 M0(^OUC.<3"O5]29(@QY"#/-]9Y&+B4K!N\`T>76@W1=T,2G69I_S;($$8P`G M=F?Z%H="72#N!P6>T^*&%HAB()]JM1MUW'+)9+KH):"`7M^QHS4>.=3LL52J M6Y+`-,`#B%3T-7C(M;K]*?\^W<6"<)ZN$XV9"4"BFP`)]HV@C^CXEW)I_3!> MJJQ?N9MED[6/;[TV47SFK1>'R"%&C=]\US[IUOO/Z)\W+YZ+.`:MM=9(;O MB'IM/2C]8>D;\YCV>PP/O:-YC=)DW\5L"Z]OH*LF MEYG`]A^@]46`RY-8+3@6UV2#MA=ZNPN:4ZX9M`;X,Z`89&WWMZ8WOW7Z:A'Q MMCA#S^Z:O9Y9LH4;X?EA1&"!-Q@-3&MD#GY6$6!Q M(ZMG](:6_;.*H`=:T+<->V3?>87"*A%4KQ(HIV%9?>,$-VMH!3C2A=`Q4I/U M':)R>?\S#>@B5O;M5$7D6]?]&HV&IK7B"H%F'-\#9W0]@@T#U[T79P]6BAKO M:G+O48BZ5@_Z+0':NO#[L-<;C?43[;%'O_&>6S39GW M.^1S7+*?+;*LZ\O7J_:7V%Q!/E-=MJ(?2X<-^X-A=U#*659`?EI*L7:8/>KV M#;N_.:7-!UKJMXU`*ZQ.52I.M7749`ZZ$#EWR[7-FN`^.FE=NC3(MH>&U=V0 M-%UJ35<2>5]4)KNF7>4+7;I,Y:<\\:)7H[_"SP^"W[E2\:2%!- MJ`4T:,0-_S7!Y%.AO)4]BP%*YW/)$$[1E'R%*W5[OMEJ*[O8[9;Q!9%#$&`0X>4LN__C*S'BB0($50 M?`L7=S=M"BAD965FY3L!&Y=JOJ!Q%X?H]IT_M.+QXFGY\!M*U;'/C=61>)JA MH]V?R-=O__@$OV#0(!BL<$IW"=RKF+A"OLN2G_@>(4["I0A-$3XN3X&G@?)@6`_X1'D1 M:RZE,933(F:#VB*\-/'_&?/LT">,3J7Y?1H,`Q\']N(([Y#'X67.EH!9I,`D M?I3Z`[Y\D2ZJ(C8R%%_0Y8F&F0]?5OR>DJ4OVW.MX#@W%[*AEHE-8L" M.^F2/#:,3?M_@@`R(K)(*"M`S9^E]&O0GB=3SHF4E4:#;N5X<531F,S1IEP6 M'B#!-Z6W7R:/T"Q:%0+D[B$24A2,7_!>-C?"MDX270F\E(])%OD-%(CCDP93 M?7ZOG%FLJR9\WC8(L'^*V>J4,[,83U)D+HPEXW\K0W5V_F$AO5O&TSC`UP%= MH9\\X*!?%;`5O5+U7JI+\N3F4CTH'U!&],LA=S6B.2T20.3<:@XONO#4!&I, MFQLD@=C[*`A#-C/SF>?[\1P5M2):.!'-J^;`JY7]8G$*RJOG5+2<\@&R/(GP M0Y>\37QT^C`8C8":Q0SD."TF9E?,,#\)"77X-X4-<&-N1!88L!3CH3,E\!S"5Y<[&)=RNO*U/(!>IYD9M(PIVPQLC."`;_4 MLB(G>P"4$$]XK_U'EE#R*#P^EV,X7PJG#WF@7"V>]34.4KH7R.:96^8G8QP_ MP5Z2E@2,?8<7>-X@W%HQYO6AYE`'WG)6)$=&6KD+.#+06V)*;;L'PP4@P5_P M/+3#4$5^AB]P:B1X[Y'>`\C%`E*XXE+Z,UYPY9M:&4TB?3AE*CTL'?/L'3B@ ME/9<3)6I(L])/&1A&RQ!H@=4N6:?IB?*GQ_&6-T:9_/48^33.)J#I8TYR(O@ M+"\-MWX<#`0_/8UCP"B<>=*B3R&[S,$'*'O`II_R54$D8``/&*\D5-6&J5`D MTPRUCD!9L!*F,<.D[^>9;U/G>Z*2.!*JM-)-RC2K*5`2NJDC2[P,Q"^D><9\;9QYN/M^<,%UUIW*P"#.0X0C1GY`57HSB M)1*E">K;I&474.!7*5%>"KT%NS">?-)W63A2U;CPM])76J)4A1?0<*FN0;1X M[@TM"1O/34^% M53*8E=&A2G/D#<>9@,09OV^HXD_^%<_@`=;*\)K@%)$A_S_`E8X@5]PM)VI_ M'(@>5B)T?8(A>@-X@C*005:09,HKU7TD,EZ&@.*MN/OAB@G*Y6R%U$1O!MV_ M>"W=%RP]&*.Q?N\/_N1,C.G[Q?I^PL0M)BK`*,&)1I4,A4_5>`@`.+R"?`/^ M,8P37E"AP.(9W[QD+9]P9KWG2@2RL>8F`@D4"D?P@*F;CB]:0I:4YI@E#NS^ M2(_S6@Z4E@`H7*-%013N$60'4/=?8BA,^=NEBT^_D*)%`"@/3MF]#.J/5BXX MA[SB-#2LSYR'.J<%IP%K@"0(TC&C:U]SEW$A#OL%54$Y)0I/A2Q9*$E^\@9A M@0N!+6HXA)#G4ZIX$976IF$`**JUJ3?%1G0S]JU*]!(ZXE@7W,Y\@C8=7,?D,YZHHU"V=/ M`DH(K_(16(+/97`QY81CQ&"$ZB@=/1,8$%,`BFPAK*^%\$`2N1_:@4PY><9JB7^@(95+(A1NX^X!A<;`=>U/G- M*Y^Z,B8G$/)+1O^,NN+0#X;EY?A**%QBO`F\=)JB[2!J#TJ:-D)6:+45YI;& MK62$B`W-^&+5H%DKY%%\SY4!49)"E4RP($,T^D65EO3?:4HDW;'22C8L/GBG'=M46JU`]L.0!PG33-::%;6@ M`WW&\XDJ&@?F7>/%D*>):K>SQ]8BA%=J_:%NV3@*G[7*5E#OGN+D3R+X*0[^ M#$'W5K8J]ND(AJK*3OPGOQ)X?Q#A@`+Q'Q`OT]4?A,1H_X-%EXEQ!U>CC]8^ M*S4RX7\ME3F+JEA1NDE.GY)^@(R-BPOX@ED_5QW_X=?,'XUT+^(O>1AB[:-Q M]O7REW-`LA( M-9;P2,)OCGA`0X*YSLA53EQJ%'S':XF"8-S?5=1YWN?/@&>\!D%/>9!-6Z;^ MLRXK^:/B"75LU(8#MZ?%$=-+93&L?#SA3=U%?7.58I?$P"?L:^2R., M?_2\N(H185-8X;O4B&`#H!JR/Z6"%20E=2]/0R8GNBM_);-/^5E:/97-%05QE/R/(GXE_-Y@=1H%D@ M2GU/N2K+09[C.9DEPGFMQ7L[2+M?N@0KK/ZU#F'S!K^T3+9J]"_?ZVL-_L.R MU76+;BU379-RZE^-375XTOL7G4HKHQU*5)3(BN*1Z%Y,R/F`TH["$60D6/;+ M$H9'@B0-4TRX%`7#B$&02>=%JC3#5*/O.%%1',Z#2-A)()5E'M/1()&2EI@K M#28@31(EJ&E'Z;S"2;FOTN$ATO4JXA?$-C.^(Q+%JZID694NA%C;L]Y%""X"Q):IX!K4Y-UXT3VH%H9`MWI[B!,6,O^"Y_]T<9*\NHLI>) M57Q36J"^T"J*[EO*T1=K`I=(Y&D,-/@$,=8V;I'8M%NV M".&UA)-+F*-%SIP.FS(2F6SN)=?BY;R*4*14GG7=K2T3JT>WP3OWB?'#3N7K MKIU&OP5PEV1Q)*.X\3.PP2L*7G:(R7U>%5]TY\6DP&$Y8$P1)^8CB9+.(;T7 MI.H])4&6H3@=H%86LJ'0^Y39ST4VC^=SS5L(GI9D8-&/^RR8R7=0`!D()E=X MN7,!%9,6Z97^8!RP1VG./_G2/3-KTTMQC*[UJ:[4D^#CGA>ID$R;\'@5FIKSKT,R) MQ8],BA:I2(HV$'B'YHOWDJMT)`>,>?H+P5:F18*-I;S-=57,3EJFZND`"_1$8#_Z+ M/"`81F5AJ:!$,0-/LI%9C<&(=/.Q+ZQC[K(61CPY$%)>V,**!1.,*#Z$O$,+ M3U&2CF[>/S!2SZJ%,\K!&:K5PF=A,%>D'>7)-$Z9T+,KGRAJYB9H_)%^"S]* M'9M+30$"1?K)=S\L;UTD/O#E%:"%,*K>BU#5=KP?](R#$/$K!D\;0O>0O#IFH"ZFH((0K MZ41-^,,7[\+"NI$&Q6F>PSYCIG?26DW8`Z;+DU\#F?W1#PL;=S;1FH?L"EDO M10*LFJ.74A3KW>?AGRU@ORFHSF#"%VDJA?%,@K&4E#+P)WH8E$KGIM20FOLD MU4B'T,\C8&F>%@QLG^0/18=3S$L7L4FM7WR`;$Z>_/G-/OF%T*%,?)ZY,:0V M]=S-*FH"10Y)99F>0@D7,CA^A^O8H%VR).)M745A1$XY[8OQ/Y/%'U-C7KZ! MV?BX'.B[W#PEZR5U,YO%@8P#^)!0'>8&!4DB0E?II\^ MA'ZDBL53#,@.=9I+6G!_P%=.-F/V\"7V51SQJ2/2`OT2I'^>YF'L4R]7K9*Q M;WB6Y!.16899*[)**7PNBAC*]=L#_9!(C`CW8@*'Q8.+:29U0!ZU'I5&>6&, M8U&O19J.E24!I<2KIU39$1>Q*-IG.X@'$>;"IXM7EF,Z2HOS[A4DC$K%W8B7 M(,LK>I4'Y'*/4]$9O-BYK"6'+P[1>\%_$_$I[J#!'%8V\E',BF*?ZB]2*W5L M(I6D%;@K]-F/US=7U/H=KU,JY)@!5K@Q4N'="`8`B!_FY38:W#^#'F^^&=4! M+9:.E@50\OWB5V>23<1"A*<\D3U"Z.Y7KSX1/MB1]'`!"[&Q&%[(0U3/!6#&9`"0GX`GHH\B44)\CJUQS M<'!\D9V0 M?X=+YR;Z*%\MY@S6;K[;[9I=S].Z::[^KN?=-;95FJ*0KM0? M<6ZRP>L;)N)("*OG=6VKZRT9H;"T@^)A[`0;(O<\K]\SU]_)F1Q<<([>`S57 M0;GJBAP$\LE=S-;+RVWZ()`JAB%7DM__P%>\C(8T\F+- M22`7/:!A<^DTD%6^>WQ[-W$@1]?U>AUW8YO_E?Q*I5SQN>:E^*,@G5^QEHV_ M4POT'EYSEN=9?0WTZH5W#9KW[F?+=;N.8SJ'!AJ.&+%!-W![W>ZAP0;$Z#J> MX_9=;V700$-+CH;O0R[:)K\A3U@YB+VM/OL3]A\R^3B`?Q[)3U>7MU^N;XTOOW7AR^7 M=Q]^_W9S]=6X^7REMT\NKU+T"!<;_@CV!=@4_\!1EQ]P.#OH_SHHXCG^&#X% M#^$SU7?!A65?.!;__*(W*R6]:C>!;4@QWUN-)RI^FOK/>)&_+.MOQ!MW_`74 MQNLRNN/T7*^W3*[/?^3P-X92PNOJ#=IK[4L-[CJ3^A=J8F`_1A>2Z:A-./=/ M*[U,)FV#%8B\JO2SY>K8YS@2%#2C+]4^2[?/IU#5_=!1[QNUDZZ'\[>L5^S\ MAGPCL[:@6BBU:YC"(LMN5SC+#`\2,V@+3,B_]1*7;9 M$PL?V045EI$P/1YYH`L&A1*UYV_N6J%/"Q&<,*\/_ MM@R_J%:252O#()WFLB/<(/2#">9Q!]0(F%80QZABR45X<*8K#7F6>$XHC7.> M805JO*F7PFL%\M1C1YM./]<>S-<<$ZK.5>6CRO*F(H^%\C8Y%(O;II3A5^W2 MZ(.XG$Q/Q0AV'.9:;56*8V,@3TA&),B&I;?R7;$]=]#G`1A-8%(`1^GB%_JT#V8U1`8@%T$KKES,1 M5#T]21C*6A+]Q+7.BN*#Q9'HJ?BK!.+K7>[ET<`4'V=6 M:NZ.I%4\^!F?>ZTY M:[FN7=[`LO4/;@MP"&9MX%7*U9D83GQ>2KXJ[N':R5?*=?:*I+(+V_1,N^]J M[+#ZUXYACR"K.E;'[5NV]:HMWBC///DIYR]\F0'%_9CJ\=K^;LOLV)Y^]U-US8[G=/1TAQ>_<@"@@U3N=#L=T[%,:RW0/U>' M2Q<'R&=W]"F.'C`-\IK=9[#88,WK$8P/MZM';:K7/2RX"?N.Z77ME>&^FTF> MFTMHY7\7JN.ZRD:G9]M.1\-FY;*[!`I0!>H/''%G5:!`0/C1`RDYEPO2">4# M_.]OTC]NF>?&'*8:1^-6Y]CQ!'!>*8V#?4,_^L_4^+W]M/J.+VR6_RWN[;6+#H)`Z5X1Y:KSO]CHM(&[Z M\RB(>'-+/E-A48\W;"T2IE3:/<4*2*0>?#V?(FSOK7Z[HSZ"X[9X#;?61WJN M99$V1TL,H\,B'EZ4K0JXY[97VG,QX(ZW2I[S\9?KG=RVJ9J.RU2'G7NR_*&8/8X=#^9_8VD7V?*7: M4UY*6S'0L)BK++MTB6F01?$_3LGB[7!%@3].[Y'JVFSA&8U,AJ\)$:/&,\HP M%E_E<_SH@P:4\N:714N*2EXKA:RTYD+E):GSP*+EJL=0:G5JO%4%JV!LFNTY M38(0N;DS4]D7\*8,XD0-T81)E$\#=MED&L;/#/\),,D!V"3RJ'L^,>],=":D MRCIL<4'C`U7IL#83FN:2R&:GO-\$(JI"@)"\`:Q([%#P18SE%F38*M61XP/% M*13D*.ED(-'"28U@Y[,%HE@?M)8&0XQ8ZC.L*9%U1G#-[)UGLXF)"0H3%>.P M9R`3="][S@5Z,VEQ#ZCA`/+RN=%[6 M>XUTW;ATO05=`CC:3YZ+G=FV['BK2Q[5CTI3960+%-4)\N/U)>D,LKD-B-\' M/E6(&L3.,Q`<,V@OQ6TM>0FI[GVO8Y(2`S]^R=,Q6B7I_3-%[7"@A]:N^E/^ M)RO%^WZC<26A<472S3C#]\\K^ULO'L$PIUA@_S51T+!0I:!.^;CA]T[;+O8E M^/MYH\H&\91L#RDQA_Q$T`YYWQABYW'"1,I$*I(E_CL'J.5>&\;:AMIB]?N` M7SH4D;C0#T>`B"088K>X,_?"GP11#+Q$/[0,]^+R MCA,FY@_DO*6Q(=S,@NO.6T6N#+;$DRT'?_LZ;4PH& M;&F24YH.(`P3X^#2U1]+,)UC1+D@SY-I%O->K?#5AN>WZA-0W=9QZ!(G?T4R(P:\7'T; M"FO;$U=?J=5U84[CF!9E0>LMU?'4(Y8G<1@_T`4HD489GJ2\V:*6"I0 MN@0".1U4G_PR3N((#+4I?HAF-$S]%(=-4*TC>@`X`E!%A1_^2:VY1".UA9Q= MW+`)T]PO$AER/%TL8)^7:#YFVF%3-I]/_2Q).&H$)J*CXDT@[EG#DA>:@#FA-$OI*AD[AX$+G\QQ$6K?W,LG3.9#SV"F?ZP#KI/8=3'N4AB/P1DXW;YATHF/C_ M1-,MJ,M0D(I$!&@^BFGR.:/BU/N!-,]]$JSWNSUU-8U4-XT0RO]HZ>M&%)QV]^!5'0T\^ M49*\.A(<;BK'+^*\(\F[Q0G-G$O)S5WX`[E:?H)_/?4'P[E?X/NG8W_ M_@XLVO]01Y(EZE]#E`P$]7V<9?%$O>!JS[_B"&?A+>.D8C1.-M1@$]_\Y?;+ M]8DC_XT["GWPU2N]XMVH*E;6'CA[UU*AJ0G;>EA)JJ8RF) MVOUPSL[WC!?*NENM'L^TD-]+_VZH?%\G+GV"Q4&!)?IFJ-WL'SNU6PVUUSCQ M#U)O?2,4KNRG-[)?98T\\D$T\>B-;'S>+MRO8/M!TZFKM.LLGI;-HRH]>]7C ML;RY\[G@OVW?)JLZ#&4`"[-W]A-EX&U-TI8/;-'IE2^0V9M!_"?YAW>C%94_ MN26DOK?Z+8='`QOD[!(YV]0P=H([ M9352;->H.7H99C8BK#[21/!!910UBM@FL.JT[$:`+?/D8T>8S=/-T8NP7B/" MZB.-LG6^B.2>7_+G.,\:(;81(6::C1!KA-CZL=I&G*V!OC\6Y9^=6>>-7-N( M">7UK);5[S2HF7,#M5S7;?7H&M7[B4_)BFGJMDE;/ M[/,:-/B6TR$.0M$Y@BR`YI`76IV>W>HXUMX/N+E):N%]8UM'F*O9;D@%0_@E(]!*OY`I8X;P1"\ MT+G]]F7>U2O1MK\.?U;HQA5;31^,*F"4NI'%YKJK"D%0.U M;J;&F$6?!2P85[U4I2/YT,NI%3/NJ)YWIOK"N,=N)0D^5F@A)=UC_D[XX^;Z MVW_!`7OM3ED8;XO,EHF,1:)-/^$=L`*&*Y;3M8IL!%&)GF53D:%H28!]1>+) M-&19,;,P84#OK/R0HO3J?K#]Y82_05%[V.)QGWT'],X8JB_0>]#Q['[+LCJB MCVO?;74L:K6H^S3D=`F]A?:"/L9JE"J`66J>)'N]S1<^T:=Y=SOL:(_]PX$B M3[4=S#YIX,-L+^C*0Q8-32I/MVA%BC1068M,1ZFZHD3L>V:,L)L:A1>P/S:V MD:8.%VG3WZ)&?XN3=JG*`L@FG^C59GNK9YHMQ^VM<>6^2;JS&KK;2'ZNA=$M MRV[(;C6RLQNRVTSZI&FU7&?E',&W3G9.0W8;(3O7,EMVMY%V*Y*=NUVR:V*F M6R-TRP,9:RW7)K<>'6CBD@U%JHB5T[(Q-MD[')K7S"Q\,S`Z?!=]QG)5!_D8M7OS!(,XQG%.,6FSA.(:YLQ?/ M?5&/?69KLS3H`[;G.?K(\B7+[QUBG//=<_I@^-0$^(.?8!^^U+ACB?%U["=L M%DCY!#Q`?W]#HZO=/P?NS%_S\_MNWZ^:@1LB"L%XQH$8AH/AV9RWHL<+ M$P>B#L3DZC#'2`^3YS2%#& MR@K6LW/,MLK.&W]^*\8*[8=O=KYC?7C2&]ERTXI^'Q;YZT69VXBR1I0UHJP1 M9<<_9Z#1RNJ<^&=E`+T1$F\DV9O8\RDH98TD:R19(\D:2;9OG6SM'![=R7=` M.3RKG,C7;__X!+]0$=Q@A5/Z9=;_O/3(5JO_=`[`1;J"P^#@8#MDO.T=ME-C MYGHZ`LU^'\039IR%<9H>1"O7;:IY.\I,LENNTVM9_>6U].L@9YN.R=T@Y\SJ MMUR[W_+,7IUFFF^%=LZL3LMU,:?8;=!3@9ZNU7*[W9;G62NC9ZHWSX'%^O$@DP%^BV=NA2!W0 M.K!2ID%#J7-U4!ZP<;_5?R%C^DW>`7`W]A`W]N:'.)P"W=A=L]4UO08W571C MFD`[VZ]I/07M_B[,TQ])BK/1B`TRS`LC:QRK\-,,$Q3C*2:,I62H8UYU$@SP MMBC=$@T=S@\DZ"`IVHUHW^D,FJ.GFP8YFT7.FY;N.U#MZ[MNWW*$;[NJ#ZC+ M7J_5=8^^+_%1I]8=@EET!&?<\/$KS;OFC(_YC%=/1]P MH\[LTENS2G.BAF&6:33['Z3QVO-M5)IC5FD:#CYUG:8YX5-2:IJ10H>@?VUH MI!!V[!D&HQ%+6#1@QCW+GG`^RGQ;'A&N"U(C&_O9W,_1(,R'C+KTJ-2-(IL# M?_;3-)]@?Y_O+!D$*!?R@9Y$F0!2]N&-OM#*8Z]G]**9)`\>F2I!@CU MX)O+#\EXDZL\'!IC_Y&#.8E30!2<23`*!CX@+8#O(;C1S.9.=*['<='I5T4= MG/[X84[CC$59X.,HJWN-\K!I%/M.)#DT1B!*JUI/+6DX]30&'O`-M&'XZ]@@ M+8ARI-,8'O,Y`;+O`8[3BA/^`GY#4?<42)"`8&R8<@:0\6]8%A?B3PCNJ*+V M$O4.8?O84PN>Y06$+=CQP,]3HN8@X2R8XMZ>"#=`N7F8T60<_+]9<#''F)&V M97]"+>8:8C\`8O]8ZG=&M;%U^INUE(3,8F.:)X.Q#U1BMSS7:EF=KA25^#C. M^#9;=L\6/Y8G&K60.DM4N(#W."N)6Z."G\2,)3'$YXE5LZ" MY@4A/Q62G:9[E:F]S"8S#/KDTP0HY-,T55?5,DY=SI5M0QX>MJC;U-FY+=,S M6V;'+I]=IVNWND[_=,^ND4:G((V^E/-^=FC]^+5Z[B>9;']?&^85ENU[?LSR]6_7+WSG([ED1H+CC[PVZ-81R&./M0_>W\I5;2O(V"OA7[I:WTWOV,Z12+V9?6/$3( M/:`I=*L?(>A=`MTUCQ!T$SFYW756!9T/&8AQ`+":%'H6L6P.ML]Q)&SZZ.&& M]OI!/%Z+-8&>+SR[XUC:^(.%2^\-2J1=U^Y;KG/(4"*9VE[?=75!=WA@(DG: MMFOWS%IG?AT/?<<[07T`I>[:S]3U,63!C_(9_@@\@0]4(@HUQ0NS?^$` M4R]\L\30`S\=@TT;/P:HP-T_&V>B\.*<9DFD5'GAHT9)#KU^UU-6RN_+%CV"(23*=K=4Q/O_C6V..9O.UQ M/X5.,F0CEB2P4=CZ,`>=6NB+%__G1_XH9-^-*W^:YF&Q8W\0)Q4JQ+58Z`M_ M_XXO]^TIKL_'7L^R3/=O/]3]TK'MU<1)+D"]GO6*O0H))N6'E&)S!'HKGQ"R MI28=PEW5,9U.OZ/+U[DU=PT5W$V.:UMNW^L<$%1DM75[P+/V(2$+R*W?=SL] MTW%7@>HK"T/XO64\L`B>"YZP7\GQ=)[;CNAK4JWWHT+8"U`K[L#J6+LJ/_?O[1V/6@ M,.?<6(30G<:B%F%A=P/#7G4.M9!^7011LV)"QZ+!7D9%>$3+H$!W;/P0D1A) MM9,<:">IG`/`[>_=ME=@=1+`31%'M/1[IVW/_:7,]&U#@_WEF62;!MVRVUVC M!++7[AL+(!56Y#/:3@O:ZVM'Q'"1>^/4TVS!BY`?BDM!B4I@])G;QD/@1/I_%!IM,P_B9L;0\ M,Z[NL?`8ES\%T_([2.D,$`C8[K=[/(CYWNK"/V<0K+&F^M?FM[,.D2W:C=,3 MN^FU._W9W33";CO"KG)$8CZ9^*CYI"_SOX$.+YQ/CY3RZ:L'A`X^!UH$4# M_45@V\Y_H!Z+2(0_]K:6PLU5!<0W$')<0W2(:Z/#\QTL.L*>&G2>N,3]@\ MDBU+YW7G5!'^XES!M\G,#4EM<O;=V*="U MSF-G/L/E()LZM]K'`_\F6.)`CN`(06ZH9N]'<(0@-U2S]R,X0I`;JCEX#6U] MW7[!!)WMY(U4(>T+2YF?#,:\*1=[9&$\Q2R/^KK]23/AUD!^7Q]2,?EJ`:C] MK8%JM2N&[YR4;#@HRCA"D(^(F,UVA?NB(>8&Y&,D9J?=;8BY(>;3(&:[W3EQ M8GYMOMI;L$M6J/NL;Z*\#K/[)IOUPE4GN*7]7;,K&D![#'-M]9`:_CF)+>WO M9G<:_FGXY^BWM"_^Z;V+?[IO4W^K:6ZZ>S`W[=Z>S4VM MMA[[;+W>M*R'Q7V3R,J#M@YB3RLZLVIM95\R"=N$K"635B2P`Y5)#>,TC/-: M9TS%R/2&GAG/F]K6Y(HS#9[DU]WI"G+H+#.R+P;U54UNV MQ0=')18V/8%VB["U)CFK"4 M1:J?X/&T/-M_Y]2YP_SZ[1^?X)<@`_$P6.&`J36M<4M-#%6SR:,Y@,4=W/;1 M9JZO"=OM=)FSMW>M;;57TG)MQ=M5PY`2^D^L8OAS3G(5.V%36^SE/M9-MBI9 M3K$[ZP:SU<-5S2QW?JY_R$:TE[P1[4YE\_ZV_4$._+W#*;X'0LQ6OR'FAIC7 MJ0*;^`$.O7LC^[V"+R1@%.0OA/I.9\4E'%_L/>/\%SY=`$?"_+7Z#8I,VVU[K[Q<&I'9B,SMBDSI M4=^-R&RB@WN4W5W;:=E]=[GPKI%T\T)`OHDF'C`Q6':[7Y'*?>2$<$@WXE8\ M]\V-N?\;4W-9SR>N-5?B,4E!EUQ`3K>B0G43>:@Z\`<@'9MKLGZ@P#;;YO)` MP;'?DPTEK$0)O?9R[^=1DD&3$U!;('2N30Z&3ZL?PO2S%_ M#-O5X6SU`?Y'%AN/\'.CIQT_UX&>9GHMV^R=G`AN=+(UDC?Z;:^BI]F14T*C MDS4Z6:.3K:N3=3RO99G+L]\:G6Q_.AD%F:CZKE''CI[A[);=\UJ.>WJ7<*.. MK:&.N6WKM$-)#26L1`F=JA88QTX&C3I66R"X3LN"_V?O6RJ\MLE(TSBB?N.( M+Z#T)0'YWW@/B:9YQ*N:1_3<;3>/Z)RB_EN3[%\H"YRY3:QIIEI/K7#LUQ^N M;K]*R1RW9:U>J]P0VKQ? MM:&S55+>+;-EFN;*Y4H-H>G8^Q@G(Q:L16N;\[\TNFI]HK=;EM=Y@>@;!JBI M66XM:+5>+^>&+VJ[IZU.J_=2M?^:GL2__9"G%P^^/_WQ.D@'89SF";L=76G= M<+^PT`=*NHK3+"7+[Q=LF'OG/T]@T^DW]CW[!?'X\[__FV'\[?]=7&B^@8&? MCB\N^%_D9VZB0<)@A6O&__KW]`P.$:5D]RW$Z/7O_T`!-.3VO![AQ5P3F-AO#->*G*0!T`J-,WW4X!3N6JNX+'>?>SZYJ.Y:T*SW4\R%$L&A]! MF/JA\0_F)\9'^%%!-V3!C_(I_A`^0X]4D@M>UW_[826X*S^[C2M3=3/?[IEMJ\#L)`A#ZN4?#>%O M;K_=J?A;2N[L^2;^^!+0R_[LQS9-IG+*T93R-@\'8`"5*VW$6`Q0CD"C&*,^`,RO6@D7H4;YF MRPA@]Q%\690-!/#2/&(L0_C[];IN.V39T1(.>&(.O# M>$IB"X$%;6(89#-(GT>WU>XN0BAH_.-UL*KC4<->PJ9Q0M0@\6AD8[!KYK`( M@.<#5K$$8KX"94$D,?X,Z$@!A0]!A&UM\2^V:9OM1E3L7U1<5EFP+])2-BM@ M@,Y'#&[K(=$4J0Q(J^_AM79O@=BPW%[;GOO;+/L+YKT'!@-Z"D.T?',Q2"0, MXR>LN6X;7P,LO<;_CV93S$*8XI]R@B_-[X'KHRP`&D;Y!T@LRH-2)'1ZM.JY M@J+YF)*4"P"X]@RXWN-D@ED-N&VK[W6-,P2!;\^S;?,G^)OZ+^NG

,OP%Y#(!6E^ZG(UB1!1RWH`EF0_;B)\B MEJ3C8&H,QG[T@!P,.((S!,(;(J[Q^P#P.9<%@S@/`7-`O\$H&`!20$01O#J: MY>:LWD^`TOL@Q!$O@,X\@W_^Q?!1V$D)M+(`Q6/"8T@"!NJHG/C/ M(,?XWMD0/C0$=,.#0(GPI7LV\/&T?F]_;=-QA/Y3JB$*O0_&,$_P)/A558$3 M^0VX$,(`74P/<&"INKV$O-7)&U^(XHQ>$K(Z\_]DG%O\X2.1\_,J/`SL@?9'&2SK,;PI.P00P4\Q<\%P!G M/22H;"O8M8/H'J!-M&"_4>P/^*!>P8X>Y17&*`]`'S" M><(A_(GW*OP<$6ST=P1Z,51/((\D7A/FA[01/LXH5H)`Z%)QE`KF?`12!60" MJ*4UPX"36\"6D"=A3HB%X1)QIVCB!;0"0%%,O]RS"'@[HP_8]FFN\Q9M,J' M3PXWW(MF=SVSLT'<9"RA*T57'R>R?]/ M`?"2U0\*>&M1D0[/DDIP@761>#()N%^`M#BX0-/_@) M.@=2[95K_D9M+_>%ZSKD=]<$S,N?V2?0#@)M>X[5]3QK+:`_Q]&%5`/(H<-% MY`!#U?!?Y/N+4>47RL0\X:@'/\71`TZH^8S/BTNZ]AET+<>V'%.U-&W`,AKF@XR,K"AG%_\'=M\H9-\-"KT7(2H?K*L?Y5MW_"41 MX%SB.OFVY/==>>R_":@%3)0"6B+(X`1.6 MA>1`(L.DO(UY2X#"?3?BW75,,;L/6J0K-O#R^H<#NXFA:LOK6?5A/Y//GAO# MI=O0/`LO6X,?@RA(QVQ(06DPR?Z(DS]O(CCV`4O3UQS1A=7O>+:[W%Q>]>M' MB00X:\]V^AUKHQC`?`3ALCM#7\V<*@@/<,_,)W00U;5Z+1MT**NO">O2>CL! MPR/J<>V^9_;V"0=1<<=U3;OK[A,.]*]T+;=;5A*KX:#5074"\W@:"X\D7#I@ M.63//.#QKSR@P,$L@+^"RHEOWT:8K'([NA-OW85^E'V0;]4F*(V25OO"@6X% MB=+Q^GI2SU'OIWLZ1T/^1Z?SBJ.YRY/!V,=8'VPDB#(_>B"+HSH'2F5IQI<# M6"H!,2[?X#E,M4^BZ_6=$FF]^(G#`-TL$='J0*,O(!C]&0?CW=UF2LTK\_K"?#UO:A[_%&>:>5![*.IA'R\^Q M7!N422V/;@;-F_ZH@^9FW^V976OQ1\^NM6!&H:)%U?:]"F"%P8#\M-(R>E%I MDW:+,%CJ7^T]LP<(7)K///.-X]HCVAIFKPM;['37V>0UFR;P`1&$G/7#+W"[ MZR_!O\&FA7]@J$=_M[:YYUF>V;=U!\++7SFT?9B8=MIS+<]9S*V;5J.ZY0J&E[^S$'O M"@[*`DGM=1UKS5W=EJ+E+R:VK^V*M;MFMZL%8N?7W"E(2.%@0W?U*,X2D#Z` M?@-,]#$(`;(K..B'.%$\B+GR_`'ZN_QSI;C^Y"'YSL/TURT4'NZ7C"RCS@S>WTJ=%KM`PK\CWZ0 M\$'PQF]PM>8\GVSN6/$Q>DI[Z"::PH)OLHZ@>VXL0-QIY@EC/NZ^$H4Q[;+( M"N4=K$2N'::Y8BZK4)/NXQS$?I[H267ZG3WAYT2EL",\/AZMQET>(6>1)8X0#0'T)Z!:Z"'AF34)(QR-X#M!I#F?V6`LD M9Q:D/"J^7X(/44%II#P_O,#!;5L&J>!H-"` M"K0G@IR!%+\E1*?/!DAO]BS.QACE$6]$/`X>QA?_RGU*"'Z('UD2\7S2.)K) M4EX&FU/L!\LJ)#\A]TSG`JT\[Y(3+.+DSL]#X-!G/\2[%P$[N_OR\=S($C]* MD:3BJ&U\CE4.-&RKDA&0VOAQQ`.1\BY2CBD%>9PPADC(QJG!(LPSG>='^@Y] M%PQ"GIO+<2ZK8&C?AD6HX_^V)7-JC#LI1+C.Q!5014!9%P24R/Q=#-J!WP6O M;PJX<@M`RS3U'H!:5X%%'?VTGH&'/05Q<7L#>WOM#;:WL*2B3?>B>_%89F7G MNLRSVS:\BT]_BUVX3__TCZ07=W/Z6SG]/??D7]1`J-0G2#=\JBZM+30-VH6U M6W4Z(NIRY8-]Q(VGPO;]L48#H17NR;U=]2OP<0/;J3-*+1QA8QWR^<-NI>-G M83VS95?5,[^"=\1_)F`+9KO1.,N?W!)2W_>Z+=-XF=-RW`OH[C)+M`7YGN@FK$V`90:W6=EFO9+:=;I\'B&V'41HIM%CFG M)L1>;4QJ$9_&9FE@.VUNJ86C^1*ZYKIO;K0&.7M#CF-YK8ZYLI*XEVEP39*) MKSIG5>2;%+DF/Y03)>JEFXB&4JK5ENJS)!(5*@+X(G1>2B+1\D>6$M7^B40Q M^P%&GVUGWVK*ZR-0O28"5>-8?O%#WJT,4TCVPSD[W_/BIIGK(N!0HJ];'`=Y M@K3_138,/*-6?;`VFOP=%-4''.97-P@3OO@&'K'#!L>_L?JUAF^OC)MM^BX.-MUR9>QLTRK8#79V M'-BM5OK@G?O$^&&GNO(I!XG_8`:#W4UH#E^Y?C@>+2J=SE.,\OIJ]H.8'&R, MPOBIJBJZ;?R>\EIC#`OCI#U_,&Z)F5\XQH@/\U%KI%1$#Q\=B$8W6!%.X*E7 MPF"DIB+=??EH^`\)HU+G%KVK09;%`"E^O@A_BPUB@!K>Q]Y3+!D$*3-2,(MP MZA4V4;S7&B,E:AY4V_B*O47%EVFVD3:7"R/G^63*!Q)-_"%U(\,'RQ^6.Z/' MA!//.`O."^*BO8IS&1JJ.[5H6(9A=3;PQ5B.LV#V39JV%(SC>$@-(>4!JFUF M("@>`*.X6I:V#14M0?EFSAP)MX#2?8.C=+^!`C M.1KGT$/U1\BJM]7,J&9*#4*@/B!$-.-P0-M<<@5O^X##^+)48].$49/(M#1R M[Y_Y\($Z!U`744Z)HHV>&#I6=+N(XDQV4`J?M=X7DOA%MX=ASF2S!7*E(0\E M_E!,I,2?4\P@H6X4-R-@X=&(R:Y,BJF>&$[0P"%@LIF%'%-7I(Z4FY1(>2,( M&3[7,N[SC*`6@^3@I5;I*T'T&(>/LCW"JHPXSWIE1FO-K%:6M7PXG-XY@X_] MNVV^^[G?ZUA6WSUP0,UW/W?Z'3C\.H#J4VC$E#<]'B.: MC,]UH@YO5_H[19OPSRR['>'YX M9\L5AO)M8.R+UW==S^YW*SM7SG;VVQE@.#?'[L/_6OV5`)/3#XP'''_PXDB. M4A/#&_5P;6*V3*MO=V>:(JKU]@D=(-!V^F[?,Y="]^__]K*(R=J##```L*D``!4`'`!A8V]R+3(P,3`P.3,P7V-A M;"YX;6Q55`D``^R]V4SLO=E,=7@+``$$)0X```0Y`0``[5U;<]NX%7[O3/^# MJGU69,?-=NV)N^/8<<8S3N2QDNZ^=6@2LM"0@`I"ONRO+T"1E`CB$,LQ)>?#XS='PP$B,4TP>3P??OMZ/?IE^.L_ M__J7]W\;C0:?$$$LXB@9/+P.KI?_P3Q?#G[_+2+)X,/1\=N?!Z.1%$TQ^7XF M?SQ$.1H(^R0_>\GQ^7#.^>)L/'Y^?G[S?/*&LL?QVZ.CX_'OGV^G\1QET0B3 MG$W-(YX4;@-]9<'EE8&3L9U7D8)^=^H$AO)1Z/CMZ.3XS3(LBQC%E-69R'^2Z$U,,V'@^.CH].2HDI-F`(6IQ%]:\B7VX]/3TW&16HL* M0]ABNJX>4&4W1/9H-Y.]O]S3V:3A62; MY"URJ_)+:=S((Y5=!V5:7#QZH81F&.4K>,M\O,Q'CU&TD"A/QRCE]1.) M]71T=%QV&#^5C_]]D><;#2B-'E!Z/FP^Y)A+7.7#\4&+>\>HX#Y_O1,5R"]( M\O&_2[R03/N"N`("(EI"LXHV`6_PX8(UL0N25G9+OEKZP8K1^3++"FLC+)I, MI3]C-&NY@7;"M%'0L\'*TH#3@=W",A>:="&5HG0X$`Q&XGUR?"1?J<\(/\[Y MZOUZ6!+<$/$*><0/*5KA$D7_^!*G2_G"_T1I\HS35"%#%Y6R`D$J/I&C!T8# M26"6#&0Y]HLL5VB&&$/))6["YXB5 M!*0D7@H`1.WDK3)EG>AE?/(H!(7!LP95@X=/_/+PJMR76L]JTQI#D4L//6DK MM<&#BHK!!!_I(#B*L,IC. MH0F@NIOV`ZOA1VE9T@1H,0CZW*.<,QR+F9`>E<(I9X]OZ?SBGC7Q'+;LB30)1IF&$3*:M**^(A`P!0[%[7&]![VK=Q0!S3I2CN M/8J1(*F8=X@9AV%8`!"M1@DV40\9T`&:G0EV0WI&_-TO1MPQM(AP\O%E@4B. M]%2PRM0K.SH9#YT/`6/WNL&"WMWO_'*W[+*(R.#U&A.O;R5N3NC7B1[ZUEI\NT]55;TO_^&A M+VVS>;-`>Y'&XU[:"0/@6]!\_Q>__'N+HP><8BZ,B.G$E-/X^YRFHJ2YG%9P MM?5"Q2)F7*$)>,,(R+;%B,O%`,RM1[83B?;9$B;,K<,JM.6"0\Y@&(&0P)IA, M[6]AJGUB13ZIMP?O&$V6,;]'8N"UK,A9/IP0=2V[HY:RI>C2\I4"_5`#"`$V MO+_5K"WH\?69]J#'AE8'>DBMD.G11KTC>A2&@UC:JM`T81@8I!=2"*,(^].,'?:0L-@K#[-IK!:A"=TL:)\W":X:[%HG*JQH) M#X>$;B#VP:!67]]63_WJE.N2E]PTNEA-5QU4AHLUMAJ.7ML` MC,@\Z)*G*$UEY*@B]&9Z09*+)),7%CDKU@?T[^1N2M4Q&)B2!S1I\8#VA*QG M3F6^.!`#-!O$\/X>Y4A4M(QJ<86>4$J+N8F>0B#9==`0BZRGA.D"T,T3A[4@ MQODRP-ED5ER#GM(T40AA2*VWCIJIGCK=#L+MYI9^$'N&VF7K`4R0&[U$7A.81 MD::5U9U913N(-_4FD**WL3=;5433=FL1+WT,`.-RM-Y$$$VX5?1/K#UGMPN9 M/+X2\L/G+T"]N(;0EAI4G!R+Z60O@L<]3!3MG4SFM_-T'`K/E"27EN7+F(X*2/ M4]/(([-F^(2"ULI.F67)-(@[)(:VLL8/&SC:E.R=FJH4/@\!=;'[SJV57Q!A MA,PSLO+*GEQ);$55!$^F(4:P/%/'"X"!XF[.-`,GH#LC1K:"C(1/W!YUM5,.P_(/XT/2TWG$ MT`J/26J%0J,;".L6=#+9#^2KU!EE'/]1E'DRDQ&V MJ@-;=PQE>)DIS`'+5W'QG/*A\:EK#6Q!+4!6!I9Y%KVJ">0:DXC$`JV\G:&^ M22&B6FXIHF'3RHI[9XQ2;4K\/XK/EM3;05B?3N3;,LY/8Q?!@VOE^PB&YC]I M;,BVX(9BMO*Y9ZOX*H/70095`@`D#9W+IF1HY("CWF$WTLAD_:[R*IZ,`>$J MJE6/*Q`61?L5")WB#W,%PETK^[@"HF M85-WQ;+".RAZU]G9Z$2WJ!-(WZ?)6U*P2YYA!.=I(;HA/"*/,C:X]DP;6-Y$ MP)9\\+QSU,`NZ=;.JMNE46]8-IV+":\,/+\.+.EDFDW'Q#:M3O",`]3$+EFG MSRZ,>)#%50B4Y->B_N5X5?31GR.^9)B_3F:?(_8=<7F2:8IB^:P]`.RM7S&R MLWYP[-RRAK9A:O>L@_BTA:$6ZL7IKM,5BZ)]NJ)3_&&F*^Y:V<=T19NKGT&W M-IO739XO99R*"5O-^K7?*84K:'I'@X)WW:&--K1''4#Z/TV>:O]GRBN(>]KW M:%$..B:SS6];*?QRB=7!'`UBH7$)B'<+!IESV%$TFC)!_G@0':-X\C]02P,$ M%`````@`#H1I/08?/3P'+```,BD"`!4`'`!A8V]R+3(P,3`P.3,P7VQA8BYX M;6Q55`D``^R]V4SLO=E,=7@+``$$)0X```0Y`0``[5UM;]VXE?Z^P/X';G:! MS0!V[(S1=C+;T<)C)X.@:6S$::?;03&0)=I7C:YX*^GZI;]^2>J-HO@J4B]V M^J&=6#J'Y-5YGD/R\)#\_?\^;%-P!_,B0=D/+UZ_.GX!8!:A.,EN?WCQI\_O M#K][\;_!O__;[__C\!#\!#.8AR6,P?4C>+?_>U(6>_"7G\,L!C\>O_[VM^#P MD(BF2?;E>_)_UV$!`2X_*[Y_*)(?7FS*H/USG:5/`R5%;EU2"_'78 MB!V21X>OOST\>?WJH8A?U$T,(Y2WE9`_XO!5A+:X@-?'QV].CALY4HQ!8QKQ MAX%\_=M?OWGSYHB^;45Q08FBZ/;SX*\,0/6='^'M6'_,_F\*/F#;2:C_@?_5JA`\ES.*N':14Q8^O?@#Y6K3DMFP4 M]4I-"5Q0+OPA9?B`,K1-8/&*_SRXBC=',"W;)^1WO3D\?MW\KOKQKU8Z(H@2B1Z>&1E_$`2TFU/M`Y+%H' M4EXCJ!^`D+[^?@V@E=D)&7U7$80Y41[)&J//#.BSL-B<9C'YS]M_[).[,,5M M*T[+LS#/'_%,X,]ANN?Q9J53?R$S'2<"6#7+C1"F5P0@$99J$\M(]6.:FN!VZ_?V@!N!_,$Q7@@EI;KD<&+=G(83IPS1T6WZ"\ M_`SS[?OL#K=T*W#**I$F["T2<0MS*RIU#&N+2U:$L44*`7UZB/WZ%B3=\X5# MU"I+(9-/RX6@!9),R-G`Z','^*(([7$S/L$(8H)=I_`C+.N0#1_G,Q!MPGTJ M4;>HGT$C'(-_ZAH4,4"58O`Y#V,(PEH&Y*W0`*,,5/+Y+LJ38P/@GA&)^'*,6JK^!1,@) MU.J*W5`M+5L.:XE*T/P);LG?=%1#Q<`&IC1SJ-Q`<(:VNS![7!;S&DLBLP_? M1[U8MH.]&3!FQOT%-DG>MHP#G_AE_:NYET[X%E?DANM!F7(\\*$R3%>% M3`TH#?`H@>)4%K0+]);D@\M7#$8:DL1QG[8I91'9,<:'$VS3_)+#(;D.H45 MJ7&+WCY$Z9YL>2&3L?LD33D)O]<`=.L4('&F(T/+>@UV4"#/0!G9N(YO(&X0XW/4#%8+12^J[]' M_YT3B835N+&%+U).B[YD\!%EA\UP:D=`CC("_KB6`A$6(P_2)"(A4Y!#/#7? MPV5)(+834G[?/JQ[(AU^E49>+OB`C13IX@]#F6$(@I'Q%8485NLM$-$KVB@6 MP6C4X8@US!#41A)%(J2V'`8C.E%A/$)N\45"$L)8A#`(X6/NZC/L8#!-;6:G M:\`<]V61^,.(9J'\]-.'(2:('AC8HXL7K-\BZLB`SB8S<_E#$EXG:5+B0O`L MZZI$T9<-2F.8%V3&53Y*=J?9JM5?PEC-":BVC7/S*1:UR5%N7$C`2-*P`BO[ MWZ"27I8=UMA`8PW7YY>I=L?`L7!X>U3?`&]=L]I$JU-K- MI&DGL_".4@,KBAACM+=4+B]DQ;IVF3:I;)?A(\EC4^=3BH6X3$I.R$L.I;AB M/]F3@[+U>9.<2M`\![OJQ3IR)"76&F1'*JW:C+.$LL.,2+7QY\=VOH?QD'M# M>*OE.H1+Y%Q!KJ[>&>?2XI50EV@%]:LV1Y(.F5`ONX%Q_(MS06-:9&R&`2/$ MXCU2F.'%A!?D\*O#YM@K"G/RI(W(7>8HWD?EIRK\6-=3/[S(>.!9:G$A7IV6 ME^"O8=,\;-`SKU$?-=:5$32"8%<];`+&AW\-L_`FA0^@)`YTZ=FX+4`&L64[ M9'%19XWR,!Z]!D3:!7%B%.W)TBM=,EL:EB02=+HE'7AO;:.&)@@+\O@Z3,DY M=Z#80%B"."S)8D>*VY_=$H,T>$89?-4:LBTB)TOQ!21CI`BE*8S(SZ;%TKWB M**\[D"H2516,U7&Y85M&50.I#@^;DSL\EP0W6/%^DT2;5FB#&YNA$CQ"<@X" MS,CV%72;)?^$\:OZK,0T?3S`?1;`K2%E$($\+H8_^WZ#U9.RW@`#20-+^I#?_4:\BT%A!-E&&1+6GE?5)NP$^GIY>OGK=CD`7ZGK9KL#K4 M0;^*.8=+.&'ZJOHQJ(5!,])IGF/Y9XY*R:D.)9N"OVZ=(S*UN$6%%N""T+PF%E.\+-! M<.ESA%C>HW^-$+_N$:*+8W`9(:[7-4)Q*NTPJRBM=93ZIQ)`#KB@-SA&C+SOD M@1H7GJE5%Y(@Z%3)-@2M)*C"T.+(S#'=&JE*'.1S5 M"E"+)Y9I$\JTB62^$\BF2ARS3!CCMRNO)FO`)%W`-$]`E2`PO:6]9I8[&WRX M0_V)FUP6BW`S^K)S.>EF*JV<>$;G:U.5MGJO\SK#S55R+>W.P37/\%3[L$QA M()[GB?9C&0-F=F+DR5U8)G=0VZF;B+;T4(@Z,D3?"%>2*&M0\42A&%SNRZ,H M3-.U3`2-K(EL/CO/";D&2PMSH"P8!Y'V%VHA033$5T^AKMA?3,2PCY"HR#J( MIQ`=4?4/1F87Q$A$/8,9.I:+E#3M8Z>A\E")2GH8*Q%*^PJ6J)KB+5HBJ<0H M7"+4E5%F_3$3I>E%01,#K`RC)B(E8=C$!%NSLVJ[3:J#YLE%"B@C:0,PBW"A M1&/`*B/IEE5J:4=6&37%E56Z2E2L4NL&C$!U?1,KLC2%S.R,+*W!4TBIQ%+( M"DBS7X/-;[8E_)9>@&TBW%Y]K11VO/3:I"%N]-'6H;KH6JD:]/>*0RJQ\&97 M0],B.POP-UBK=-B[JVV0LT"?@S+:1.%MJI+73*_2>^W@((\.@#_=?SJ^/@U'EOEX(Z\?P5.]^4&Y309[;OC@^-C^C]0;,(0;B7R\6*E^;Z4"Z-S;<>.87ED?II=A$K_/SL)=4H8ITTJ.&.8*S09=O8+; M3EWC!CENV36I1[%W5Z\>=#*`W/AQ2'))*[&%-^R:VQS9FX7;PJO58_;R6D-K M]MLX22HQC-^&.;GZMSCMCN<\AS=)E/`#0'.%]D9.K8+C98JF#7)CEU$]JNL4 MM>K!:>\48OIPZ=L3C8V-[.W!WY^HTV-O4+3%U/QG2#0-HL<&DCMR%3@NNJ3)C M_6.L\[Q?(\H,4FP]XVRY18C+,+_(KTHR7*8!VTN87Y$PMWQ=0J[I>JR-)7TI&D%K*+SGZ M57LF1ENX!2EJ'8X0];KW>EG`F5#.`*&M9>BOA!7(%V-B:=1?=*D).N@+1&7X M9T7]DD#0",],Z-=@00=6D>,$FP"R7F*(#"QGAQP.,HHP&@J>*+`S^Q6>))Q/ MQW@D05*2=JB1:B_J%$LYWLVIK-J-&/+"53=PBG6"Z@5HWX!?FG=_6_IV3;7U MD.&WYN_0%`JSUV8:P6'VC`NZ4:>0(%WVNLVFX%X[YDZ(*W/-E!B4JLJ+X(2# MYLG"Z;!20R#=U^/S&OI2;!:#VI9SKV.&*2SJ-I%;98N?XRLK_#Z<2T M@O.DJ&Z/.U9(L:"62[LA5-\'#:NKO[6T.;\E9OAU>Z+&T M[;&V40[CA%P,GV3U5>8`%F6RK;(?FX))ZGVYSS/ZCVO\KCBH-IOA:`7.Q8`&)`P=@A@2W]V>Q'M+ M?5NWO1I+Y0D]ASL-"A*#^'O];5;;X%%Q^(-0-`HXR M"DU%).Y773?S:_6#J=;)LW"4AA\:Y3',?WCQ^M7Q="[.TZG&4[@V;&OZFO$A M6`"2SIVK2`]^:5G&X MDKQM$S'[;QU3XX15N:99\H6J,M[ZLL&'-9V%)[,$TGP_/C^M)\2FHRE-N6!' MJNY#U=VG5X\Z2:=IXT!I5UGE7#(3PQ6Y4*WW-.HII1[3MS4GZQHMC=JETCY= MLYKTAS:&G3VGHJ!3B;?U[=&2U3.=6)M+(1%SS*-05^Z:0R$M794_(5$*Z!L: MIV@NY%YXO4UK.F3ZG?D,";$TFQUAAH8%(']Q0T>A5R@=)LT)WS(`9]\ZXUI0 ME3N<^X6J4NU!`_$TVF"SGN&=( MT8XL+M2\&20R&,BV60TJ6<<4!X-FN.8[J*M0)3^H-(/F-773<2>P=&*$B6&1 ME0'XE`F%"IL_88&:N2=(,,4%W]870Y(8:+Q-LH1T+.04*3%E[)2:Z929DMNX MW*IACI,OT[H4PW>S(H):[@#<5I+5LDU/=N%!OAT@T#A[<1,"(UUFGC`*?S/3 M\6)';U?-;ILQ'@=SZ?OZVPS?._%)6IT;=43%REDRE*XGN:AYT4X-EF6!W#A( M^T'[V!Z(=3">VL)>8QF.AN[B&<_!U++(AHNQEW)/W>$V,@>1CN[V[G# M#2.!T\HI-DT=^!^U6.N()&*.'DE=N:MKDI:N\E$2I0[":S@(5FLV9/J->=\D MEF:=E!D29H;[3V&2D:'S14;R&RYN+G,R*"@?+[&=2W*P%UU#X%!HIU1_*4,E M)V+8-FV_%P6ABRG9Q931,.+,2Z73--*A@&DR8*(@P^>&=%$UCHZ/*U(!Y9XDW;BT_(J0^,,CY0?C$,F*,"B\-FX2D@.;B`/3`SWN?TQ,@-V4VY(W%W_%=5V<('F_C#K\Q!KQK! MGL["F`:Y)R^"YCW``J`ZR9V*@//GY?QD)V+X!X]#W_\S3&XWN,C3.SQ1N84? M]^0:XXN;P9FOBC&!2Q'UEQE5A!.#7!KM86PQLGHYZ485:(*S46L]?'9G/ MNOM]@<7(Y;UHN]M37Y_Q`V]F1%./8]9SJK(32)$/U/2=P)B2.N?P-/CB>RRU M"M+0*2<5)&.H7^C0_6\UQ@]`>(.)#\+X[_MJ);,ZP`YEA##XS_21GL,?7J>P MO5<^:RX%K1]DJ`0QA%O8NZ#^`#_#16_)';;DX+H!H)K\/OG##==:T(:D=T<5.-HPO` MGN6_HD'U@OB7#,*7Q__L=P[7A]I?W)R%Q>9=BNYE1V*8B+;W$"M$':^IU3?" M<=NHN@;5G;4*Q:"[3`'W1>0]H`*KN5K!R+K(Q@S\K;9R#?9^6W/@S+\\1IIT MF:.[)(;QCX]_PD..]UF[F^(T*I.[ZI9'R:Z%T05T"VVV!;BNZXQLL/.2G7V] MRJ4AV^("2M`;2E!Z=G.WO3%LI9?>&S$>3LC=PH.5*LM7CJB>V1&4FJ<+)W4SYH]T M,OO8W#Q$*,O,0(S`,/>0@]G`=G%S#J_+YE3\RQQND_V6'S^8RC>#`:V\6\]N MVAS';MJ@&D6?J]4.3KE]A*2OW%4OBSI5HKG+@0;2L?0A"5&#I-W#M'`ZH3DP MD+7QN/Y,I\9T3K;H6Y1][Y(LQ+UG=DM/^U023RPJY!PGZI%NXD;X9-J@!E.2 M<8H#?G5W)34[(9OUG`@KK(E)$DM+2*3$A9`_?0T9==0@FIDUYQ"[QBBA3N[ M1T)S<=:>1M5\XA.,8')'$H2T?)6K2)DJ4/',47FC?+-36),-+P4%!(T4:,0P M#D$C"#K)M?%2@04%([4(DG)QJ*EBH3_8]8_(T==CMT>-S=G5GTJDKYT[..!E MH_,-B!MX$=??P"M_HO`:8935'!HP;.]E#G=A$I_#&YCGL+GB`X_ZZ*EYI[2? MUOIFFT*DWMJH$,_^VZ;AOCVZ8=TV/MZHR,[K8S;N*HWV=&,F03?:XS*RLAZK MK8VC5I!3=`HCH"OM)DS*4G4<8QBPN`-Y1\ZRW\"87L&"V_HSRK^0GX(B6!3D MD*L,MR<9'"CO7I#4D1@7Y-F9V/X`WP[%HGX;IV)`7?P1E) M@SQLEC.JS"HBPZL'YTIVTNY_=1V^%`*J&(P:-O+8"Z>GC+G,C#3?V\PFAUNS M?9]F8-$0H&HS?;.1Z1JA+^`N3/=TDU/"V`+_&8(L+/C MY":!;2'UB.=QX?U0TX!9MM?IB<'9TZZEZ6%\(HF75TM./@";' MM=V8Z`#`ARC=Q_P&^#+\`LD`'ENKCM\=-",?S(\V@-N=;CPI'RDF_[O-TFTJ1+L\5]5`!$_WQ;5T4M9D<1T:1(W MZSYL8O]D:WM.\_5SDI"/GX?,JL#J!FW3D-5\&/=4Z3K9"&]ZFLK&?%@#U"J@ MT0&?OJ8^QGQ`."UL%X]_TS%LMYW$;,%,I:2.:?%*4TS/)`V;9((VK,MZDL87 M(8M#5[W2.I>SE(#0S=/40%+/U#A=[6S-$_[4B^BBFN;,;1#5SV4WG#\38(TR MQ(KS&9K\B\OPD0PB2?IJ%.5[&'_H\@R-<\U,"M%FGRD+F2@?S:3A4V6H:>H> MD[.F++(;H;ULO/TWO42C7:5]0)X0Y3;9X8#+=&!24==&8RM$&N3`62!;VG^8 ME&62)V=#D,7]2W--5]WHCU"?:2Y7D?H.@8IG3R%OE&^_(*S)Q@L("NCE,`VV M4S4\?NP>U3Y@;;160$-!8BV@I)0=:JH(JD?AXG2T#>7;!O`G#IHX!.MM*.@6 M'AG$Y%^>,_ULQT-=3'[EL?@1T9&1<7>+.(B'Z(?Q`AE7UV6.XGU47F36K!IJ MFO*+T9R6:<,F3LRY7H4.[&/*$8?%'2F-.P*L"#D M`H"=?OEKI7-P!D=MMW9T@C<@@4Y03*(+L@5L#\#G=2!;/Z MA9M`UK'^M?PU$5G-E[_605?:=XJ#9=*ZK!;`C$*7MCTX&[P\D0[@VI%:0X^: M.H=_#;,0D^0!4PXC[=&"EG/)'.PEVQ3]<79]2#R=K)#Y%HZ>)Q`?8N?DX4+S4B\PCEU8S( MRGOTKQ'9HF1U'9&MGZZ3)21-3U-90I)TUH^5OA+8&B-8!RP5FWVD&E32'2\:51(9Y9;]/P24:=A@VP<0=&10:=%.WVUL9Z*T0I M',`(9$H]@4E9*J>P5H#;#4AM>KB%T$V&I\)^CP%]=?D,'K^U^J`KX&MF@_F` M;@D^K/:Z&XZ/]HK6U]O,=:V-'^=@59^/:VRJR^3IE*ZY0U%T@<-3N;YF2._1 M$*L);:X_YIJ:N=!IUWG1*SOEX[/904HO3&U@^K+&Z3?:6T>^!M#*^J%Y8;N. M_N8]/3G?X7HU@P+4_8^J@"F8;M#@2?HC=;W6E%<5-[A>+6F$UW._D`.<=)0W MAZ2:^(IRM`[``M4S.X++\+&^I^@T^L<^R4D("7NK\O$2`[`\S>*W^.F.B'"L MLE>LO[*%HA/A[1OH1G2K^N0$MR@FN,0_?A,6U>DSNUJ.GI4(&Z%E:3T")&B\ M_?HT-M?OZ#L]-MF-3>:UB<>>/.D[@!YE\#947H#]J[T#X+::/5/PC3;0:G:? M#5K]/BLQ`A*RF46T#]A87N;`!_)^_;:L.9[=M:`:"R\]T.[S(VE?KV)#IKG) MY>Y8@Q*9%^;5%,[7%ZZ4E.8KF=/5\G6K/.Q31I"M`=;K2J_(+7.?8;Y]W]TQ MIW.G*AV92Q7J^'6KJF9Y=JV2JBS`&@'1;DOM8`0C)_*U)5^%R? MP%/27E31G+Y75+_*_SX+>(VQR'J<,3D-&L;%._S;KT*Z,_N/Y+S5I'R\N/EC MF'^!-`_\"D;DV7"I;+1^XZ2M]=T<]MCF>L@?&5.WPIM;EQ8T*E7`C%N;D6Y>9>C/.T",>LNK-K[:(5N*>R`.>R\.:ZX#9F MH6TNA,Z1(#(=4'L)(BQ4NV21KQ6TE@DB$\%V'7U.>^?YV`01@P+4?9"J@"F8 M;M#@2?HD=;W6E%<5-T@0N6F$5Y\@8@(G'>7-(:DFOJ(?YH,+P>Z]F5<=\0#1Z@C%Z M8C'7A&+NB82G"80D8B":/3R5R8/+I,%ULC!FDC`70N<(;DT'5&EPZVN%JF5( M:R*PSMS3D%:>9G0/,!G:W^%!/CGFG1X=Q&\:YN@R1K7^LE:J3FP>TTBW'L>R M1CF5K0JB5&;/-:.T)G->^@_8%;`LE4>!!KE8LT]FFQ(Z.J\3KU[[GT5@V_1! M+7#[UX)\]1B6=4GSHWCF;NEJO]NED!Z]E]+S*5)T_SXCA\+1<^`DRRN66O4W M-=5RXK5ET]RZ(//*Y#0V+2-@!4&<%%&*BGT.%UX:L84"&FFH/B\-E3M*CL3> M[`>7-9>+)#&';M&K]I`QYI7CR4K#2EQ/2^J5J#H#B1&LU@1W^)_TW,HF$K;T M@44""R#5I^./%NHDV`.#Y,9S.$SY(RIA\1G5\Z`PO2K#DL)?NF)NK-`$LO0* M;N$!XP8Y!JY,ZE'$`?3J`94!GQ%HI4`G!GYI!/^V\.3?'`'(WDC<5%^KQTSQ MK8$VL]>^R&_#+/DG[4C.4%:@-(FK7B6++S'&87VN\<6-X#><&J:SCWO3&ZSY":)R$D&U967279[B7]4A(N5>4([I6;6::;D M-NFT:ICCG-.T+L64TZP(/./<;L.<'D_/J(!.!S1*"\]![7"!QIF-FX$:Z3(3 MT%$PG)F5G9^XN#E#6W(C,'4JG\BE!#`^0T597&W"'/X8%C!N]W!*Z.JIM/J[ MNY;F1'!//\6-^>Z-D+L$U[(#^O+PFKP%;`'+>@9?$$2>@=#W)8Z%=D[&,T?F M/[8?;>'G\$$_)S(1[8[@EXNZGD.N;83S6>.J&I0GBLL5@^HMP*^7[KF-[(AL M/OC@.&^I1N_0;F.(S,R)=V&2_SE,]_"/,"3M(H1]G^WV)HKU][/3=:+1 MJ&:Z\S(WC$-=26P99TJ#EL5%3#R=,&II[$TF4=! M!KE9DJ>T31DLJUT0.W\R4^]H59.HCK%&E_JDU7#-B#)MDG.BE$%%ROPIK7[0 M"8'3%1SC:V-O-,(B@_PKG6(O+.2RB/*''[\@@*!#AD>@RD@($*VR^0*]=[99[F\7G82GK MOH4R7#_>E_'2H0NK]=.S\T7KN_B^1M?75\\!?@'(FW5T^V*##?I_E5VY@4!/ M=#@B4%I_1E2_S7#S'V5S-,G;^A?S;YTP+*G*#;W#0N6XY66#ZL&*)E4R:R#- M-^P#E!/JH*DQY^R@_`1O$[*-)BL_AEL>-"J1'CPY$0\8%5?J`ZB#DG5HY10: MR':/`7F^!M1*+(5,/JT(OWU)'L1JH\^.Y#/L\/,P?9_%\.$/D#\95"G3PS(O MXP',DFI]H'E8M`[.O$:#Y_HYH"\`?K,&1,L,AHP^L`C3G"@/:HWU9T3UV3[/ MRV4B;FM:VHJ=US!E)>N6*N4*07U&U"]`N3=2@;( M6ALBTP_.+31*I)DE14-8S.[-?X9I^H<,W6=7,"Q0!F-R0B[,A5Y=(]OS[C)9 M#UY>TPP?WEY>A<[KRS0;[T_>'WXA`J"1`)7(&KH!G861E25$W8)$A>\>#.$S M.UW^C-)]5H;YX[LDA3E_7*E2IDWQOCSC^BKSND3W*&H8' M;+`W`%U?F`;;]8'6A9Z0:RU3-`'ZX! ML"*[(.VW%(&5$>.AJC#N_$,1>L7-%;GAANZ@+B[V95&&68R[`O&`Q$"A/RQ1 M*?@8G!@TR,L015V/=J"B4F^'*]6%0U3J`%1R@!%<`T6,`,`/7LQ!TQ_"*/0& M`QD+G"VP\-]%HM[A)_Q@7R-5]A?_>2DOR_^2JOTD``P+UZ<`\#I=$@`;Z*3O MUI$&(#/>(!%`;>6:`1+A83*`!@V+8;U*4M"C72`GQ#LKYQ'Q@NI]8KY?O"GJ M6:T![NLBGQ&7X5^!CKG/S2PW,*_.WN#@)WA3_VKVC=M! MD\,J',^([!6H.-Z1D0OH'^14?K1T_H#HDR/%Q^JCD!%@CBR4VVIFI/T4)MD' M5!07676YXCGFP!W=&LM[7`/)^I>K))V0:=`$-Z2J*Y`C5Z47O"1OOP$I?@_P MR'RW+X^PLTG7_),;*IK3P9*(PZ92 MIIG'"F7_?-PI-4I4&1D0&XJ:A(E)E]FJ!C8>2?)^F^NMI3A7U.2H+^1LHK_KFJ M_3*@*]R<`XV.D@5Q)?0D>,`;5\H$,0HD7*B%Y6R0H&5F/OP,D]L-;L;I'RS*REHQ$%8R;<7M59(9=6M540MS>!STD!,D^GRW*J+S`DZX7X=OJ!V7 M;E%DI+;:/TBUI_`0NJ9.XB,4E5I["6E9T_D)MN-?LZ?0PE#G*PQQK/86LD*T M_L*4!PN/KJ7[WW1RDA&VKSUQNNK]CK(-]\E)M8+F%8EO5VN?:]H]I[6E=$"M MVU$G$YY<$*N?!TBY>F#0W95JP=XL!_G`_X7?M@\PO]' M[C;`3_X?4$L#!!0````(``Z$:3T9NE[1NQ4``"%(`0`5`!P`86-O&UL550)``/LO=E,[+W93'5X"P`!!"4.```$.0$``.U=67/D MMA%^3U7^@R(_:R7MQHZUE4UJ5L>6RO*.2I+MY,E%D9@1;0XQ`4D=_O4!>`T) MXFB`G"$HZV6/87>CCP]`X_[GOY]7T=XC(DF(XT_[Q^^.]O=0[.,@C)>?]G^Z MNSCX?O_?__KK7_[YMX.#O2\H1L1+4;!W_[)WD?T6IDFV]Y]?O#C8^WQT_/Z[ MO8,#1AJ%\>\?V1_W7H+VJ/PX^?B8+`_?'QT= M'_[GQZM;_P&MO(,P3E(O]M'^'J7_F.0_7F'?2W/E&NS/]R2J!'PXK,N24K#_ M'51D!^RG@^/W!Q^.WSTGP7ZIHN=C4A?"_A-X[WR\H@*.CXY./AQ5=$P,0)F* M_+E#7]I^?')R7N%G@B-T@Q9[[.^?;BY%!K!/AZ"%I_VF:B#R@O,8]_( MA1WV5.TVI7^N4)PF\\5\S=!&0]];1XE4B+)Y!++D,$L.EIZW+C2.O'L4'<9H MR83KE1,%-"*DD%5*8:#\_H#BL@#E-Y5P.X=&5$-J(VJUQZAX7Y`:>A[T1V^>T"#=A$M\6=> MZFF*L#'A]H$6\IGVM;3^K]8H3G(7V6@KD62G%";I'2*KR_@1):EUY13*L5(H M6ZT\\C)?W(;+.%S0>,3IS/=QEC>9US0,X[QBBKRCB^$=KDGARA*\U]8B0GKA4\.CHZK7C@(!]#^G+HC?=FY M[K8=];E'8AJ^Y!J1O%K8(*,CHZG(FJ"$*I>[XHK^T)*/GE,4!YNLBJG4H[G- MBZT*CK#?*BMB0PM,=,:P7W[]BE.4W.&+,*:-5NA%F^Y\=I^DQ//K_"I/#C_M MPQDH.IB-`(9##T03UC+0#XQ&_4H;^LX7H[B"OI#A%5HLT"(L7T1=G2'`J;FJVT0L!N\*TI&JXI M4GI:UL"8,96N`#)-I#&P5D-'DA:Z;R^TB92YX=UFDUCT%N#45N)YN346],P7--0^U4_ M-("0EF8K22=28PW,M:F.:O&CUC7QC/1;K1NNUHD\?!FO,\@(W8JW=(P9[T0J M:A^'V-1V?8U%RCTD:NP?*M+V_5>,AJ+/4SI";;,->5V8AY,O6YATOLJK19@2-/,W'[ MC]ZJ\I!S36WG0J:8R(UU=QXNWDH0"D[K9/FNY"VANH8Q\7_`A1V M=B6A\%>!,M)5$P!IM22B(MU>%88:>T=+DAC7_,09DW\:K>:!O(^5AK0KETI@ MOMK2$M2I/V/$;T;U"9A.%Y&WY"R_.Y#9G'=V*(^&OD(562HC^5J&A?\Z7ATJ-+E! MRY"ENW'ZU5OQ54A%TK*'(QFM`LE\CT&VM*L,)XO5$K$,)]*70K53JC[QHDM: MQYY_0"_"<$IH6O'D:=P-J-H:8$0[0IQ(9DXSPMQR08><7O1?Y!%Q/Z;D((T028<@E-*U0\S3NAEAM#3"T'2%E2+]U M(*1EDW.#UIBPN7PVKYB)(ZLF;7?(8E)WXPRR#=H]2V254?_.@:CG0#RE/9W=1Z%_$6&/7W&2?F\%L?G=W1#* MK0`&L"6@#-_W#H2/+:?B^#:ERN:[]9-YEK(+:=A=0>(V&,#0;HE5#.Y&W,!. M:*NLE%ABXL2):<)-_G]!?^$[8PT5-U7(4[D88N=3' M5T`GC'"3SOT8RZTRC')+4!7G<7:;F-S^,NY)WVKK0.,P^#5.PAP@XNTK)BS5 M*5\(R\A'GEEG\(`CBIKD_'\911K;92%U`82X-EY)/%H%-8HC-C2Z774A1>7' MFC5%9`D5C?/5/"_:T>PU="MCF4_0FC\GN;U!?I2$O^:EL7\1R-'8M*CC&!%+ M(&Q@&\-Y**E*JK8E:DMH0&>/%K!`=)@>7!6QD?IA4UX"B?9]9BJ$TEPT])-47L"`WLC9M* MZD[6;ZS"+Y]Q,!B#NSG+T`,-T.D&"TB(YAUVLV-%>RW=V_[XX2H:[USI_AL= M736=)Z6;R`YXJ*$V^]X5LNVSOI36:735Z+)W>R+-T;D#)X;,.S\8[OO9*LNO MUIFG#XBP*W<(>D!Q$CZBXO*/*YPD7Q$=[=YYSYP?++FK[;V&W!/H;OLYQ+0' M-BY-/.6PW0T8=I5/6^&TE6P*<-&:98H(D4!QT+^UZ#9PZD57#HST;E#JA3$* MJLZQ40_.T"+T0[Z]AC.4?@QF:;P@U2@!A^XX\79T$0%DI=>V%P&9]Z MZY#BNS&JX3L[,$/5O^D9)@`B8[.->S%``6(0;7=;L.&D0SXG*Y]H:'WN3BX4 MGR<`!XU)/2812G'R99$)SDF^K4A6K6U^:EMBLOACU8JV/TYFA5%IE-V*(B_2 MF27#0K%R>Z@RR!*:5JQYFM%"+@DAAAG3CG%;UB::'1G.!)4]/,6N0J%_L;;[ MT8ORR:GTU"/DA69[P@[/A*?J!4$\(X-`%FIL9[,(&UP1>>\($^T,9&X0U3WT MV3W-0LT[PS(8>3THTY"[BQ%#2X'PT$NU7]'MS!&/ED(IWLBJ4B;5,UIEBB1_ M(J4*8 M'16,P^0!!5\P#OB&7$V45G>G"8G3B*_Y8 M>H#[Z&X\E58`X\C+V,G).W#\6FJ+8B@D:,:Q3>!X+%76F,23D[.3XWC&TS.J M:1G5=(S#01P@?N+0G4QXD?2:X#4BZN?/?I2Q79HL=W@*HZB3A<%9ZIP,P.(N/"PL M!N=K$,G=\WVCO<%7MG7Y.VL<+H3?JC.;K6_N1EIE`S"DG(@J=N,O1C=RD*\X M]G796Y>FF\`U:-R-*<0F\S2N*:J*L0/S9<5][Z(<3IB\.1PVH=9&Z=HF,'^? M<*)V%7KW892_^T/SB.Z6"W%WIKU8)KKT7MD2@7GX1$W$++QR1"Z@`K+LH M39-B0+'LP@MT*>(DHQUEQXINT-5TF[A+Z-P//:G-^@1Q5D%NO+'>=RYEMV,BQOGZ;@<#[N=\28@`)?06(K?Z1:-'F"Z>\(6 M8&IP&8")<;T",'6-'QI,>0F-%?VI[O>I;&T;*<&;F(B#%TLAU*9^A>LO5'05$-2004C@=:;Y1)E(72G-D5H$TTM0G8]%++07-* M13+Y_83GODYQ_(A(RM9'\OL0E"-0&'%]MDI)[#AVC$PUP9%.L#/[4!J*5DU; M4V$Y-%3476P(J5T`!W@2R\QT^YDL;3G.Y!.*IWP91PY2H"W'F'!`W22%M/+1TXKF?J38A M4'/[X$-:@HLKV$)[#'=&&.Z(F!9B#(T?9&5;4I#D)@^;E0Y^OF*L"PLWES3. M%^RP[46$GT:_N+#>N5)KI+]:1$K:O5*D2SIN:\!.,%*5K@E^#&D,/[_\E*#@ M,IZO$?'8P&+FT]ZNP*7D2E9K`=45K>8"7-A-)8\Y'L`ITOU4G6)9ZV%3G#.[ M)ZCRF]L5N^#J?MO@IO%MO-MM[4.-U09R-]P:EU,BHRG?F:#/@M^R\OS\';Y! M/DV4POPX]4;;.]RO8=IF$?6==%LH8J)(WH&[AZ@0VU'3F>0^O];ZLY>P`Q4K M=G@]=Q:?N2B)ZCL^A$3C[8#?)KXPT"G\6>K/TC5VN^ M8%-F9V&2;]*\)F@59BN^*8;25^VJEO[5PM#45;M!)$`K9YK`MJ[E^8-X*3J# M!R$50I(C_9.@4>F@,8#(*^30!"QUAQ_F:M)_1RC'0APTU>_,Q<)9ZFE9`,NK MQ::%PW:#49ABSBPL46L)HLG&&2K^;MA77AXM&6"9,];GV\&,KQ:]UL[;#89- MU'-F7V17Z>Z-;5H,RUFDZ!6PC(9;"UP)T:AU0QN'\&+%Z!(5-^"33.X@LKQ9 MKEHH+&^8H[U#X["\%J,F0J2H!0F9/(XM7#4LLF$*.#-ZZAK0NAN/ZOT+)K\S ML["/DJ2Z=(V6J46MJ2`I2Y<-BV"X$OW&7Y(S=`+UF]?]09`G8Y#G MHSS#Y)&D<<&PB.D6-M91.C"FON*XW,?%[>'1@DO+*469G'/R<(,Z95C<*4KM M\5";N\ED7L\V(SE8\JAB4C>(/-/D40IPQ18:QDZ!C0'TZ\$F=VL'F__JW.0` M'HQ#A&B'YTHAD\>RA:NV,X17*]`X73'!%\BZ5E_&M`ZB)"VM[EX':\(BA;"` M9?*`U;IA6'B*BG/F3NFNNJ99J&GN^>HRSEWFF;+L\F3+`U^N7.EM1!:<4*"X M<"O1EB`#O*EH8/`(;B_*+[IV.`N*5/O>#YK9L)0O&`;8\#O@`!ZH1!)6"J!WSA3AGD@*^R.&>V%%U[+V7E MF_FT:2=(^MH7ASQSQNI=-3BC:ZF1E/:*:*IJM73,$C$T*[[&OU)49 M68FY]>%JVQD"@``UGE4"ICI#`'?*(#,$RN*<.2[?[#(')J@"!Y()[,Z[JWE@@ ME_.8M#/?#)/@,ARZ8ZLZ1A<&'%Y$G^J-\(U/XT7>,*)8:1,7:9CL8KMZ4V9G MFL2%USC*G6_TZ[C/<10[]&K-Y!<1JJ@VAS&$5&-/3N5G<&13Z[+/]604]WG, M'??*&&"M+9U-]")YQ302+\>9J48V`YJ4^N77)7TAW4O)_R?-E5Z+.;_!+N MP'G];)KP:_U*6ONKD^%7FZ"/?(??F2N/FYA4UV%U]9U$S>U;:7-^\>MS.]_U M(#FGGJM;O4C`KBB<133]9HN2PKY73=F,LX32W9B#3`/&7R9+\A+ANV^GNW:7 MOQ_`-JX7M[/*LG$=6?VLN83,Y>P<:!LX2Y?+<^9@"E-QOLB3DEL<\=,9DJ^- M&#>_CA9:;=RPSI1V2&7RJIBVY,B:@K$C>T,MHJYC\[UGM'F+<'X:I32I,\0& MT-;C;16MTQ@P,1.."(U4,3[&K_FW***"EU]0C(@7L?XM6+%;CE.2G]\4`\6, MJ4HC8$Q.0\?*<#B&H.+%8!I_]V)]3+@RCL.-]'OIJ>YWI]&@,P<>>($D<8RG MO!FA-E+ZR*V"@D>("P_>`G))O47@-%(HROX246=@\95*:)M6O0PAV6,/I:_V M!FKI70:0J;5@.`$$.W0I:+%.*,Y&)%^Y!=?1\PMX)+'.)FXOG$YPU&0U<"1D4T$0R$HK*,DDNSK(>;MIRPI"`UR;!0(4M!SY ML&>"%ZA+/0--=Z!ISD3`!K73`E\*T:]PE%6\.,2LY$=7W2_5J*KQ91IHD=MB M@8^6L+K3[%E=%_!^C1_P7%"X?J$ZS1]HG+='7;'6/R'R1JYO,LS1)O3B@-HAJO!5O MZ4,S7I38?+(9[$D9_M*K^P/^Z]!-%?_@]02P,$%`````@`#H1I/;NJ?"?:!0`` M(B@``!$`'`!A8V]R+3(P,3`P.3,P+GAS9%54"0`#[+W93.R]V4QU>`L``00E M#@``!#D!``#M6L%RVS80O7>F_X#RE!XH2E:2VAXK&=F*,YY)+(^M-+YE('(I MH04!%@`M.5\?`"1%2J1)R7;:I*.316#W8=\^$%@0/GF[C"BZ`R$)9P.GU^DZ M")C/`\)F`^?3Y-P]=-Z^^?67D]]<%[T'!@(K"-#T'ITG?Q$E$W3[&;,`G79[ M!Z^1ZV:F9P)RNW>C]\-K\A7$;=J[E,?2GT.$D<)B!NH21R!C[,/`F2L5'WL> M]KD(<,?GD7?0[76[1WT3%(4(F#KG(AI!B!.J!LX_":8D)!`X2+-@\G@I5R"+ MQ:*SZ'>XF&F0;L^[_?CAQ@Z;VYI1FH=,[1+IJOL8"N3E5-!.(KV\P^`?N=V> MV^_E/I2PO]B;8IJPQC@D+>=:BVXS/<4[A&D)D48Y-+@:. M)%%,S>BV;2X@'#@FN6Z>UB^Q@(Z.+3<1G$(#']/M:1>IM;>1?2@&SB&P\"LH M%98:A,<@%-&"K?+O/1LK']-=66D7/Z$_,BF*I[N2TBY`ORL=`S/1!)#Y\>GZ MHNX=MJ&<<28Y)8%9B$XQ-6_%S1Q`20>18.`\W+T:,!\R@)`P8M^+KLE-%[GH M1D]'NR+IWV4HE&&A%`R]2!A.`J)[?C_Q-M$V!THD!&/VQO[>G/29=V;2Y+DQ ML;9W+")[V"]KS55X#G%6J93CGF6,"I MKEJ",Q[%P*0--Y.JOJ]-FGY5&@/DFMHH0&6HO1"%$!?Z"!O!!"_S%Z7Y`JI((M3UM&OQ1L^)H&-?@H!+07H)R54SUR9>G9X?A3("=I7DI M7-O7)L-A188U(+1"VNM0UB&*2#H]=?FJ3PRF5`%6%$Q-!FV*'-4HLD*SE>T: MWEZ7\GZL,)N1*86AE*M/,)76%@5ZW9J=.8=`*<8^ZT76KW2AR-0Z81/ MYM#R36S-8805;G%J^U+6>^27,O0B+D>R/\F71'V'!=-KC+P"84\"J7*5UK;% M[&7E5!M7&VG#^@6(N?X@4:R+'\0JMU2E:Z`9QO':+5!Z MP?6!^Q9KY:+PDC,>Z;VA4^?M`56K%K?`ZRQED'T&WRJB`,AS1,,X2Y\TWA.B MR3$9S,Q;;[`/W6Z_*;*UNP4J1#KQ,P"W`-@VE*9KLFU"L"[FR>L)=R<5*G>)6PZ:.YAQ7SU"]^KUZ!-?#`OX\%S, M[HAM4`-G!"$(`<&5X$'BJVNX`Y;`62+,SI(UCEFV?II5]LO6'ND%FKV+/8XX M`X7%_87>Y,P"HTDF4ZF(2@S%]X(G<6ZJ][;(08R8,M[05)>H9[D-@%TTG!$D:0_KU@8UT+"7/X9HH+LL9O&^/_1K]' M\+SD+)M^^=S,)F4CX0:OGX;Y1N2U"]1.7C\Y\_65:B>O'Y3Y)5<@)_R<,`U% M,"WN,(&UL550%``/L MO=E,=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`#H1I/>*(R=J##```L*D` M`!4`&````````0```*2!7%<``&%C;W(M,C`Q,#`Y,S!?8V%L+GAM;%54!0`# M[+W93'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(``Z$:3T&'ST\!RP``#(I M`@`5`!@```````$```"D@2YD``!A8V]R+3(P,3`P.3,P7VQA8BYX;6Q55`4` M`^R]V4QU>`L``00E#@``!#D!``!02P$"'@,4````"``.A&D]&;I>T;L5```A M2`$`%0`8```````!````I(&$D```86-O&UL550% M``/LO=E,=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`#H1I/;NJ?"?:!0`` M(B@``!$`&````````0```*2!CJ8``&%C;W(M,C`Q,#`Y,S`N>'-D550%``/L HO=E,=7@+``$$)0X```0Y`0``4$L%!@`````%``4`OP$``+.L```````` ` end XML 15 R12.xml IDEA: Collaboration Agreement  2.2.0.7 false Collaboration Agreement 006080 - Disclosure - Collaboration Agreement true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 0 acor_NotesToFinancialStatementsAbstract acor false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 1 us-gaap_CollaborativeArrangementDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(8) Biogen Collaboration Agreement</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June&#160;30, 2009, the Company entered into an exclusive collaboration and license agreement with Biogen Idec International&#160;GmbH (Biogen Idec) to develop and commercialize Ampyra (known as fampridine outside the U.S.) in markets outside the United States (the &#8220;Collaboration Agreement&#8221;). Under the Collaboration Agreement, Biogen Idec was granted the exclusive right to c ommercialize Ampyra and other products containing aminopyridines developed under that agreement in all countries outside of the United States, which grant includes a sublicense of the Company&#8217;s rights under an existing license agreement between the Company and Elan Pharma International Limited, a subsidiary of Elan Corporation&#160;plc (Elan). Biogen Idec will have responsibility for regulatory activities and future clinical development of Ampyra in ex-U.S. markets worldwide. The Company also entered into a related supply agreement with Biogen Idec (the &#8220;Supply Agreement&#8221;), pursuant to which the Company will supply Biogen Idec with its requirements for the licensed products through the Company&#8217;s existing supply agreement with Elan.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0p t; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under the Collaboration Agreement, the Company was entitled to an upfront payment of $110.0&#160;million as of June&#160;30, 2009, which was received on July&#160;1, 2009, and will be entitled to receive additional payments of up to approximately $400&#160;million based on the successful achievement of future regulatory and sales milestones. Due to the uncertainty surrounding the achievement of the future regulatory and sales milestones, these payments will not be recognized as revenue unless and until they are earned. The Company is not able to reasonably predict if and when the milestones will be achieved. Under the Collaboration Agreement, Biogen Idec will be required to make double-digit tiered royalty payments to the Company on ex-U.S. sales. In addition, the consideration that Biogen Idec will pay for licensed products under the Supply Agreement will reflect the price owed to the C ompany&#8217;s suppliers under its supply arrangements with Elan or other suppliers for ex-U.S. sales, including manufacturing costs and royalties owed. The Company and Biogen Idec may also carry out future joint development activities regarding licensed product under a cost-sharing arrangement. Under the terms of the Collaboration Agreement, the Company, in part through its participation in joint committees with Biogen Idec, will participate in overseeing the development and commercialization of Ampyra and other licensed products in markets outside the United States pursuant to that agreement. Acorda will continue to develop and commercialize Ampyra independently in the United States.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of June&#160;30, 2009, the Company recorded a license receivable and deferred revenue of $110.0&#160;million for the upfront payment due to the Company from Biogen Idec under the Collaboration Agreement. Also, as a result of such payment to Acorda, a payment of $7.7&#160;million became payable by Acorda to Elan and was recorded as a cost of license payable and deferred expense. The payment of $110.0&#160;million was received from Biogen Idec on July&#160;1, 2009 and the payment of $7.7&#160;million was made to Elan on July&#160;7, 2009.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">The Company considered the following deliverables with respect to the revenue recognition of the $110.0 million upfront payment:&#160;&#160;(1) the license to use the Company&#8217;s technology, (2) the Collaboration Agreement to develop and commercialize licensed product in all countries outside the U.S., and (3) the supply agreement. The Company has determined that the identified deliverables would have no value on a standalone basis if they were sold separately by a vendor and the customer could not resell the delivered items on a standalone basis, nor does the Company have objective and reliable evidence of fair value for the deliverables.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline">Accordingly, the deliverables are treated as one unit of accounting.&#160;&#160;</font>As a result, the Company will recognize the non-refundable upfront payment from Biogen Idec as revenue and the associated payment to Elan as expense ratably over the estimated term of regulatory exclusivity for the licensed products under the Collaboration Agreement as we had determined this was the most probable expected benefit period. The Company recognized $7.1&#160;million in license revenue, a portion of the $110.0&#160;million received from Biogen Idec and $495,000 in cost of license revenue, a portion of the $7.7&#160;million paid to Elan during the nine-month period ended September 30, 2010. The Company currently estimates the recognition period to be approximately 12&#160;years from the date of the Collaboration Agreement.</font></div> (8) Biogen Collaboration Agreement&#160;On June&#160;30, 2009, the Company entered into an exclusive collaboration and license agreement with Biogen Idec false false false us-types:textBlockItemType textblock Description of collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations under thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 07-1 -Paragraph 21 false 1 2 false UnKnown UnKnown UnKnown false true XML 16 R3.xml IDEA: Consolidated Statements Of Operations (unaudited)  2.2.0.7 false Consolidated Statements Of Operations (unaudited) (USD $) 002000 - Statement - Consolidated Statements Of Operations (unaudited) true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 2 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 3 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 4 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 3 1 us-gaap_RevenuesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false 4 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 4 2 us-gaap_SalesRevenueGoodsGross us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 true true false false 66188194 66188194 false false false 2 true true false false 14463303 14463303 false false false 3 true true false false 126884766 126884766 false false false 4 true true false false 43834948 43834948 false false false xbrli:monetaryItemType monetary Aggregate revenue during the period from sale of goods in the normal course of business, before deducting returns, allowances and discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false 5 2 acor_SalesDiscountsAndAllowances acor false debit duration Aggregate allowances for customer credits, including estimated discounts, returns, rebates, and chargebacks given by the... false false false false false false false false false false true negated false 1 false true false false -4923295 -4923295 false false false 2 false true false false -1606126 -1606126 false false false 3 false true false false -9751194 -9751194 false false false 4 false true false false -5959234 -5959234 false false false xbrli:monetaryItemType monetary Aggregate allowances for customer credits, including estimated discounts, returns, rebates, and chargebacks given by the entity for goods sold to customers. Discounts and allowance are a deduction from gross revenue in arriving at net revenue. No authoritative reference available. false 6 2 us-gaap_SalesRevenueGoodsNet us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 61264899 61264899 false false false 2 false true false false 12857177 12857177 false false false 3 false true false false 117133572 117133572 false false false 4 false true false false 37875714 37875714 false false false xbrli:monetaryItemType monetary Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 true 7 2 us-gaap_LicensesRevenue us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 false true false false 2357143 2357143 false false false 2 false true false false 2357144 2357144 false false false 3 false true false false 7071428 7071428 false false false 4 false true false false 2357144 2357144 false false false xbrli:monetaryItemType monetary Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. No authoritative reference available. false 8 2 us-gaap_SalesRevenueNet us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 63622042 63622042 false false false 2 false true false false 15214321 15214321 false false false 3 false true false false 124205000 124205000 false false false 4 false true false false 40232858 40232858 false false false xbrli:monetaryItemType monetary Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 true 9 1 us-gaap_CostsAndExpensesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false 4 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 10 2 us-gaap_CostOfGoodsSold us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 11666020 11666020 false false false 2 false true false false 2602064 2602064 false false false 3 false true false false 22573938 22573938 false false false 4 false true false false 8112490 8112490 false false false xbrli:monetaryItemType monetary Total costs related to goods produced and sold during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 false 11 2 us-gaap_ResearchAndDevelopmentExpense us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 7970073 7970073 false false false 2 false true false false 8197789 8197789 false false false 3 false true false false 22627938 22627938 false false false 4 false true false false 23982123 23982123 false false false xbrli:monetaryItemType monetary The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph g Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 12, 13 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11, 12 false 12 2 us-gaap_SellingGeneralAndAdministrativeExpense us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 30723444 30723444 false false false 2 false true false false 23415132 23415132 false false false 3 false true false false 91548951 91548951 false false false 4 false true false false 67362421 67362421 false false false xbrli:monetaryItemType monetary The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 4 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 4 -Paragraph 5A false 13 2 us-gaap_OperatingExpenses us-gaap true debit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 50359537 50359537 false false false 2 false true false false 34214985 34214985 false false false 3 false true false false 136750827 136750827 false false false 4 false true false false 99457034 99457034 false false false xbrli:monetaryItemType monetary Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No authoritative reference available. true 14 1 us-gaap_OperatingIncomeLoss us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 13262505 13262505 false false false 2 false true false false -19000664 -19000664 false false false 3 false true false false -12545827 -12545827 false false false 4 false true false false -59224176 -59224176 false false false xbrli:monetaryItemType monetary The net result for the period of deducting operating expenses from operating revenues. No authoritative reference available. true 15 1 us-gaap_NonoperatingIncomeExpenseAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false 4 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 16 2 us-gaap_InterestExpense us-gaap true debit duration No definition available. false false false false false false false false false false true negated false 1 false true false false -943975 -943975 false false false 2 false true false false -704229 -704229 false false false 3 false true false false -3352305 -3352305 false false false 4 false true false false -3703552 -3703552 false false false xbrli:monetaryItemType monetary The cost of borrowed funds accounted for as interest that was charged against earnings during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 34 -Paragraph 21 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher OTS -Name Federal Regulation (FR) -Number Title 12 -Chapter V -Section 563c.102 -Paragraph 9 -Subsection II Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 9 -Article 9 false 17 2 us-gaap_InvestmentIncomeInterest us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 false true false false 110528 110528 false false false 2 false true false false 314000 314000 false false false 3 false true false false 449736 449736 false false false 4 false true false false 1478996 1478996 false false false xbrli:monetaryItemType monetary Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 115 -Paragraph 14 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 5 false 18 2 us-gaap_OtherIncome us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 false true false false 8132 8132 false false false 2 false true false false 0 0 false false false 3 false true false false 8132 8132 false false false 4 false true false false 5365 5365 false false false xbrli:monetaryItemType monetary Reflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 4 -Article 7 false 19 2 us-gaap_GainLossOnSaleOfPropertyPlantEquipment us-gaap true credit duration No definition available. false false false false false false false false false false false label false 1 false true false false 0 0 false false false 2 false true false false -38914 -38914 false false false 3 false true false false 0 0 false false false 4 false true false false -23514 -23514 false false false xbrli:monetaryItemType monetary The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 20 2 us-gaap_NonoperatingIncomeExpense us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false -825315 -825315 false false false 2 false true false false -429143 -429143 false false false 3 false true false false -2894437 -2894437 false false false 4 false true false false -2242705 -2242705 false false false xbrli:monetaryItemType monetary The aggregate amount of income (expense) from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 5 true 21 1 us-gaap_NetIncomeLoss us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 true true false false 12437190 12437190 false false false 2 true true false false -19429807 -19429807 false false false 3 true true false false -15440264 -15440264 false false false 4 true true false false -61466881 -61466881 false false false xbrli:monetaryItemType monetary The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 true 22 1 us-gaap_EarningsPerShareBasic us-gaap true na duration No definition available. false false false false false false false false false false false true 1 true true false false 0.32 0.32 false false false 2 true true false false -0.51 -0.51 false false false 3 true true false false -0.40 -0.40 false false false 4 true true false false -1.63 -1.63 false false false us-types:perShareItemType decimal The amount of net income or loss for the period per each share of common stock outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 36, 37, 38 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 false 23 1 us-gaap_EarningsPerShareDiluted us-gaap true na duration No definition available. false false false false false false false false false false false true 1 true true false false 0.31 0.31 false false false 2 true true false false -0.51 -0.51 false false false 3 true true false false -0.40 -0.40 false false false 4 true true false false -1.63 -1.63 false false false us-types:perShareItemType decimal The amount of net income or loss for the period per each share of common stock and dilutive common stock equivalents outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 11, 12, 36 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 false 24 1 us-gaap_WeightedAverageNumberOfSharesOutstandingBasic us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false true false false 38449917 38449917 false false false 2 false true false false 37749920 37749920 false false false 3 false true false false 38260608 38260608 false false false 4 false true false false 37700747 37700747 false false false xbrli:sharesItemType shares Number of [basic] shares, after adjustment for contingently issuable shares and other shares not deemed outstanding, determined by relating the portion of time within a reporting period that common shares have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 171 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 false 25 1 us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false true false false 39987644 39987644 false false false 2 false true false false 37749920 37749920 false false false 3 false true false false 38260608 38260608 false false false 4 false true false false 37700747 37700747 false false false xbrli:sharesItemType shares The average number of shares issued and outstanding that are used in calculating diluted EPS, determined based on the timing of issuance of shares in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 false 4 23 false NoRounding NoRounding NoRounding false true XML 17 R14.xml IDEA: Intangible Assets  2.2.0.7 false Intangible Assets 006100 - Disclosure - Intangible Assets true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 0 acor_NotesToFinancialStatementsAbstract acor false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 1 us-gaap_IntangibleAssetsDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(10) Intangible Assets</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company acquired all of Elan's U.S. sales, marketing and distribution rights to Zanaflex Capsules and Zanaflex tablets in July 2004 for $2.0 million plus $675,000 for finished goods inventory. The Company was also responsible for up to $19.5 million in future contingent milestone payments based on cumulative gross sales of Zanaflex tablets and Zanaflex Capsules. As of December 31, 2009, the Company made $19.5 million of thes e milestone payments which were recorded as intangible assets in the consolidated financial statements.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with this transaction, the Company acquired the rights to the trade name "Zanaflex&#174;", one issued U.S. patent and two patent applications related to Zanaflex Capsules, and the remaining tablet inventory on hand with Elan. Additionally, the Company assumed Elan's existing contract with Novartis to manufacture Zanaflex tablets and entered into a separate contract with Elan to manufacture Zanaflex Capsules. The Company separately launched Zanaflex Capsules in April 2005. The Company did not acquire any receivables, employees, facilities or fixed assets. The Company allocated, on a relative fair value basis, the initial and milestone payments made to Elan to the assets acquired, principally the Zanaflex trade name and the capsules patent. There is no expected residual value of these intangible assets. The Company amortizes the allocated fair value of the trade name and patent over their estimated future economic benefit to be achieved. The Zanaflex trade name was fully amortized as of December 31, 2008.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January&#160;22, 2010, the Company received marketing approval from the FDA for Ampyra triggering two milestone payments of $2.5 million to Elan and $750,000 to Rush-Presbyterian St.&#160;Luke&#8217;s Medical Center (Rush).&#160;&#160;As of September 30, 2010, the Company made or accrued these milestone payments totaling $3.25 million and they were recorded as intangible assets in the consolidated financial statements. The payment to Elan was made during the three-months ended June 30, 2010.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In 1990, Elan licensed from Rush know-how relating to dalfampridine (4-aminopyridine, 4-AP, the formulation used in Ampyra), for the treatment of MS. The Company subsequently licensed this know-how from Elan. In September 2003, the Company entered into an agreement with Rush and Elan terminating the Rush license to Elan and providing for mutual releases. The Company also entered into a license agreement with Rush in 2003 in which Rush granted the Company an exclusive worldwide license to its know-how relating to dalfampridine for the treatment of MS. Rush has also assigned to the Company its Orphan Drug Designation for dalfampridine for the relief of symptoms of MS.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company agreed to pay Rush a license fee, milestone payments of up to $850,000 and royalties based on net sales of the product for neurological indications. As of December 31, 2009, the Company had made an aggregate of $100,000 in payments under this agreement.&#160;&#160;The FDA approval of Ampyra triggered the final milestone of $750,000 which was paid during the three-months ended March 31, 2010.&#160;&#160;As of September 30, 2010, the Company made or accrued royalty payments totaling $1.6 million.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In August 2003, the Company entered into an Amended and Restated License Agreement with the Canadian Spinal Research Organization (CSRO). Under this agreement, the Company was granted an exclusive and worldwide license under certain patent assets and know-how of CSRO relating to the use of dalfampridine in the reduction of chronic pain and spasticity in a spinal cord injured subject.&#160;&#160;The agreement required the Company to pay to CSRO royalties based on a percentage of net sales of any product incorporating the licensed rights, including royal ties on the sale of Ampyra and on the sale of dalfampridine for any other indication. No royalty payments have been made to date. During the three-month period ended March 31, 2010, the Company purchased CSRO&#8217;s rights to all royalty payments under the agreement with CSRO for $3.0 million.&#160;&#160;This payment was recorded as an intangible asset in the consolidated financial statements.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intangible assets also include certain website development costs which have been capitalized. The Company has developed several websites, each with its own purpose, including the general corporate website, product information websites and websites focused on the MS community. </font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its intangible assets may warrant revision or that the carrying value of these assets may be impaired. The Company evaluates the realizability of its intangible assets based on profitability and cash flow expectations for the related assets. As of September 30, 2010, the Company does not believe that there are any facts or circumstances that would indicate a need for changing the estimated useful life of the Zanaflex or Ampyra patents.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0p t" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intangible assets consisted of the following:</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT - -WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31,</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10p t; FONT-FAMILY: times new roman">2009</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Estimated</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">remaining</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">useful li ves as of</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2010</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Zanaflex patents<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$19,350,000</font></div></td&g t;<td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$19,350,000</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11&#160;years</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Zanaflex trade name<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,150,000</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,150,000</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0&#160;years</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new ro man">Ampyra milestones<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,250,000</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7&#160;years</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CSRO Royalty Buyout<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,000,000</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align=" right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;7&#160;years</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Website development costs(1)<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,871,195</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAM ILY: times new roman">1,444,749</font></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3&#160;years</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Website development costs &#8211; in process websites (2)</font></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SI ZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">782,531</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td valign="bottom" align="right" width="11%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3&#160;years</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" a lign="right">&#160;</div></td></tr><tr><td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30,621,195</font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23,727,280</font></div></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less accumulated amortization<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,607,764</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIG HT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,578,649</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$22,013,431</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;&l t;/div></div></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$17,148,631</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><fo nt style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>(1)&#160;&#160;Represents capitalized website development costs for fully developed and launched websites.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><tr valign="top"><td style="WIDTH: 38.5pt"><div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div></td><td><div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;Represents websites in development which had not been completed and therefore had not been launched as of December 31, 2009.</font></di v></td></tr></table></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recorded $2,029,115 and $794,513 in amortization expense related to these intangible assets in the nine-month periods ended September 30, 2010 and 2009, respectively.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Estimated future amortization expense for these intangible assets subsequent to December&#160;31, 2009 for the next five years is as foll ows:</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$2,700,347</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT - -INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,127,212</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font sty le="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,801,439</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2013<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td valign="bottom" align="right" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,410,262</font></div></td></tr><tr><td valign="top" align="left" width="40%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2014<font style= "MARGIN-LEFT: 12pt"></font></font></div></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,182,817</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="10%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$13,222,077</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> (10) Intangible Assets&#160;The Company acquired all of Elan's U.S. sales, marketing and distribution rights to Zanaflex Capsules and Zanaflex tablets in July false false false us-types:textBlockItemType textblock This block of text may be used to disclose all or part of the information related to intangible assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 44, 45, 46 false 1 2 false UnKnown UnKnown UnKnown false true XML 18 R15.xml IDEA: Document Information  2.2.0.7 false Document Information 995200 - Document - Document Information true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 3 1 dei_DocumentType dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 10-Q 10-Q false false false us-types:SECReportItemType na The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type should be limited to the same value as the supporting SEC submission type. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, NCSR, N-Q, and Other. No authoritative reference available. false 4 1 dei_AmendmentFlag dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false false false xbrli:booleanItemType na If the value is true, then the document as an amendment to previously-filed/accepted document. No authoritative reference available. false 5 1 dei_DocumentPeriodEndDate dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 2010-09-30 2010-09-30 false false false xbrli:dateItemType date The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements this will be the filing date. The format of the date is CCYY-MM-DD. No authoritative reference available. false 1 3 false UnKnown UnKnown UnKnown false true XML 19 R4.xml IDEA: Consolidated Statements Of Cash Flows (unaudited)  2.2.0.7 false Consolidated Statements Of Cash Flows (unaudited) (USD $) 003000 - Statement - Consolidated Statements Of Cash Flows (unaudited) true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 2 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 3 1 us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities include all transactions and events that are not defined as investing or financing activities. Operating activities generally involve producing and delivering goods and providing services. Cash flows from operating activities are generally the cash effects of transactions and other events that enter into the determination of net income. false 4 2 us-gaap_NetIncomeLoss us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 true true false false -15440264 -15440264 false false false 2 true true false false -61466881 -61466881 false false false xbrli:monetaryItemType monetary The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 false 5 2 us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 6 3 us-gaap_ShareBasedCompensation us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 12557768 12557768 false false false 2 false true false false 8885986 8885986 false false false xbrli:monetaryItemType monetary The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock options, amortization of restricted stock, and adjustment for officers compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 7 3 us-gaap_AmortizationOfDebtDiscountPremium us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 2891356 2891356 false false false 2 false true false false 3399860 3399860 false false false xbrli:monetaryItemType monetary The component of interest income or expense representing the periodic increase in or charge against earnings to reflect amortization of debt discounts and premiums over the life of the related debt instruments, which are liabilities of the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 21 -Paragraph 16 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 5 false 8 3 us-gaap_AmortizationOfFinancingCosts us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 80693 80693 false false false 2 false true false false 78242 78242 false false false xbrli:monetaryItemType monetary The component of interest expense comprised of the periodic charge against earnings over the life of the financing arrangement to which such costs relate. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 8 -Article 9 false 9 3 us-gaap_DepreciationDepletionAndAmortization us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 2818092 2818092 false false false 2 false true false false 2074183 2074183 false false false xbrli:monetaryItemType monetary The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. No authoritative reference available. false 10 3 us-gaap_GainLossOnSaleOfDerivatives us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 false true false false -319000 -319000 false false false 2 false true false false 75000 75000 false false false xbrli:monetaryItemType monetary The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings . Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 11 3 us-gaap_GainLossOnSaleOfPropertyPlantEquipment us-gaap true credit duration No definition available. false false false false false false false false false false true negated false 1 false true false false 0 0 false false false 2 false true false false 23514 23514 false false false xbrli:monetaryItemType monetary The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 12 3 us-gaap_IncreaseDecreaseInOperatingCapitalAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 13 4 us-gaap_IncreaseDecreaseInAccountsReceivable us-gaap true credit duration No definition available. false false false false false false false false false false false terselabel false 1 false true false false -12489818 -12489818 false false false 2 false true false false 376637 376637 false false false xbrli:monetaryItemType monetary The net change during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 14 4 us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 false true false false -727800 -727800 false false false 2 false true false false -3648754 -3648754 false false false xbrli:monetaryItemType monetary The net change during the reporting period in the value of this group of assets within the working capital section. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 15 4 us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 false true false false -19582404 -19582404 false false false 2 false true false false 823951 823951 false false false xbrli:monetaryItemType monetary The net change during the reporting period in the book value of finished goods inventory and work in process inventory. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 16 4 acor_IncreaseDecreaseInOtherInventories acor false credit duration The net change during the reporting period in the book value of inventories of a nature not otherwise specified in the... false false false false false false false false false false false terselabel false 1 false true false false 293054 293054 false false false 2 false true false false 111871 111871 false false false xbrli:monetaryItemType monetary The net change during the reporting period in the book value of inventories of a nature not otherwise specified in the taxonomy. No authoritative reference available. false 17 4 acor_IncreaseDecreaseInNonCurrentDeferredRevenue acor false credit duration The net change during the reporting period, excluding the portion taken into expense, in the non current deferred cost... false false false false false false false false false false false terselabel false 1 false true false false 495000 495000 false false false 2 false true false false -6875001 -6875001 false false false xbrli:monetaryItemType monetary The net change during the reporting period, excluding the portion taken into expense, in the non current deferred cost reflecting the cost of license revenue yet to be incurred by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable. No authoritative reference available. false 18 4 us-gaap_IncreaseDecreaseInOtherOperatingAssets us-gaap true credit duration No definition available. false false false false false false false false false false false terselabel false 1 false true false false 580 580 false false false 2 false true false false 6279 6279 false false false xbrli:monetaryItemType monetary The net change during the reporting period in other operating assets not otherwise defined in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 19 4 us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities us-gaap true debit duration No definition available. false false false false false false false false false false false label false 1 false true false false 16731204 16731204 false false false 2 false true false false -2826805 -2826805 false false false xbrli:monetaryItemType monetary The net change during the reporting period in the aggregate amount of obligations and expenses incurred but not paid. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 20 4 us-gaap_IncreaseDecreaseInInterestPayableNet us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 337487 337487 false false false 2 false true false false 48675 48675 false false false xbrli:monetaryItemType monetary The net change during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 21 4 us-gaap_IncreaseDecreaseInDeferredRevenue us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false -7071428 -7071428 false false false 2 false true false false 107642856 107642856 false false false xbrli:monetaryItemType monetary The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 22 4 acor_IncreaseDecreaseInDeferredRevenueProductOne acor false credit duration The net change during the reporting period, excluding the portion taken into income, in the liability of revenue relating to... false false false false false false false false false false false terselabel false 1 false true false false -505677 -505677 false false false 2 false true false false 335887 335887 false false false xbrli:monetaryItemType monetary The net change during the reporting period, excluding the portion taken into income, in the liability of revenue relating to product one reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable. No authoritative reference available. false 23 4 acor_IncreaseDecreaseInDeferredRevenueProductTwo acor false credit duration The net change during the reporting period, excluding the portion taken into income, in the liability of revenue relating to... false false false false false false false false false false false terselabel false 1 false true false false -871104 -871104 false false false 2 false true false false 2486481 2486481 false false false xbrli:monetaryItemType monetary The net change during the reporting period, excluding the portion taken into income, in the liability of revenue relating to product two reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable. No authoritative reference available. false 24 4 us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities us-gaap true credit duration No definition available. false false false false false false false false false false false terselabel false 1 false true false false -688 -688 false false false 2 false true false false -2860 -2860 false false false xbrli:monetaryItemType monetary The net cash inflow (outflow) for the net change associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as operating activities. This may include cash restricted for regulatory purposes. No authoritative reference available. false 25 4 us-gaap_NetCashProvidedByUsedInOperatingActivities us-gaap true na duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false -20802949 -20802949 false false false 2 false true false false 51549121 51549121 false false false xbrli:monetaryItemType monetary The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 26 1 us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 27 2 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment us-gaap true credit duration No definition available. false false false false false false false false false false true negated false 1 false true false false -2207442 -2207442 false false false 2 false true false false -1903764 -1903764 false false false xbrli:monetaryItemType monetary The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph c false 28 2 us-gaap_PaymentsToAcquireIntangibleAssets us-gaap true credit duration No definition available. false false false false false false false false false false true negated false 1 false true false false -6893914 -6893914 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph c false 29 2 us-gaap_PaymentsToAcquireShortTermInvestments us-gaap true credit duration No definition available. false false false false false false false false false false true negated false 1 false true false false -217862168 -217862168 false false false 2 false true false false -278897068 -278897068 false false false xbrli:monetaryItemType monetary The cash outflow for securities or other assets acquired with excess cash, having ready marketability, which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15, 17 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 159 -Section Appendix C -Paragraph 5 -Subparagraph c false 30 2 us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities us-gaap true debit duration No definition available. false false false false false false false false false false false terselabel false 1 false true false false 276250000 276250000 false false false 2 false true false false 224650000 224650000 false false false xbrli:monetaryItemType monetary The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (trading, held-to-maturity, or available-for-sale) during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 16 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 16 -Subparagraph a false 31 2 us-gaap_NetCashProvidedByUsedInInvestingActivities us-gaap true debit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 49286476 49286476 false false false 2 false true false false -56150832 -56150832 false false false xbrli:monetaryItemType monetary The net cash inflow (outflow) from investing activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 32 1 us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 33 2 us-gaap_ProceedsFromIssuanceOrSaleOfEquity us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 7998120 7998120 false false false 2 false true false false 2277073 2277073 false false false xbrli:monetaryItemType monetary The cash inflow from the issuance of common, preferred, and treasury stocks, stock options, and such forth. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph a false 34 2 us-gaap_RepaymentsOfLongTermDebt us-gaap true credit duration No definition available. false false false false false false false false false false true negated false 1 false true false false -1391232 -1391232 false false false 2 false true false false -1580300 -1580300 false false false xbrli:monetaryItemType monetary The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph b false 35 2 us-gaap_NetCashProvidedByUsedInFinancingActivities us-gaap true debit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 6606888 6606888 false false false 2 false true false false 696773 696773 false false false xbrli:monetaryItemType monetary The net cash inflow (outflow) from financing activity for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 36 2 us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease us-gaap true na duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 35090415 35090415 false false false 2 false true false false -3904938 -3904938 false false false xbrli:monetaryItemType monetary The net change between the beginning and ending balance of cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 37 1 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant No definition available. false false false false false false false false true false false periodstartlabel false 1 false true false false 47314412 47314412 false false false 2 false true false false 29612916 29612916 false false false xbrli:monetaryItemType monetary Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 38 1 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant No definition available. false false false false false false false false false true false periodendlabel false 1 false true false false 82404827 82404827 false false false 2 false true false false 25707978 25707978 false false false xbrli:monetaryItemType monetary Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 39 1 us-gaap_SupplementalCashFlowInformationAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 40 2 us-gaap_InterestPaid us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 true true false false 2850437 2850437 false false false 2 true true false false 3158931 3158931 false false false xbrli:monetaryItemType monetary The amount of cash paid during the current period for interest owed on money borrowed; includes amount of interest capitalized Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 29 false 2 38 false NoRounding UnKnown UnKnown false true XML 20 R16.xml IDEA: Entity Information  2.2.0.7 false Entity Information 995400 - Document - Entity Information true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 2 false false u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 3 1 dei_EntityRegistrantName dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 ACORDA THERAPEUTICS INC ACORDA THERAPEUTICS INC false false false 2 false false false false 0 0 false false false xbrli:normalizedStringItemType normalizedstring The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false 4 1 dei_EntityCentralIndexKey dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 0001008848 0001008848 false false false 2 false false false false 0 0 false false false us-types:centralIndexKeyItemType na A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false 5 1 dei_CurrentFiscalYearEndDate dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 --12-31 --12-31 false false false 2 false false false false 0 0 false false false xbrli:gMonthDayItemType monthday End date of current fiscal year in the format --MM-DD. No authoritative reference available. false 6 1 dei_EntityWellKnownSeasonedIssuer dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Yes Yes false false false 2 false false false false 0 0 false false false us-types:yesNoItemType na Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. No authoritative reference available. false 7 1 dei_EntityVoluntaryFilers dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 No No false false false 2 false false false false 0 0 false false false us-types:yesNoItemType na Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. No authoritative reference available. false 8 1 dei_EntityCurrentReportingStatus dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Yes Yes false false false 2 false false false false 0 0 false false false us-types:yesNoItemType na Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. No authoritative reference available. false 9 1 dei_EntityFilerCategory dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Large Accelerated Filer Large Accelerated Filer false false false 2 false false false false 0 0 false false false us-types:filerCategoryItemType na Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. No authoritative reference available. false 10 1 dei_EntityCommonStockSharesOutstanding dei false na instant No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false 2 false true false false 39079688 39079688 false false false xbrli:sharesItemType shares Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument No authoritative reference available. false 11 1 dei_DocumentFiscalYearFocus dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 2010 2010 false false false 2 false false false false 0 0 false false false xbrli:gYearItemType positiveinteger This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No authoritative reference available. false 12 1 dei_DocumentFiscalPeriodFocus dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Q3 Q3 false false false 2 false false false false 0 0 false false false us-types:fiscalPeriodItemType na This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No authoritative reference available. false 2 10 false UnKnown NoRounding UnKnown false true XML 21 R9.xml IDEA: Income Taxes  2.2.0.7 false Income Taxes 006050 - Disclosure - Income Taxes true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 0 acor_NotesToFinancialStatementsAbstract acor false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 1 us-gaap_IncomeTaxDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(5) Income Taxes</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>The Company had available net operating loss carryforwards (NOL) of approximately $270.1&#160;million and $249.5&#160;million as of September 30, 2010 and December&#160;31, 2009, respectively, for federal and state income tax purposes, which are available to offset future federal and state taxable income, if any, and expire between 2019 and 2030. The Company also has resear ch and development tax credit carryforwards of approximately $1.6&#160;million as of both September 30, 2010 and December&#160;31, 2009, for federal income tax reporting purposes that are available to reduce federal income taxes, if any, and expire in future years beginning in 2020.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="MARGIN-LEFT: 36pt"></font>At September 30, 2010 and December&#160;31, 2009, the Company had a deferred tax asset of $160.7&#160;million and $147.2&#160;million, respectively, offset by a full valuation allowance. Since inception, the Company has incurred substantial losses and expects to incur substantial losses in future periods. The Tax Reform Act of 198 6 (the &#8220;Act&#8221;) provides for a limitation of the annual use of NOL and research and development tax credit carryforwards (following certain ownership changes, as defined by the Act) that could significantly limit the Company&#8217;s ability to utilize these carryforwards. The Company has experienced various ownership changes as a result of past financings. Accordingly, the Company&#8217;s ability to utilize the aforementioned carryforwards may be limited. Additionally, because U.S. tax laws limit the time during which these carryforwards may be applied against future taxes, the Company may not be able to take full advantage of these attributes for federal income tax purposes. Because of the above mentioned factors, the Company has not recognized its gross deferred tax assets as of and for all periods presented. As of September 30, 2010, management believes that it is more likely than not that the gross deferred tax assets will not be realized based on future operations and reversal of deferred tax liabilities. Accordingly, the Company has provided a full valuation allowance against its gross deferred tax assets and no tax benefit has been recognized relative to its pretax losses.</font></div> (5) Income Taxes&#160;The Company had available net operating loss carryforwards (NOL) of approximately $270.1&#160;million and $249.5&#160;million as of false false false us-types:textBlockItemType textblock Description containing the entire income tax disclosure. Examples include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 136, 172 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 43, 44, 45, 46, 47, 48, 49 false 1 2 false UnKnown UnKnown UnKnown false true XML 22 R6.xml IDEA: Summary of Significant Accounting Policies  2.2.0.7 false Summary of Significant Accounting Policies 006020 - Disclosure - Summary of Significant Accounting Policies true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 0 acor_NotesToFinancialStatementsAbstract acor false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 1 us-gaap_SignificantAccountingPoliciesTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2) Summary of Significant Accounting Policies</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Principles of Consolidation</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The a ccompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America and include the results of operations of the Company and its majority owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Use of Estimates</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT - -FAMILY: Times New Roman">The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include research and development and share-based compensation accounting, which are largely dependent on the fair value of the Company&#8217;s equity securities. In addition, the Company recognizes Zanaflex revenue based on estimated prescriptions filled. The Company adjusts its Zanaflex inventory value based on an estimate of inventory that may be returned. Actual results could differ from those estimates.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</d iv><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Revenue Recognition</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Zanaflex</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company applies the revenue recognition guidance in Accounting Stan dards Codification (ASC) 605-15-25, which among other criteria requires that future returns can be reasonably estimated in order to recognize revenue. The amount of future tablet returns is uncertain due to generic competition and customer conversion to Zanaflex Capsules. The Company has accumulated some sales history with Zanaflex Capsules; however, due to existing and potential generic competition and customer conversion from Zanaflex tablets to Zanaflex Capsules, we do not believe we can reasonably determine a return rate at this time. As a result, the Company accounts for these product shipments using a deferred revenue recognition model. Under the deferred revenue model, the Company does not recognize revenue upon product shipment. For these product shipments, the Company invoices the wholesaler, records deferred revenue at gross invoice sales price, and classifies the cost basis of the product held by the wholesaler as a component of inventory. The Company recognizes revenue when prescribed to the end- user, on a first-in first-out (FIFO) basis. The Company&#8217;s revenue to be recognized is based on (1)&#160;the estimated prescription demand, based on pharmacy sales for its products; and (2)&#160;the Company&#8217;s analysis of third-party information, including third-party market research data. The Company&#8217;s estimates are subject to the inherent limitations of estimates that rely on third-party data, as certain third-party information was itself in the form of estimates, and reflect other limitations. The Company&#8217;s sales and revenue recognition reflects the Company&#8217;s estimates of actual product prescribed to the end-user. The Company expects to be able to apply a more traditional revenue recognition policy such that revenue is recognized following shipment to the customer when it believes it has sufficient data to develop reasonable estimates of expected returns based upon historical returns and greater certainty regarding generic competition.</font>&l t;/div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s net revenues represent total revenues less allowances for customer credits, including estimated discounts, rebates, and chargebacks. These allowances are recorded for cash consideration given by a vendor to a customer that is presumed to be a reduction of the selling prices of the vendor&#8217;s products or services and, therefore, should be characterized as a reduction of revenue when recognized in the vendor&#8217;s statement of operations. Adjustments are recorded for estimated chargebacks, rebates, and discounts. These allowances are established by management as its best estimate based on available information and are adjusted to reflect known changes in t he factors that impact such allowances. Allowances for chargebacks, rebates and discounts are established based on the contractual terms with customers, analysis of historical levels of discounts, chargebacks and rebates, communications with customers and the levels of inventory remaining in the distribution channel, as well as expectations about the market for each product and anticipated introduction of competitive products. In addition, the Company records a charge to cost of goods sold for the cost basis of the estimated product returns the Company believes may ultimately be realized at the time of product shipment to wholesalers. The Company has recognized this charge at the date of shipment since it is probable that it will receive a level of returned products; upon the return of such product it will be unable to resell the product considering its expiration dating; and it can reasonably estimate a range of returns. This charge represents the cost basis for the low end of the range of the Company&# 8217;s estimated returns. Product shipping and handling costs are included in cost of sales.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Ampyra</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ampyra is available only through a network of specialty pharmacy providers that provide the medication to patients by mail and Kaiser Permanente (&#8220;Kaiser&#8221;). Ampyra will not be available in retail pharmacies. Th e Company applies the revenue recognition guidance in Staff Accounting Bulletin (SAB) 104 and does not recognize revenue from product sales until there is persuasive evidence of an arrangement, delivery has occurred, the price is fixed and determinable, the buyer is obligated to pay the Company, the obligation to pay is not contingent on resale of the product, the buyer has economic substance apart from the Company, the Company has no obligation to bring about the sale of the product, the amount of returns can be reasonably estimated and collectability is reasonably assured. The Company recognizes product sales of Ampyra following shipment of product to a network of specialty pharmacy providers and Kaiser. As of September 30, 2010, inventory levels at specialty pharmacy providers that distribute Ampyra (excluding Kaiser) represented approximately two weeks of their anticipated usage. The specialty pharmacy providers and Kaiser are contractually obligated to hold no more than 30 days of inventory.</font> ;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s net revenues represent total revenues less allowances for customer credits, including estimated rebates, discounts and returns. These allowances are recorded for cash consideration given by a vendor to a customer that is presumed to be a reduction of the selling prices of the vendor&#8217;s products or services and, therefore, are characterized as a reduction of revenue. At the time product is shipped to specialty pharmacies and Kaiser, an adjustment is recorded for estimated rebates, discounts and returns. These allowances are established by management as its best estimate based on available information and will be adjusted to reflect known changes in the fact ors that impact such allowances. Allowances for rebates, discounts and returns are established based on the contractual terms with customers, communications with customers and the levels of inventory remaining in the distribution channel, as well as expectations about the market for the product and anticipated introduction of competitive products.&#160;&#160;Product shipping and handling costs are included in cost of sales.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on the Company&#8217;s specialty distribution model where it sells to only 12 specialty pharmacies and Kaiser, the inventory and prescription data it receives from these distributors, and returns experience of other specialty products with similar selling models, the Company has been able to make a reasonable estimate for product returns. At September 30, 2010, inventory levels at the specialty pharmacies (excluding Kaiser) represented approximately two weeks of their anticipated usage. The specialty pharmacy providers and Kaiser have contractually agreed to hold no more than 30 days inventory. The Company will accept returns of Ampyra for two months prior to and six months after the product expiration date. The Company will provide a credit for such returns to customers with whom we have a direct relationship. Once product is prescribed, it cannot be returned. The Company does not exchange product from inventory for the returned product.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Miles tones and royalties</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenue from milestones is recognized when earned, as evidenced by written acknowledgement from the other party to a contract, provided that (i)&#160;the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, and the Company has no further performance obligations relating to that event, and (ii)&#160;collectability is reasonably assured. If these criteria are not met, the milestone payment is recognized over the remaining period of our performance obligations under the arrangement. Royalties are recognized as earned in accordance with the terms of various research and collaboration agreements. </font></div><div style="DISPLAY: bl ock; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Collaborations</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recognizes collaboration revenues and expenses by analyzing each element of the agreement to determine if it shall be accounted for as a separate element or single unit of accounting. If an element shall be treated separately for revenue recognition purposes, the revenue recognition principles most appropriate for that element are applied to determine when revenue shall be recognize d. If an element shall not be treated separately for revenue recognition purposes, the revenue recognition principles most appropriate for the bundled group of elements are applied to determine when revenue shall be recognized. Payments received in excess of revenues recognized are recorded as deferred revenue until such time as the revenue recognition criteria have been met.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Ampyra Inventory</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"&g t;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior to regulatory approval of Ampyra, the Company incurred expenses for the manufacture of bulk, unpackaged product of Ampyra that ultimately became available to support the commercial launch of this drug candidate. Until the necessary initial regulatory approval was received, we charged all such amounts to research and development expenses as there was no alternative future use prior to regulatory approval. As a result, our initial sales of Ampyra will result in higher gross margins than if the inventory costs had not previously been expensed. Upon regulatory approval of Ampyra, the Company began capitalizing the commercial inventory costs associated with manufacturing with Elan and its second manufacturer, Patheon.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDE NT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Concentration of Risk</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of investments in cash and cash equivalents, restricted cash and accounts receivable. The Company maintains cash and cash equivalents and restricted cash with approved financial institutions. The Company is exposed to credit risks and liquidity risks in the event of default by the financial institutions or issuers of investments in excess of FDIC insured limits. The Company performs periodic evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any institution.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Segment Information</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is managed and operated as one business. The entire business is managed by a single management team that reports to the chief execu tive officer. The Company does not operate separate lines of business with respect to any of its product candidates. Accordingly, the Company does not prepare discrete financial information with respect to separate product candidates or by location and does not have separately reportable segments.</font></div> (2) Summary of Significant Accounting Policies&#160;Principles of Consolidation&#160;The accompanying consolidated financial statements are prepared in false false false us-types:textBlockItemType textblock This element may be used to describe all significant accounting policies of the reporting entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 8 false 1 2 false UnKnown UnKnown UnKnown false true XML 23 R5.xml IDEA: Organization and Business Activities  2.2.0.7 false Organization and Business Activities 006010 - Disclosure - Organization and Business Activities true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 0 acor_NotesToFinancialStatementsAbstract acor false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 1 us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1) Organization and Business Activities</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Acorda Therapeutics,&#160;Inc. (&#8220;Acorda&#8221; or the &#8220;Company&#8221;) is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the central nervous system (CNS).</font></div ><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The management of the Company is responsible for the accompanying unaudited interim consolidated financial statements and the related information included in the notes to the consolidated financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, including normal recurring adjustments necessary for the fair presentation of the Company&#8217;s financial position and results of operations and cash flows for the periods presented. Results of operations for interim periods are not necessarily indicative of the results to be expected for the entire year.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December&#160;31, 2009 included in the Company&#8217;s Annual Report on Form&#160;10-K for such year, as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company finances its operations th rough a combination of issuance of equity securities, revenues from Zanaflex Capsules and Ampyra, loans, collaborations, and, to a lesser extent, grants. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed to fund its development and commercialization efforts. To the extent the Company&#8217;s capital resources are insufficient to meet future operating requirements, the Company will need to raise additional capital, reduce planned expenditures, or incur indebtedness to fund its operations. The Company may be unable to obtain additional debt or equity financing on acceptable terms, if at all. If adequate funds are not available, the Company may be required to curtail its sales and marketing efforts, delay, reduce the scope of or eliminate some of its research and development programs or obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain product candidates that it might otherw ise seek to develop or commercialize independently.</font></div> (1) Organization and Business Activities&#160;Acorda Therapeutics,&#160;Inc. (&#8220;Acorda&#8221; or the &#8220;Company&#8221;) is a commercial stage false false false us-types:textBlockItemType textblock Description containing the entire organization, consolidation and basis of presentation of financial statements disclosure. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number FAS140-4 and FIN46(R)-8 -Paragraph 8, C1, C7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 2-6 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 10 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 46R -Paragraph 4, 14, 15 false 1 2 false UnKnown UnKnown UnKnown false true XML 24 defnref.xml IDEA: XBRL DOCUMENT Amount of deferred revenue as of balance sheet date relating to product two. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The net change during the reporting period, excluding the portion taken into expense, in the non current deferred cost reflecting the cost of license revenue yet to be incurred by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Aggregate allowances for customer credits, including estimated discounts, returns, rebates, and chargebacks given by the entity for goods sold to customers. Discounts and allowance are a deduction from gross revenue in arriving at net revenue. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The net change during the reporting period in the book value of inventories of a nature not otherwise specified in the taxonomy. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount of deferred revenue as of balance sheet date relating to product one. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The net change during the reporting period, excluding the portion taken into income, in the liability of revenue relating to product one reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The net change during the reporting period, excluding the portion taken into income, in the liability of revenue relating to product two reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. XML 25 R13.xml IDEA: Commitments and Contingencies  2.2.0.7 false Commitments and Contingencies 006090 - Disclosure - Commitments and Contingencies true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 0 acor_NotesToFinancialStatementsAbstract acor false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 1 us-gaap_CommitmentsAndContingenciesDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(9) Commitments and Contingencies</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of the Company&#8217;s commitments and contingencies was included in the Company&#8217;s Annual Report on Form 10-K for the twelve-month period ended December 31, 2009. The Company&#8217;s long-term contractual obligations include commitments and estimated purchase obligations entered into in the normal course of business.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; T EXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when information available indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated. The Company believes that the ultimate resolution of these matters will not have a material adverse effect on the Company&#8217;s financial condition or liquidity. However, adjustments, if any, to the Company&#8217;s estimates could be material to operating results for the periods in which adjustments to the liability are recorded.</font></div> (9) Commitments and Contingencies&#160;A summary of the Company&#8217;s commitments and contingencies was included in the Company&#8217;s Annual Report on Form false false false us-types:textBlockItemType textblock Includes disclosure of commitments and contingencies. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 14 -Paragraph 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 9, 10, 11, 12 false 1 2 false UnKnown UnKnown UnKnown false true XML 26 R1.xml IDEA: Consolidated Balance Sheets (unaudited)  2.2.0.7 false Consolidated Balance Sheets (unaudited) (USD $) 001000 - Statement - Consolidated Balance Sheets (unaudited) true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 2 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 4 2 us-gaap_AssetsCurrentAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 5 3 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 true true false false 82404827 82404827 false false false 2 true true false false 47314412 47314412 false false false xbrli:monetaryItemType monetary Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 6 3 us-gaap_RestrictedCashAndCashEquivalents us-gaap true debit instant No definition available. false false false false false false false false false false false terselabel false 1 false true false false 301848 301848 false false false 2 false true false false 301160 301160 false false false xbrli:monetaryItemType monetary The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Audit and Accounting Guide (AAG) -Number AAG-BRD -Chapter 4 -Paragraph 80 -Subparagraph Exhibit 4-8, 3 -IssueDate 2006-05-01 false 7 3 us-gaap_ShortTermInvestments us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 163412360 163412360 false false false 2 false true false false 224778023 224778023 false false false xbrli:monetaryItemType monetary Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Subparagraph g -Article 7 false 8 3 us-gaap_AccountsReceivableNetCurrent us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 18228831 18228831 false false false 2 false true false false 5739013 5739013 false false false xbrli:monetaryItemType monetary Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 false 9 3 us-gaap_PrepaidExpenseCurrent us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 5722357 5722357 false false false 2 false true false false 4274625 4274625 false false false xbrli:monetaryItemType monetary Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 3 -Section A -Paragraph 4 false 10 3 us-gaap_InventoryFinishedGoods us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 24079937 24079937 false false false 2 false true false false 4497533 4497533 false false false xbrli:monetaryItemType monetary Carrying amount as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a -Article 5 false 11 3 us-gaap_OtherInventory us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 2101926 2101926 false false false 2 false true false false 2394980 2394980 false false false xbrli:monetaryItemType monetary Carrying amount as of the balance sheet date of inventories of a nature not otherwise specified in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 3 -Section A -Paragraph 9 false 12 3 us-gaap_OtherAssetsCurrent us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 3260669 3260669 false false false 2 false true false false 3980601 3980601 false false false xbrli:monetaryItemType monetary Aggregate carrying amount, as of the balance sheet date, of current assets not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5 false 13 3 us-gaap_AssetsCurrent us-gaap true debit instant No definition available. false false false false false false false false false false false totallabel false 1 false true false false 299512755 299512755 false false false 2 false true false false 293280347 293280347 false false false xbrli:monetaryItemType monetary Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 true 14 3 us-gaap_PropertyPlantAndEquipmentNet us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 3320957 3320957 false false false 2 false true false false 1891321 1891321 false false false xbrli:monetaryItemType monetary Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, and production equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 12 -Paragraph 5 -Subparagraph b, c Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7 false 15 3 us-gaap_IntangibleAssetsNetExcludingGoodwill us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 22013430 22013430 false false false 2 false true false false 17148631 17148631 false false false xbrli:monetaryItemType monetary Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 42, 45 false 16 3 us-gaap_DeferredCosts us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 6215001 6215001 false false false 2 false true false false 6710001 6710001 false false false xbrli:monetaryItemType monetary Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 false 17 3 us-gaap_OtherAssetsNoncurrent us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 359045 359045 false false false 2 false true false false 440318 440318 false false false xbrli:monetaryItemType monetary Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 false 18 3 us-gaap_Assets us-gaap true debit instant No definition available. false false false false false false false false false false false totallabel false 1 false true false false 331421188 331421188 false false false 2 false true false false 319470618 319470618 false false false xbrli:monetaryItemType monetary Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Concepts (CON) -Number 6 -Paragraph 25 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 true 20 2 us-gaap_LiabilitiesCurrentAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 21 3 us-gaap_AccountsPayableCurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 17363236 17363236 false false false 2 false true false false 11613434 11613434 false false false xbrli:monetaryItemType monetary Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 false 22 3 us-gaap_AccruedLiabilitiesCurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 25803985 25803985 false false false 2 false true false false 14975794 14975794 false false false xbrli:monetaryItemType monetary Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 false 23 3 acor_DeferredProductRevenueCurrentProductOne acor false credit instant Amount of deferred revenue as of balance sheet date relating to product one. Deferred revenue represents collections of cash... false false false false false false false false false false false terselabel false 1 false true false false 8709065 8709065 false false false 2 false true false false 9214742 9214742 false false false xbrli:monetaryItemType monetary Amount of deferred revenue as of balance sheet date relating to product one. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. No authoritative reference available. false 24 3 acor_DeferredProductRevenueCurrentProductTwo acor false credit instant Amount of deferred revenue as of balance sheet date relating to product two. Deferred revenue represents collections of cash... false false false false false false false false false false false terselabel false 1 false true false false 20617977 20617977 false false false 2 false true false false 21489081 21489081 false false false xbrli:monetaryItemType monetary Amount of deferred revenue as of balance sheet date relating to product two. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. No authoritative reference available. false 25 3 us-gaap_DeferredRevenueCurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 9428571 9428571 false false false 2 false true false false 9428571 9428571 false false false xbrli:monetaryItemType monetary The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 3 -Section A -Paragraph 7, 8 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A false 26 3 us-gaap_LongTermDebtCurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 6381187 6381187 false false false 2 false true false false 6178697 6178697 false false false xbrli:monetaryItemType monetary Total of the portions of the carrying amounts as of the balance sheet date of long-term debt, which may include notes payable, bonds payable, debentures, mortgage loans, and commercial paper, which are scheduled to be repaid within one year or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Article 5 false 27 3 us-gaap_ConvertibleNotesPayableCurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 1144275 1144275 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 false 28 3 us-gaap_LiabilitiesCurrent us-gaap true credit instant No definition available. false false false false false false false false false false false totallabel false 1 false true false false 89448296 89448296 false false false 2 false true false false 72900319 72900319 false false false xbrli:monetaryItemType monetary Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 true 29 2 us-gaap_DeferredRevenueNoncurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 88785714 88785714 false false false 2 false true false false 95857142 95857142 false false false xbrli:monetaryItemType monetary The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 3 -Section A -Paragraph 7, 8 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 48 -Paragraph 6 false 30 2 us-gaap_DerivativeLiabilitiesCurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 318500 318500 false false false 2 false true false false 637500 637500 false false false xbrli:monetaryItemType monetary Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 3 -Section A -Paragraph 7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number FIN39-1 -Paragraph 10A, 10B Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 4, 17 false 31 2 us-gaap_LongTermDebtNoncurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 4374627 4374627 false false false 2 false true false false 5630862 5630862 false false false xbrli:monetaryItemType monetary Sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year (current maturities) or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 false 32 2 us-gaap_ConvertibleLongTermNotesPayable us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 6132134 6132134 false false false 2 false true false false 7112027 7112027 false false false xbrli:monetaryItemType monetary Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 false 33 2 us-gaap_CommitmentsAndContingencies2009 us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 &nbsp; &nbsp; false false false 2 false false false false 0 0 &nbsp; &nbsp; false false false xbrli:stringItemType string Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. This caption alerts the reader that one or more notes to the financial statements disclose pertinent information about the entity's commitments and contingencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 25 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 9 false 34 2 us-gaap_StockholdersEquityNoteAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 35 3 us-gaap_CommonStockValue us-gaap true credit instant No definition available. false false false false false false false false false false false label false 1 false true false false 38569 38569 false false false 2 false true false false 37935 37935 false false false xbrli:monetaryItemType monetary Dollar value of issued common stock whether issued at par value, no par or stated value. This item includes treasury stock repurchased by the entity. Note: elements for number of common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 36 3 us-gaap_AdditionalPaidInCapitalCommonStock us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 586058355 586058355 false false false 2 false true false false 565503101 565503101 false false false xbrli:monetaryItemType monetary Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 false 37 3 us-gaap_RetainedEarningsAccumulatedDeficit us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false -443757145 -443757145 false false false 2 false true false false -428316881 -428316881 false false false xbrli:monetaryItemType monetary The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 false 38 3 us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 22138 22138 false false false 2 false true false false 108613 108613 false false false xbrli:monetaryItemType monetary Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at fiscal year-end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, and unrealized gains and losses on certain investments in debt and equity securities as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 14, 17, 26 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 false 39 3 us-gaap_StockholdersEquity us-gaap true credit instant No definition available. false false false false false false false false false false false totallabel false 1 false true false false 142361917 142361917 false false false 2 false true false false 137332768 137332768 false false false xbrli:monetaryItemType monetary Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 true 40 2 us-gaap_LiabilitiesAndStockholdersEquity us-gaap true credit instant No definition available. false false false false false false false false false false false totallabel false 1 true true false false 331421188 331421188 false false false 2 true true false false 319470618 319470618 false false false xbrli:monetaryItemType monetary Total of all Liabilities and Stockholders' Equity items. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 true 2 36 false NoRounding UnKnown UnKnown false true XML 27 R2.xml IDEA: Consolidated Balance Sheets (unaudited) (parenthetical)  2.2.0.7 false Consolidated Balance Sheets (unaudited) (parenthetical) (USD $) 001010 - Statement - Consolidated Balance Sheets (unaudited) (parenthetical) true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 2 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 3 1 us-gaap_StockholdersEquityNoteAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 4 2 us-gaap_CommonStockParOrStatedValuePerShare us-gaap true na instant No definition available. false false false false false false false false false false false label true 1 true true false false 0.001 0.001 false false false 2 true true false false 0.001 0.001 false false false us-types:perShareItemType decimal Face amount or stated value of common stock per share; generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 5 2 us-gaap_CommonStockSharesAuthorized us-gaap true na instant No definition available. false false false false false false false false false false false label false 1 false true false false 80000000 80000000 false false false 2 false true false false 80000000 80000000 false false false xbrli:sharesItemType shares The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 6 2 us-gaap_CommonStockSharesIssued us-gaap true na instant No definition available. false false false false false false false false false false false false 1 false true false false 38568369 38568369 false false false 2 false true false false 37935075 37935075 false false false xbrli:sharesItemType shares Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 7 2 us-gaap_CommonStockSharesOutstanding us-gaap true na instant No definition available. false false false false false false false false false false false false 1 false true false false 38568369 38568369 false false false 2 false true false false 37935075 37935075 false false false xbrli:sharesItemType shares Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Excludes common shares repurchased by the entity and held as Treasury shares. Shares outstanding equals shares issued minus shares held in treasury. Does not include common shares that have been repurchased. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 2 5 false UnKnown NoRounding NoRounding false true XML 28 FilingSummary.xml IDEA: XBRL DOCUMENT 2.2.0.7 true Sheet 001000 - Statement - Consolidated Balance Sheets (unaudited) Consolidated Balance Sheets (unaudited) http://acorda.com/role/ConsolidatedBalanceSheets false R1.xml false Sheet 001010 - Statement - Consolidated Balance Sheets (unaudited) (parenthetical) Consolidated Balance Sheets (unaudited) (parenthetical) http://acorda.com/role/ParentheticalToTheConsolidatedBalanceSheets false R2.xml false Sheet 002000 - Statement - Consolidated Statements Of Operations (unaudited) Consolidated Statements Of Operations (unaudited) http://acorda.com/role/ConsolidatedStatementsOfOperations false R3.xml false Sheet 003000 - Statement - Consolidated Statements Of Cash Flows (unaudited) Consolidated Statements Of Cash Flows (unaudited) http://acorda.com/role/ConsolidatedStatementsOfCashFlows false R4.xml false Sheet 006010 - Disclosure - Organization and Business Activities Organization and Business Activities http://acorda.com/role/OrganizationAndBusinessActivities false R5.xml false Sheet 006020 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies http://acorda.com/role/SummaryOfSignificantAccountingPolicies false R6.xml false Sheet 006030 - Disclosure - Share-based Compensation Share-based Compensation http://acorda.com/role/ShareBasedCompensation false R7.xml false Sheet 006040 - Disclosure - Earnings Per Share Earnings Per Share http://acorda.com/role/EarningsPerShare false R8.xml false Sheet 006050 - Disclosure - Income Taxes Income Taxes http://acorda.com/role/IncomeTaxes false R9.xml false Sheet 006060 - Disclosure - Fair Value Measurements Fair Value Measurements http://acorda.com/role/FairValueMeasurements false R10.xml false Sheet 006070 - Disclosure - Short-Term Investments Short-Term Investments http://acorda.com/role/ShortTermInvestments false R11.xml false Sheet 006080 - Disclosure - Collaboration Agreement Collaboration Agreement http://acorda.com/role/CollaborationAgreement false R12.xml false Sheet 006090 - Disclosure - Commitments and Contingencies Commitments and Contingencies http://acorda.com/role/CommitmentsAndContingencies false R13.xml false Sheet 006100 - Disclosure - Intangible Assets Intangible Assets http://acorda.com/role/IntangibleAssets false R14.xml false Sheet 995200 - Document - Document Information Document Information http://xbrl.us/us-gaap/role/document/DocumentInformation false R15.xml false Sheet 995400 - Document - Entity Information Entity Information http://xbrl.us/us-gaap/role/document/EntityInformation false R16.xml false Book All Reports All Reports false 1 10 0 0 3 108 false false c00005 36 c00001 1 c00003 36 c00004 1 c00007 20 c00006 71 c00000 48 c00009 1 c00008 20 c00002 1 true true EXCEL 29 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]F.#@Y,#DT8E\W.6)C7S0P-F1?830X-%\R-C-E M,C9E-#0W830B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K M#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DEN8V]M95]487AE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O M#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H M965T&-E;"!84"!O M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]F.#@Y,#DT8E\W.6)C7S0P-F1?830X-%\R-C-E,C9E-#0W830- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C@X.3`Y-&)?-SEB8U\T M,#9D7V$T.#1?,C8S93(V930T-V$T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E M;G-E2!T M:&4@0V]M<&%N>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E;G-E"!T86)L971S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#"!#87!S=6QE M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3H\+W-TF5D(#@P+#`P,"PP,#`@ M3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F.#@Y,#DT8E\W.6)C7S0P-F1?830X-%\R M-C-E,C9E-#0W830-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C@X M.3`Y-&)?-SEB8U\T,#9D7V$T.#1?,C8S93(V930T-V$T+U=O'0O:'1M;#L@8VAA3H\+W-T3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F.#@Y,#DT8E\W.6)C7S0P M-F1?830X-%\R-C-E,C9E-#0W830-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO9C@X.3`Y-&)?-SEB8U\T,#9D7V$T.#1?,C8S93(V930T-V$T+U=O M'0O:'1M M;#L@8VAA'!E;G-E'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M/B@Y-#,L.37!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N M(&]F(&YE="!PF%T:6]N(&]F(')E=F5N=64@:6YT M97)E'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR M+#@Q."PP.3(\3PO=&0^#0H@("`@("`@(#QT9"!C;&%S2!H96QD(&)Y('1H92!#;VUP86YY/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B@Q.2PU.#(L-#`T*3QS<&%N/CPO2!H96QD(&)Y(&]T:&5R6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA"!#87!S=6QE2!O<&5R871I;F<@86-T:79I=&EE&5R8VES97,\+W1D/@T*("`@("`@("`\=&0@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M2!F:6YA;F-I;F<@86-T:79I=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]F.#@Y,#DT8E\W.6)C7S0P-F1?830X-%\R-C-E,C9E-#0W830-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C@X.3`Y-&)?-SEB8U\T,#9D7V$T M.#1?,C8S93(V930T-V$T+U=O'0O:'1M;#L@8VAAF%T:6]N(&%N M9"!"=7-I;F5S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N(&%N9"!"=7-I;F5SF%T:6]N(&]F(&YO=F5L('1H97)A<&EE3XF(S$V,#L\+V1I=CX\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,S9P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE M(&UA;F%G96UE;G0@;V8@=&AE($-O;7!A;GD@:7,@65A3XF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,S9P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE28C.#(Q-SMS($%N M;G5A;"!297!O65A3XF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE($-O;7!A;GD@9FEN86YC97,@:71S M(&]P97)A=&EO;G,@=&AR;W5G:"!A(&-O;6)I;F%T:6]N(&]F(&ES2!S96-U'1E;G0L(&=R86YT2!W:6QL(&)E('-U8V-EF%T:6]N(&5F9F]R=',N(%1O('1H92!E>'1E;G0@=&AE($-O;7!A;GDF M(S@R,3<[2!B M92!U;F%B;&4@=&\@;V)T86EN(&%D9&ET:6]N86P@9&5B="!O2!B92!R97%U:7)E9"!T;R!C=7)T86EL(&ET'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE3XF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SY03XF(S$V,#L\+V1I=CX\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,S9P=#L@34%21TE.+5))1TA4.B`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`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`H)B,X,C(P.TMA:7-E M2!A<'!L:65S('1H92!R979E M;G5E(')E8V]G;FET:6]N(&=U:61A;F-E(&EN(%-T869F($%C8V]U;G1I;F<@ M0G5L;&5T:6X@*%-!0BD@,3`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`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`Q,'!T.R!&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%- M24Q9.B!4:6UE6%L=&EE M6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!4 M15A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,S9P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^4F5V96YU92!F6UE;G0@:7,@6%L=&EE6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z M(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY#;VQL86)O6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/CQD:78@2!R M96-O9VYI>F5S(&-O;&QA8F]R871I;VX@FEN9R!E86-H(&5L96UE;G0@;V8@=&AE(&%G7)A($EN=F5N=&]R>3PO9F]N M=#X\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/CQD:78@7)A('1H870@=6QT:6UA=&5L>2!B96-A;64@ M879A:6QA8FQE('1O('-U<'!O7)A('=I;&P@2!C;W-T'!E;G-E9"X@57!O M;B!R96=U;&%T;W)Y(&%P<')O=F%L(&]F($%M<'ER82P@=&AE($-O;7!A;GD@ M8F5G86X@8V%P:71A;&EZ:6YG('1H92!C;VUM97)C:6%L(&EN=F5N=&]R>2!C M;W-T6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/CQD:78@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/CQD:78@2!S=6)J96-T('1H92!#;VUP86YY('1O M(&-O;F-E;G1R871I;VYS(&]F(&-R961I="!R:7-K(&-O;G-I2!M86EN=&%I;G,@8V%S:"!A;F0@8V%S:"!E<75I=F%L M96YT2!P97)F;W)M'!O2!I;G-T:71U=&EO;BX\ M+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O M;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY396=M96YT($EN9F]R;6%T:6]N M/"]F;VYT/CPO9&EV/CQD:78@2!D;V5S(&YO="!O<&5R871E('-E<&%R M871E(&QI;F5S(&]F(&)U2!R97!O'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1% M6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^*#,I(%-H87)E+6)A6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@;&5F="<^)B,Q-C`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`P<'0[(%1%6%0M M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SY4:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!A;&EG;CTS1&QE9G0^/'1A8FQE('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M5$585"U!3$E'3CH@;&5F="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,"!W:61T:#TS1#$P,"4^/'1R('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0S,"4^/&9O;G0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@ M8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,R4@8V]L6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O M;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^*$EN(&UI;&QI;VYS*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,C`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`[/"]F;VYT/CPO=&0^/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U! M3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24@8V]L M6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,C`P.3PO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!4 M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M,2XT/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXP+CD\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^,BXU/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%2 M1TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SY396QL:6YG+"!G96YE6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXR M+C,\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58 M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O M;G0@6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,C=P=#L@34%2 M1TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#M4;W1A;#PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^-"XX/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS+C(\+V9O;G0^/"]T9#X\=&0@ M#L@5$585"U!3$E'3CH@;&5F M="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@#L@5$58 M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O M;G0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@#L@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U) M3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`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`[/"]D:78^/&1I=B!S M='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$58 M5"U)3D1%3E0Z(#,V<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=. M.B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^02!S M=6UM87)Y(&]F('-H87)E+6)A2!F M;W(@=&AE(&YI;F4M;6]N=&@@<&5R:6]D(&5N9&5D(%-E<'1E;6)E6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM M4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQT86)L M92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R.24^/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^3G5M8F5R(&]F(%-H87)E M6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@;&5F="<^/&1I=B!S M='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$58 M5"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`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`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`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^5&5R;3PO9F]N=#X\ M+V1I=CX\+V1I=CX\+W1D/CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM M4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@;&5F="<^/&1I=B!S='EL93TS1"=$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$58 M5"U!3$E'3CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^,RPW,3$L-S6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF;F)S<#LD,34N,C4\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R M/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1T;W`@ M=VED=&@],T0R.24^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#$X<'0[(%1%6%0M24Y$14Y4.B`M,3AP=#L@34%21TE.+5)) M1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`[(#PO9F]N=#X\+W1D/CPO='(^/'1R M/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1T;W`@ M=VED=&@],T0R.24^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#$X<'0[(%1%6%0M24Y$14Y4.B`M,3AP=#L@34%21TE.+5)) M1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SY#86YC96QL960\9F]N="!S='EL93TS1"=-05)' M24XM3$5&5#H@,3)P="<^/"]F;VYT/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S M='EL93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$X)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^*#@X+#(X.2D\+V9O;G0^/"]D:78^/"]T9#X\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXH-C(S+#(Y-"D\+V9O;G0^/"]D:78^/&1I=B!S='EL M93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^)B,Q-C`[ M/"]D:78^/"]D:78^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ,BXY,CPO9F]N M=#X\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E. M1$5.5#H@,'!T)SXF(S$V,#L\+V1I=CX\+V1I=CX\+W1D/CQT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY"86QA;F-E(&%T(%-E M<'1E;6)E6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@;&5F M="<^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T.R!415A4+4%,24=..B!C M96YT97(G/B8C,38P.SPO9&EV/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`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`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5. M5#H@,'!T)SXF(S$V,#L\+V1I=CX\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@;&5F="<^ M/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SXF(S$V,#L\+V1I=CX\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R M<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P=#L@5$585"U!3$E'3CH@;&5F="<^/&1I=B!S='EL93TS1"=$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T M)SXF(S$V,#L\+V1I=CX\+V1I=CX\+W1D/CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@;&5F="<^/&1I=B!S M='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$58 M5"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`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`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`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/CQD:78@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)3X\9&EV('-T>6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@;&5F="<^/&1I M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SY.;VYV97-T960@870@2F%N=6%R>28C,38P.S$L(#(P,3`\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,S,T+#$W.#PO M9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T)R!V86QI9VX],T1T;W`@=VED=&@],T0U."4^/&1I=B!S='EL M93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[(%1%6%0M M24Y$14Y4.B`M,3AP=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ M(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY697-T M960\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#4X)3X\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@ M5$585"U)3D1%3E0Z("TQ.'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U! M3$E'3CH@;&5F="<^/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@;&5F="<^/&1I M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`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`@("`\=&%B;&4@8VQA'0^/&1I=B!S M='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$58 M5"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4 M.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE3XF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@ M34%21TE.+5))1TA4.B`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`Q,#PO9F]N=#X\+V1I=CX\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T M)SXF(S$V,#L\+V1I=CX\+V1I=CX\+W1D/CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`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`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T.R!415A4+4E.1$5. M5#H@+3EP=#L@34%21TE.+5))1TA4.B`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`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ+#4S-RPW,C<\ M+V9O;G0^/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,3AP=#L@5$585"U)3D1%3E0Z("TQ.'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SY796EG:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R97,@;W5T6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`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`R<'@@6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS-RPW M,#`L-S0W/"]F;VYT/CPO9&EV/CQD:78@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/CQD M:78@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD*#`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`R<'@@ M6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^/&1I=B!S='EL93TS1"=$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY.970@:6YC M;VUE("AL;W-S*2!P97(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD,"XS,3PO9F]N M=#X\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E. M1$5.5#H@,'!T)SXF(S$V,#L\+V1I=CX\+V1I=CX\+W1D/CQT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q-"4^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G/CQD:78@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF;F)S<#LD*#`N-3$I/"]F;VYT/CPO9&EV/CQD:78@6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S M)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^/&1I M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`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`S-G!T)SX\+V9O;G0^5&AE(&1I9F9E M&5R8VES92!P&-E M961S('1H92!A=F5R86=E(&-L;W-I;F<@<')I8V4@;V8@=&AE($-O;7!A;GDF M(S@R,3<[3XF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)SX\9F]N="!S='EL93TS1"=-05)'24XM M3$5&5#H@,S9P="<^/"]F;VYT/D9O2P@;V8@8V]M;6]N('-T;V-K('1H870@8V]U;&0@ M<&]T96YT:6%L;'D@9&EL=71E(&)A2!D:6QU=&4@8F%S:6,@96%R;FEN9W,@<&5R('-H87)E(&EN('1H92!F=71U M&-L=61E9"!F2P@;V8@=6YV97-T960@2!D:6QU=&4@8F%S:6,@ M96%R;FEN9W,@<&5R('-H87)E(&EN('1H92!F=71U&-L=61E M9"!F'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE3XF(S$V,#L\+V1I=CX\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX\9F]N="!S='EL M93TS1"=-05)'24XM3$5&5#H@,S9P="<^/"]F;VYT/E1H92!#;VUP86YY(&AA M9"!A=F%I;&%B;&4@;F5T(&]P97)A=&EN9R!L;W-S(&-A2`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3(E/CQD:78@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5. M5#H@,'!T)SXF(S$V,#L\+V1I=CX\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^3&5V96PF(S$V,#LS/"]F;VYT M/CPO9&EV/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^ M/"]T6QE/3-$)TU!4D=)3BU, M1494.B`Q,G!T)SX\+V9O;G0^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT('=I9'1H/3-$,3(E/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD-S8L M,3`T+#(P,3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H="!W:61T:#TS1#$P)3X\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$)TU!4D=) M3BU,1494.B`Q,G!T)SX\+V9O;G0^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT('=I9'1H/3-$,3(E/CQD:78@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`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`@86QI9VX],T1L969T('=I9'1H/3-$-30E/CQD:78@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T M3XF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^5&AE(&9O;&QO=VEN9R!T86)L92!PF5S($QE=F5L M)B,Q-C`[,R!I;G!U=',@=&\@9&5T97)M:6YE(&9A:7(@=F%L=64N/"]F;VYT M/CPO9&EV/CQD:78@6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^/&1I=B!S='EL93TS1"=$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z M(#!P=#L@34%21TE.+5))1TA4.B`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`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^ M/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$X)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q-24^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L@/"]F;VYT/CPO=&0^/"]T6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF;F)S<#LD-C,W+#4P,#PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!W:61T:#TS1#$X M)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M*"9N8G-P.R0S,3DL,#`P*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H="!W:61T:#TS1#$U)3X\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB'!E8W1E9"!F=71U'!E8W1E9"!L:69E(&]F('1H92!04D8@86=R965M96YT M+"!A&5R8VES92!T2!O8G-E M2!B92!R97%U:7)E9"!T;R!R96-O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^*#3XF M(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@34%21TE.+5))1TA4 M.B`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`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^17-T:6UA=&5D/"]F;VYT/CPO M9&EV/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E' M2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^=F%L=64\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=$ M25-03$%9.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^)B,Q-C`[/"]D:78^ M/"]D:78^/"]T9#X\+W1R/CQT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M,24^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT M/CPO=&0^/"]T6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ,C8L,38Y/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT('=I M9'1H/3-$,3$E/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXH,36QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,C(T+#3XF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^5&AE(&-O;G1R86-T=6%L(&UA='5R:71I97,@;V8@879A M:6QA8FQE+69O65A2!O9B!T:')E92!M;VYT:',@;W(@;&5S2X\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]F.#@Y,#DT8E\W.6)C7S0P-F1?830X-%\R-C-E,C9E M-#0W830-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C@X.3`Y-&)? M-SEB8U\T,#9D7V$T.#1?,C8S93(V930T-V$T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@ M6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,S9P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY/;B!*=6YE)B,Q-C`[ M,S`L(#(P,#DL('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A;B!E>&-L=7-I M=F4@8V]L;&%B;W)A=&EO;B!A;F0@;&EC96YS92!A9W)E96UE;G0@=VET:"!" M:6]G96X@261E8R!);G1EF4@06UP>7)A("AK;F]W M;B!A"U5+E,N(&UA2!A;'-O(&5N=&5R960@:6YT;R!A(')E M;&%T960@2!!9W)E96UE;G0F(S@R,C$[*2P@<'5R2!A M9W)E96UE;G0@=VET:"!%;&%N+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#,V<'0[($U!4D=)3BU224=( M5#H@,'!T.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<^56YD97(@=&AE($-O;&QA8F]R871I;VX@06=R965M M96YT+"!T:&4@0V]M<&%N>2!W87,@96YT:71L960@=&\@86X@=7!F28C M,38P.S$L(#(P,#DL(&%N9"!W:6QL(&)E(&5N=&ET;&5D('1O(')E8V5I=F4@ M861D:71I;VYA;"!P87EM96YT2!P2!P87EM96YT2!O;B!E>"U5+E,N('-A;&5S+B!);B!A9&1I=&EO;BP@=&AE(&-O;G-I9&5R M871I;VX@=&AA="!":6]G96X@261E8R!W:6QL('!A>2!F;W(@;&EC96YS960@ M<')O9'5C=',@=6YD97(@=&AE(%-U<'!L>2!!9W)E96UE;G0@=VEL;"!R969L M96-T('1H92!P2!A;'-O(&-AF%T:6]N(&]F($%M<'ER82!A;F0@ M;W1H97(@;&EC96YS960@<')O9'5C=',@:6X@;6%R:V5T6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P=#L@5$585"U!3$E'3CH@;&5F="<^)B,Q-C`[/"]D:78^/&1I=B!S M='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$58 M5"U)3D1%3E0Z(#,V<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=. M.B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^07,@ M;V8@2G5N928C,38P.S,P+"`R,#`Y+"!T:&4@0V]M<&%N>2!R96-O2!F6UE;G0@ M;V8@)FYB6UE;G0@;V8@)FYB6QE/3-$)T1)4U!,05DZ M(&EN;&EN92<^5&AE($-O;7!A;GD@8V]N2P@*#(I('1H92!#;VQL86)O M2!H87,@9&5T97)M:6YE9"!T:&%T('1H92!I9&5N=&EF:65D(&1E;&EV M97)A8FQE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^/&9O;G0@2P@=&AE(&1E;&EV97)A8FQEF4@=&AE(&YO M;BUR969U;F1A8FQE('5P9G)O;G0@<&%Y;65N="!F6UE;G0@=&\@16QA M;B!A'!E;G-E(')A=&%B;'D@;W9E2!E>&-L=7-I=FET>2!F;W(@=&AE(&QI8V5N'!E8W1E9"!B96YE9FET('!E2!E65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS M1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1% M3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/CQD:78@2!B92P@9G)O;2!T:6UE('1O('1I;64L(&$@<&%R='D@=&\@=F%R:6]U M28C.#(Q-SMS(&5S=&EM871E2!A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE3XF(S$V,#L\+V1I=CX\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,S9P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE($-O M;7!A;GD@86-Q=6ER960@86QL(&]F($5L86XG2!W87,@86QS;R!R M97-P;VYS:6)L92!F;W(@=7`@=&\@)FYB"!T86)L971S(&%N M9"!:86YA9FQE>"!#87!S=6QE6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO M9&EV/CQD:78@2!S97!A65E6UE;G1S(&UA9&4@=&\@ M16QA;B!T;R!T:&4@87-S971S(&%C<75I2!T:&4@ M6F%N869L97@@=')A9&4@;F%M92!A;F0@=&AE(&-A<'-U;&5S('!A=&5N="X@ M5&AE3XF(S$V,#L\+V1I=CX\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,S9P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^3VX@2F%N=6%R>28C M,38P.S(R+"`R,#$P+"!T:&4@0V]M<&%N>2!R96-E:79E9"!M87)K971I;F<@ M87!P6UE;G1S(&]F("9N8G-P.R0R+C4@;6EL;&EO;B!T M;R!%;&%N(&%N9"`F;F)S<#LD-S4P+#`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`L,#`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`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<^26YT86YG:6)L92!A6EN9R!V86QU92!O M9B!T:&5S92!A2!E M=F%L=6%T97,@=&AE(')E86QI>F%B:6QI='D@;V8@:71S(&EN=&%N9VEB;&4@ M87-S971S(&)A'!E8W1A=&EO;G,@9F]R('1H92!R96QA=&5D(&%S2!D;V5S(&YO="!B96QI979E M('1H870@=&AE2!F86-T"!O3XF(S$V,#L\+V1I=CX\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@-#5P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^26YT M86YG:6)L92!A6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^/&1I=B!S='EL93TS M1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1% M3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O M;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^4V5P=&5M8F5R(#,P+#PO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O M;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SY:86YA9FQE>"!P871E;G1S/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD,3DL,S4P+#`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`L M,#`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT('=I9'1H/3-$,3`E/CQD:78@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXR+#$U,"PP,#`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`Q,G!T)SX\+V9O;G0^/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT('=I9'1H M/3-$,3`E/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXS+#`P,"PP,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^,BPX-S$L,3DU/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT('=I9'1H/3-$,3`E/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ+#0T-"PW-#D\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXW.#(L-3,Q/"]F;VYT/CPO M9&EV/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS)B,Q-C`[>65A6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT('=I9'1H/3-$,3`E/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS,"PV,C$L,3DU M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT('=I9'1H/3-$,3`E/CQD:78@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXR,RPW,CF%T:6]N/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXX+#8P-RPW-C0\+V9O;G0^/"]D:78^/&1I M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^ M)B,Q-C`[/"]D:78^/"]D:78^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXV M+#4W."PV-#D\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=$25-03$%9.B!B M;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^)B,Q-C`[/"]D:78^/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD,C(L,#$S+#0S,3PO9F]N=#X\ M+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5. M5#H@,'!T)SXF(S$V,#L\+V1I=CX\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q,"4^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF;F)S<#LD,36QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SXF(S$V M,#L\+V1I=CX\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q,24^/&9O;G0@3XF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`@86QI9VX],T1L969T('=I9'1H M/3-$-#`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`Q,G!T)SX\+V9O;G0^/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT('=I9'1H/3-$,3`E/CQD M:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXR+#@P M,2PT,SD\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@5$585"U)3D1%3E0Z M("TQ.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXR,#$S/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^/&1I=B!S='EL93TS1"=$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5. M5#H@,'!T)SXF(S$V,#L\+V1I=CX\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!V M86QI9VX],T1T;W`@=VED=&@],T0T,"4^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)FYB3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]F.#@Y,#DT8E\W.6)C7S0P-F1?830X-%\R-C-E,C9E-#0W830-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C@X.3`Y-&)?-SEB8U\T,#9D M7V$T.#1?,C8S93(V930T-V$T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^,3`M43QS<&%N/CPO'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!&:6QE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!& M:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M3&%R9V4@06-C96QE2!#;VUM;VX@4W1O8VLL M(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]F.#@Y,#DT8E\W.6)C7S0P-F1?830X-%\R-C-E,C9E-#0W830-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C@X.3`Y-&)?-SEB8U\T,#9D M7V$T.#1?,C8S93(V930T-V$T+U=O&UL#0I# M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I# M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U&UL/@T*+2TM+2TM/5].97AT4&%R=%]F.#@Y D,#DT8E\W.6)C7S0P-F1?830X-%\R-C-E,C9E-#0W830M+0T* ` end XML 30 R7.xml IDEA: Share-based Compensation  2.2.0.7 false Share-based Compensation 006030 - Disclosure - Share-based Compensation true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 0 acor_NotesToFinancialStatementsAbstract acor false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 1 us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3) Share-based Compensation</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the three-month periods ended September 30, 2010 and 2009, the Company recognized share-based compensation expense of $4.8&#160;million and $3.2&#160;million, respectively. During the nine-month periods ended September 30, 2010 and 2009, the Company recognized share-based compensation expense of $12.6 million and $8.9 million, respectively. Activity in options and restricted stock during the nine - -month period ended September 30, 2010 and related balances outstanding as of that date are reflected below. The weighted average fair value per share of options granted to employees for the three-month periods ended September 30, 2010 and 2009 were approximately $19.75 and $16.75, respectively.&#160;&#160;The weighted average fair value per share of options granted to employees for the nine-month periods ended September 30, 2010 and 2009 were approximately $19.37 and $17.59, respectively.</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes share-based compensation expense included within our consolidated statements of operations:</font></div><div style="DISPLAY: block ; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="TEXT-ALIGN: left" align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left" cellspacing="0" cellpadding="0" width="100%"><tr style="TEXT-ALIGN: left"><td style="TEXT-ALIGN: left" valign="bottom" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="TEXT-ALIGN: center" valign="bottom" width="23%" colspan="7"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For the three-month</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">& #160;</font></td><td style="TEXT-ALIGN: center" valign="bottom" width="23%" colspan="7"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For the nine-month</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr><tr><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="23%" colspan="7"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center "><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">period ended September&#160;30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="23%" colspan="7"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">period ended September&#160;30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</fon t></td></tr><tr><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="30%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(In millions)</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="11%" colspan="3"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="11%" colspan="3"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="11%" colspan="3"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%">< ;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="11%" colspan="3"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr><tr><td style="TEXT-ALIGN: left" valign="bottom" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline ; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</fon t></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width= "1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr><tr><td style="TEXT-ALIGN: left" valign="bottom" width="30%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.4</font></td><td style="TEXT-ALIGN: left" valign="b ottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.9</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#1 60;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.6</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10 pt; FONT-FAMILY: times new roman">2.5</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr><tr><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="30%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Selling, general and administrative</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font& gt;</td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.4</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> ;2.3</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9.0</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: t imes new roman">&#160;</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.4</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr><tr><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" width="30%"><div style="DISPLAY: block; MA RGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;Total</font></div></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.8</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font&g t;</td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12.6</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="PADDING-BOTTOM: 4px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td><td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign= "bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.9</font></td><td style="PADDING-BOTTOM: 4px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: l eft"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of share-based compensation activity for the nine-month period ended September 30, 2010 is presented below:</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stock Option Activity</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="TEXT-ALIGN: left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left" cellspacing="0" cellpadding="0" width="91%"><tr style="TEXT-ALIGN: left"><td style="TEXT-ALIGN: left" valign="bottom" width="29%"><font styl e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of Shares</font></div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted Average</font>< /div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise Price</font></div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="19%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted Average</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Remaining</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDE NT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contractual</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Term</font></div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="15%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intrinsic Value</font></div></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at January&#160;1, 2010</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,711,778</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$15.25</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>& lt;td style="TEXT-ALIGN: left" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,098,169</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"> ;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.61</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cancelled<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: cen ter"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(88,289)</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24.89</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT - -SIZE: 10pt; FONT-FAMILY: times new roman">Exercised<font style="MARGIN-LEFT: 12pt"></font></font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(623,294)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 1 0pt; FONT-FAMILY: times new roman">12.92</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at September 30, 2010</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="18%"&g t;<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,098,364</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$20.05</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEX T-ALIGN: left" valign="bottom" width="19%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7.1</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="15%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$53,896,144</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><t d style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested and expected to vest at September 30, 2010</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,008,207</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MAR GIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$19.83</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="19%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7.1</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="15%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEX T-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$53,588,108</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="29%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested and exercisable at September 30, 2010</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="18%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; T EXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,278,343</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="20%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$14.12</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="19%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0 pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.9</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="15%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$43,143,212</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></div></td></tr></table></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RI GHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Restricted Stock Activity</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div><div style="TEXT-ALIGN: left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left" cellspacing="0" cellpadding="0" width="74%"><tr style="TEXT-ALIGN: left"><td style="TEXT-ALIGN: left" valign="bottom" width="58%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; BORDER-BOTTOM: 1pt double; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">Restricted Stock</font></div></div></td><td style ="TEXT-ALIGN: left" valign="bottom" width="16%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; BORDER-BOTTOM: 1pt double; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">Number of Shares</font></div></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="58%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nonvested at January&#160;1, 2010</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="16%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style ="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">203,776</font></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="58%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div></td><td style="TEXT-ALIGN: center" valign="bottom" width="16%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">334,178</font></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="58%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested</font>& lt;/div></td><td style="TEXT-ALIGN: center" valign="bottom" width="16%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(10,000)</font></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="58%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Forfeited</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="16%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times n ew roman">(12,185)</font></div></div></td></tr><tr><td style="TEXT-ALIGN: left" valign="top" width="58%"><div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nonvested at September 30, 2010</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="16%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">515,769</font></div></div></td></tr></table></div> (3) Share-based Compensation&#160;During the three-month periods ended September 30, 2010 and 2009, the Company recognized share-based compensation expense of false false false us-types:textBlockItemType textblock Disclosure of compensation-related costs for share-based compensation which may include disclosure of policies, compensation plan details, allocation of stock compensation, incentive distributions, share-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64, 65, A240 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 93-6 -Paragraph 53 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 false 1 2 false UnKnown UnKnown UnKnown false true -----END PRIVACY-ENHANCED MESSAGE-----